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RESUMO 
A Síndrome da Imunodeficiência Adquirida (SIDA) representa hoje um dos principais 
problemas de Saúde Pública a nível mundial, tendo contraído a doença mais de 60 
milhões de pessoas em todo o mundo desde a sua descoberta em 1981, um terço das 
quais faleceram subsequentemente.  
Apesar dos grandes progressos realizados no tratamento da SIDA, especialmente desde 
a introdução do regime terapêutico HAART em 1996, as alternativas terapêuticas 
actuamente disponíveis não permitem erradicar completamente o VIH-1 do organismo, 
o que resulta em toxicidade a longo prazo e leva eventualmente à emergência de estirpes 
de VIH-1 resistentes à terapêutica disponivel.  Estes problemas levam à procura e 
desenvolvimento de novos fármacos activos contra o VIH, nomeadamente contra as 
estirpes de VIH resistentes aos fármacos actualmente utilizados. Entre os novos 
fármacos actualmente disponíveis encontra-se uma nova classe, os inibidores de 
entrada.  
O processo de fusão do VIH-1 é mediado  pelas proteínas Env (gp120 e gp41) e inicia-
se através da ligação da gp120 ao receptor celular CD4.  A interacção gp120-CD4 dá 
origem a uma alteração conformacional na loop V3 da gp120 que expõe o epitopo de 
ligação ao receptor de quimiocinas, o que por sua vez induz alterações conformacionais 
na gp41 que culminam na conformação activa do péptido de fusão (conformação 
fusogénica). Portanto, a interação gp120-CD4 é fundamental para o processo de fusão 
vírus-célula. 
Igualmente, uma descoberta recente identificou na gp120 uma região 
conformacionalmente invariável que se sobrepõe parcialmente ao local de ligação ao 
CD4, esta região corresponde à zona de ligação do anticorpo b12 e possui a 
particularidade que se encontrar  constitutivamente exposta no domínio exterior da 
gp120. Esta região encontra-se envolvida na ligação metaestável ao CD4, antes de 
ocorrer o rearanjo necessário para a existência de uma ligação estável. Este é por 
conseguinte um local de vulnerabilidade, relacionado com um requisito funcional para 
existência de uma associação eficiente com o CD4. 
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O anticorpo b12 é um dos poucos anticorpos monoclonais humanos conhecidos que 
pode eficientemente neutralizar uma ampla gama de isolados primários de VIH-1 in 
vitro e pode proteger contra o desafio viral in vivo. 
 
O objetivo deste trabalho foi a avaliação da sequência alvo do anticorpo neutralizante 
b12 ou o epítopo de ligação ao CD4 fora do contexto da glicoproteína gp120. Para tal 
procedeu-se à construção de anticorpos de domínio, por meio de “grafting” da 
sequência alvo do anticorpo neutralizante b12 ou o epítopo de ligação ao CD4 num dos 
CDR’s, CDR1 ou CDR3 de um anticorpo de coelho de único domínio VL,.altamente 
estável. O potencial das construções VLB12 e VLCD4 foi testado para ligação ao CD4 
por ELISA e por Citometria de Fluxo. A Citometria de Fluxo foi efectuada recorrendo a 
células HEK293T, HeLa-P4 e Jurkat, ambas as construções apresentam ligação ao 
receptor CD4, e o VLB12 CDR1, em particular, e parece ter uma ligação ao CD4 de 
elevada afinidade. A partir dos resultados de Citometria de Fluxo e dos rendimentos 
obtidos para as purificações as construções VLB12 CDR1 e VLCD4 CDR3 foram 
selecionados para análise posterior. Pretendeu-se também caracterizar o local de ligação 
das construções VLB12 CDR1 e VLCD4 CDR3 no receptor CD4, nomeadamente 
identificar qual o domínio do CD4 ao qual se ligam os anticorpos VLB12 e VLCD4. Para 
tal, realizaram-se ensaios de ELISA utilizando como antigénios que o receptor celular 
humano CD4 na sua forma solúvel, quer uma construção em que os domínios 1 e 2 do 
CD4 humano foram colocados em fusão com uma IgG2 humana na qual as regiões 
variáveis das cadeias leves e das cadeias pesadas foram substituidas pelos domínios 1 e 
2 do CD4 humano dando origem a uma proteína de fusão designada CD4-IgG2. Dos 
ensaios de ELISA foi possivel concluir que ambos os anticorpos VLB12 e VLCD4 se 
ligam ou ao domínio 1 ou ao domínio 2 do CD4 humano. Para identificar 
especificamente a qual dos domínios se ligavam o VLB12 e o VLCD4, foram realizadas 
experiências em que células HEK293T foram transfectadas com CD4 humano (hCD4), 
CD4 de murganho (mCD4) ou com CD4 humano em que o domínio 1 foi substituido 
pelo domínio 1 de murganho (hCD4mD1). Estas células transfectadas com os diferentes 
receptores celulares CD4 foram submetidas a ensaios de Citometria de Fluxo para 
avaliação da ligação dos anticorpos VLB12 e VLCD4 aos diferentes receptores celulares 
CD4 e concluiu-se que o VLB12 se liga ao domínio 2 e que o VLCD4 se liga ao domínio 
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1 do CD4 humano. Realizaram-se também ensaios de ELISa em que se verificou que os 
epitopos reconhecidos pelo VLB12 e pelo VLCD4 são ambos conformacionais. 
 A fim de avaliar a capacidade do VLB12 e do VLCD4 na inibição da  infecção por VIH-
1, foram realizados ensaios de inibição com o clone molecular NL4-3 do VIH-1 
(subtipo B) e com os subtipos J e H de isolados primários de VIH-1. Os ensaios de 
inibição foram realizados em células TZM-bl num ensaio de um ciclo único de infecção. 
O VLB12 foi capaz de inibir o VIH-1NL4-3 com um IC50 = 3,89 M e o VLCD4 foi capaz 
de inibir o HIV-1NL4-3 com um IC50 = 6,57 M. Realizaram-se igualmente ensaios de 
inibição com o T20 para o qual se obteve um IC50 = 0,0694 M.Quanto aos isolados 
primários, o VLB12 foi capaz de inibir o VIH-1 subtipo H com um IC50 = 3,97 M e o 
VIH-1 subtipo J com um IC50 = 3,86 M, mas o VLCD4 não foi capaz de inibir os 
subtipo J e H de isolados primários de VIH-1. Para o T20 obteve-se um IC50 = 1,33 
nanoM para o subtipo H do VIH-1 e para o subtipo J do VIH-1 obteve-se um IC50 = 
0,42 nanoM. 
Estes resultados indicam que o VLB12 apresenta um amplo potencial de inibição ao 
contrário do VLCD4 que não foi capaz de inibir qualquer um dos isolados primários dos 
subtipo não B. 
Devido à elevada afinidade de ligação ao receptor CD4 apresentada pelo VLB12, uma 
das abordagens desta Tese teve por objectivo avaliar o potencial de um novo sistema de 
entrega de moleculas para terapia génica em que se utilizaram nanopartículas revestidas 
com VLB12 para avaliar a entrega de biomoléculas a células que expressam o receptor 
CD4. 
Foram testados dois tipos diferentes de formulações de nanopartículas, de quitosano e 
de PEI, para a entrega do plasmídeo FUGW-dsRed em células Jurkat. Ambas as 
formulações de nanopartículas foram bem sucedidos na entrega do plasmídeo FUGW-
dsRed às células Jurkat, conforme determinado por imunofluorescência. 
A formulação de nanopartículas de quitosano provou globalmente ser mais eficaz, 
devido à reduzida toxicidade celular. A quantidade ideal de VLB12 adsorvido às 
nanopartículas deu origem a um aumento de 16% da população dsREd positiva 
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fluorescente com um direccionamento das nanopartículas para o receptor alvo (CD4) 
devido à presença do VLB12. 
Numa abordagem distintadas anteriores, pretendeu-se avaliar as propriedades 
antigénicas do VLB12 para utilização numa formulação de vacina. Deste modo, a 
imunidade das mucosas foi testada utilizando o  VLB12 encapsulado em nanopartículas 
de quitosano, por comparação com a via subcutânea, utilizando como adjuvante  
alumínio e realizando as mesmas formulações sem adjuvante.  A resposta de IgG total 
específico nas amostras de soro foi avaliada por ELISA utilizando como antigénio o 
VLB12. Foram também avaliadas as respostas Th1 ou Th2 através do racio dos 
antigénios específicos IgG1-IgG2 nas amostras de soro.  
Para avaliar o potencial antigénico do VLB12 como vacina, foram realizados ensaios de 
inibição de VIH-1 usando os soros dos diferentes grupos de murganhos, aos quais foi 
administrado cada uma das formulações. Os ensaios de inibição foram realizados em 
células TZM-bl, com uma MOI de 0,1, num ensaio de um ciclo único de infecção. 
Apesar de os grupos vacinados apresentarem títulos de IgG específico elevados, 
nenhum dos soros obtidos apresentou efeito inibitório sobre o VIH-1NL4-3. Confirmou-se 
por ELISA que os soros obtidos não reconheciam a gp120 o que indica que a framework 
do VL é altamente imunogénica, não tendo sido obtida uma proporção de anticorpos 
dirigidos contra a região alvo b12 suficiente para se obter um efeito inibitório nos 
ensaios de inibição do VIH-1NL4-3. 
 
 
 
 
 
Palavras-chave: VIH-1; gp120; anticorpos de domínio único VL; inibidores de entrada; 
vacina.  
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ABSTRACT 
The HIV-1 entry process is mediated by the Env proteins, and begins with the binding 
of gp120 to the CD4 cellular receptor. A recent discovery has identified in gp120 a 
conformationally invariant surface that overlaps a distinct subset of the CD4-binding 
site, which is a binding site for the b12 natural antibody.  
The goal of this work was to evaluate both the b12 target sequence and the CD4 binding 
epitope outside of the gp120 context and to evaluate the potential for CD4 binding of 
these two epitopes individually. This was done through grafting of the b12 target 
sequence or CD4 binding epitope into either CDR1 or CDR3 of a highly stable VL 
antibody. The potential of the VLB12 and VLCD4 constructs was tested for CD4 binding 
by ELISA assay and Flow Citometry analysis; both graftings present binding to the 
CD4 receptor and VLB12, in particular. 
In order to evaluate the VLB12 and VLCD4 ability to inhibit HIV-1 infection, inhibition 
assays were performed with the HIV‐1NL4‐3 subtype B molecular clone and with HIV‐1 
subtypes J and H primary isolates. VLB12 was able to inhibit HIV‐1NL4‐3 with an IC50 = 
3,89 M and  VLCD4 was able to inhibit HIV‐1NL4‐3 with an IC50 = 6,57 M. As for the 
HIV‐1 primary isolates, VLB12 was able to inhibit subtype H with an IC50 = 3,97 M 
and subtype J with an IC50 = 3,86 M but VLCD4 was not able to inhibit either subtype 
J or subtype H. These results indicate that VLB12 presents potentially a broad inhibition 
spectrum as opposed to VLCD4 that was not able to inhibit either of the non subtype B 
primary isolates. 
Due to the VLB12 high binding affinity to the CD4 receptor the potential of VLB12 
coated nanoparticles as a new therapeutic delivery system was evaluated. Chitosan and 
PEI nanoparticle formulations were tested, for the delivery of FUGW-dsRed plasmid to 
Jurkat cells. Both nanoparticle formulations were successful in delivery of specific CD4 
targeted FUGW-dsRed as determined by immunofluorescence.  Chitosan nanoparticle 
formulation proved to be more effective due to the lower cell toxicity. The optimal 
amount of VLB12 adsorbed to the nanoparticles gave a 16 % positive dsREd fluorescent 
population with specific VLB12 targeting. 
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To evaluate the vaccine antigen properties, of VLB12 the mucosal immunity was tested 
by using encapsulated VLB12 in nanoparticles of chitosan in comparison with 
subcutaneous routes with aluminium adjuvant and without adjuvant. Th1 or Th2 
responses were evaluated by the ratio of antigen-specific IgG2a-IgG1 in the serum 
samples. HIV-1 neutralization assays using serum from different groups to evaluate the 
VLB12 as potential vaccine antigen were performed but the serum presented no 
inhibitory effect on HIV-1NL4-3. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: HIV-1, single domain antibody, entry inhibitor, nanoparticles, vaccine.  
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Introduction 
1  General Introduction 
The Acquired Immune Deficiency Syndrome (AIDS) is now a major public health 
problem worldwide, having contracted the disease more than 60 million people since its 
discovery in 1981, one third of whom subsequently died.
1,106
   
The etiological agents responsible for AIDS are the human immunodeficiency virus 
type-1 and type-2 (HIV-1 and HIV-2). The first agent to be isolated was  HIV-1
21,113
  in 
1983. In 1986 HIV-2 was identified,
69,70
 having similar biological properties to those of 
HIV-1, but a greater genetic homology with Simian Immunodeficiency Virus than with 
HIV-1. This translates into a significant difference in some of its molecular and 
antigenic properties.   
HIV-1 is more virulent and has higher transmission rates than HIV-2, which explains 
why HIV-1 is responsible for a worldwide pandemic and HIV-2 accounts for more 
localized epidemics, particularly in countries of West Africa and in some European 
countries such as Portugal.
69,70
 Only HIV-1 will be studied in this Thesis.  
HIV-1 has the ability to infect cells that have a specific receptor, cluster of 
differentiation 4 (CD4), and chemokine co-receptors, especially CCR5 and CXCR4, 
which are mainly on the surface of CD4
+
 T lymphocytes.
26,162
  Other cells that express 
these receptors and likely to be susceptible to HIV-1 are, for example, cells of the 
mononuclear phagocytic system, particularly monocytes, macrophages, B lymphocytes 
and dendritic cells.   
The cell tropism of HIV suggests that once infection is established it will be very 
difficult to eliminate the virus from the body. This leads to progressive destruction of 
the immune system, leading to AIDS, with its multiple opportunistic infections, and/or 
complications such as neurological disorders and cancer. With this type of 
epidemiological characteristics it is imperative a commitment to a preventative therapy 
or acting in the early stages of infection.
106,323
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Despite the stunning advances in the treatment of AIDS, especially since the 
introduction of highly active antiretroviral therapy (HAART) in 1996, current therapy 
cannot completely eradicate HIV-1 from the body, resulting in long-term toxicity and 
eventually leading to the emergence of drug-resistant HIV-1 strains. These problems 
prompt the search for potent new drugs that are active against drug-resistant viral 
strains. Among these drugs appears a new class, the entry inhibitors.  
The monoclonal antibody therapy has had an important development in recent years 
particularly with regard to new therapeutic approaches for treating HIV infection and 
AIDS.  This form of therapy can be complementary and add to the effectiveness of the 
existing drugs. Studies with "natural" antibodies (hmAbs) that neutralize  the virus by 
binding to conserved epitopes of gp120 or gp41 proteins have shown a half-life of 50 to 
100 times higher than fusion inhibitor peptides, showing no toxicity associated with 
pharmacological anti-HIV drug therapy.
17,171,239,266,320
 
This type of strategy is a priority in the activities of the Unit of Retrovirus and 
Associated Infections (URIA) of the Faculty of Pharmacy of Lisbon, particularly in 
identifying new forms of biological therapies against HIV-1, and specifically the 
identification of recombinant antibodies against various therapeutic targets, whose 
large-scale production is easily optimized. Thus, it will be presented and discussed in 
this Thesis a new way to inhibit the infectivity of HIV-1 using synthetic recombinant 
antibodies with inhibitory capacity of the entry process. Moreover the potential for other 
therapeutic applications was also explored for one of these molecules, in particular as 
part of a new therapeutic delivery system and also as a vaccine antigen.  
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1.1 Human Immunodeficiency Virus type 1 
1.1.1 Genetic structure   
HIV-1 belongs to the genus Lentivirus and family Retroviridae. These are enveloped 
viruses with a nucleocapsid that resembles a truncated cone. They have a diploid 
positive-strand RNA genome which replicates via a double strand DNA intermediate 
(reverse transcription), being afterwards integrated in the host genome in the form of a 
provirus. These features are common to all retroviruses.
222,322,344
   
 
Figure 1.1– Genetic organization of HIV-1. 
(Reprinted with permission from: W.H. Freeman and Company, copyright (2006)).
176
 
The genome of HIV-1 is composed of three essential genes, gag, pol and  env, the 
regulatory genes tat and rev, four accessory genes, nef, vif, vpr and  vpu, and two 
identical sequences, called long terminal repeats (LTRs) flanking the 
genome.
222,322,323,352
   
The gag and pol genes are translated into long precursor polyproteins (Figure 1.1). The 
gag gene codes for a precursor polyprotein of 55 kDa (p55) that is subsequently cleaved 
by the action of the viral protease giving rise to the major internal structural proteins, 
designated matrix (p17, MA),  capsid (p24, CA), nucleocapsid p7 (NC) and p6. After 
cleavage the Gag-Pol precursor polyprotein gives rise to the protease (p10, PR),  reverse 
transcriptase (p66/p51, RT) and integrase (p31, IN) .
322
   
The product of the env gene is translated in the form of a precursor of 160  kDa (gp160) 
that is subsequently cleaved generating the two subunits of the viral envelope, the 
surface glycoprotein (gp120, SU) and the transmembrane glycoprotein (gp41, TM).
93
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The tat and rev regulatory genes give rise, respectively, to the Tat (p14) and Rev (p19) 
proteins. The Tat protein is a trans-activator of transcription that increases the 
processivity of RNA polymerase II. The Rev protein is the regulator of expression that 
inhibits the splicing of viral RNAs and is also involved in the translocation to the 
cytoplasm of RNAs that did not undergo splicing.
322,352
   
The down-regulating factor (Nef), the viral infectivity factor (Vif), viral protein R (Vpr) 
and protein U (Vpu) are all small accessory proteins encoded  respectively by genes nef, 
vif, vpr and vpu, and each play more than one  function in the replication cycle of    
HIV-1.
322,323
   
 The Vif protein averts the lethal threat of deamination, precluding the packaging of 
APOBEC3G (A3G) into assembling virions by mediating its proteasomal 
degradation.
238
  Vpr functions early in the viral life cycle, in the transport of the PIC to 
the nucleus. Vpr has several other critical functions including activation of HIV-1 LTR 
transcription, cell-cycle arrest due to DCAF-1 binding, and both direct and indirect 
contributions to T-cell dysfunction. 
165,233
 Vpu enhances virus budding and degrades 
cellular CD4.
37
  Nef also has similar functions, and appears to be required for disease 
induction in vivo.
108
 
The LTR regions are important for replication and transcription of viral RNA.  These 
sequences are divided into three parts: U3 (derived from a unique sequence of the 3' 
region of the viral RNA), R and U5 (derived from a unique sequence of 5' region of the 
viral RNA). The LTR sequences include promoters, enhancer elements and other 
genomic sequences used to connect to different cellular transcription factors.
222
 
  
1.1.2 Morphology   
HIV-1 is a virus whose virions have an icosahedral structure of about 100 nm in 
diameter. The mature virion consists of an outer layer, called the viral envelope, which 
derives from the host cell membrane and is acquired during their release (budding) of 
the cell. The viral envelope is formed by a lipid bilayer impregnated with some human 
proteins, such as Major Histocompatibility Complex (MHC) proteins, and viral 
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glycoproteins gp120 and gp41 that form a trimer of heterodimers and whose function is 
to mediate the entry process allowing the virus to infect target cells.
327
    
The coating of the inner viral envelope is the matrix protein (MA). In the center there is 
a nucleo-shaped truncated cone, formed by p24 (CA), within which there are two copies 
of the viral genome. The single-stranded RNA copies associate with one another by 
base-pairing near its 5 'end. Each of these molecules is coupled with a transfer RNA 
(tRNA lysine) which acts as an oligonucleotide to initiate reverse transcription of viral 
RNA. The viral RNA forms a ribonucleoprotein complex with NC, p6 and a few 
molecules of IN, PR and RT.  Nef, Vif and Vpr are also incorporated in the viral particle 
(Figure 1.2).
72,176,327
  
 
Figure 1.2 - Schematic representation of the HIV-1 virion. 
(Reprinted with permission from Elsevier science, copyright (2009)).
179 
 
1.1.3 Replication Cycle   
HIV-1 has a typical retroviral life cycle, divided into two phases: the early phase and the 
late phase. The early phase begins with the recognition of the target cell by the mature 
virion and involves all processes leading to and including integration of the genomic 
DNA into the chromosome of the host cell. The late phase begins with the regulated 
expression of the integrated proviral genome and involves all processes up to and 
including virus budding and maturation (see Figure 1.3).
322
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The first step in HIV-1 infection is the Env mediated direct fusion of the viral 
membrane with the plasma membrane of the host cells. The Env glycoproteins
62,89,114,355
 
are organized into trimeric spikes,
342
 anchored to the viral membrane by the gp41 
transmembrane protein. The Env glycoprotein gp120, forms surface trimeric spikes, 
which are associated by noncovalent interactions with each subunit of the also trimeric, 
and normally hidden, gp41.
169
 
 
Figure 1.3 - Steps involved in HIV-1 replication. 
(Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Immunol, copyright (2004).) 
364
 
 
The fusion process begins with the binding of gp120 to the CD4 cellular receptor. The 
binding of gp120 to CD4 induces conformational changes in gp120, exposing the 
chemokine receptor binding site and promoting the interaction between gp120 and the 
chemokine receptor, usually CXCR4 or CCR5. This interaction subsequently induces 
conformational changes in gp41 that result in an active conformation of the fusion 
peptide (fusogenic conformation) promoting the fusion of the cellular and viral 
membranes. 
16,237,277,285,322,369
 Membrane fusion is followed by the release and uncoating 
of the HIV capsid into the cytoplasm of the host cell. Completion of uncoating leads to 
the formation of the reverse transcription complex (RTC), composed of viral RNA, 
reverse transcriptase, integrase, tRNA
lys3
, MA, nucleocapsid (p7), Vpr (Viral protein R) 
                                                                                                                                                      Introduction 
8 
 
and several host proteins.
111,317,327
   Reverse transcription is performed by RT, which 
copies the viral RNA template into a complementary double strand DNA. To initiate the 
synthesis of viral DNA, a oligonucleotide of cellular origin is used, tRNA
lys3
. The 
binding site of the lysine tRNA is designated primer binding site (PBS) and is located in 
the 5 'end of the unspliced viral RNA.
163,193
  The process of synthesis also depends on 
NC, MA and the accessory protein Vif.
322
   
Once synthesized, the viral DNA is transported to the nucleus as part of a preintegration 
complex (PIC), containing the viral proteins IN, MA, RT and Vpr and the cellular 
protein High Mobility Group protein I(Y) (HMG-I (Y)).
317,322
 The integration of HIV 
DNA into the host cell chromossome, giving rise to the provirus, is promoted by the 
catalytic activity of IN.
111,190,317,322
  
The provirus thus becomes an integral part of the host cell genome and is treated by the 
cell as a cellular gene. After integration, the provirus may either remain latent 
(post‐integration latency) or become transcriptionally active. The provirus acts as a 
template for the synthesis of viral RNA that can be subsequently used as genomic RNA 
for virion progeny or translated into viral proteins.
322
 HIV‐1 transcription is controlled 
by the inducible viral promoter located at U3 of 5´LTR.300 
The transcription of the viral DNA is mediated by cellular RNA polymerase II and 
involves regulatory sequences in the region of the 5'- LTR U3 viral promoter, which 
functions as an activator of transcription,  since it has binding sites for several cellular 
transcription factors.
317,322,327
  
The late phase of the replication cycle begins with the synthesis of spliced and 
unspliced mRNAs that are transported out of the nucleus to be translated.  Transcription 
from the HIV-1 LTR leads to the generation of  three major classes of viral RNAs:
264
 
 1) unspliced RNAs, which function as the mRNAs for the Gag and Gag-Pol 
polyprotein precursors, and are packaged into progeny virions as genomic RNA;  
2)  partially spliced mRNAs, which are around 5 kb in size and encode the Env, Vif, 
Vpu, and Vpr proteins; 
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3)  small (1.7 to 2.0 kb), multiply spliced mRNAs, which are translated into Rev, Tat, 
and Nef.  
Initially, only short spliced RNAs are translated and these code for proteins Tat, Rev 
and  Nef.
322,327
 Since most cellular mRNAs are fully spliced before their transport out of 
the nucleus, the need for unspliced and partially spliced RNAs in the cytoplasm has 
been overcome through the evolution of viral protein, Rev (for “regulator of expression 
of viral proteins”), and a cis-acting RNA element, the Rev responsive element (RRE). 
The RRE is a large (250 nucleotide), highly structured RNA element that is located in 
the env gene and is present in all unspliced and partially spliced HIV-1 RNAs. 111,255    
The basal transcriptional activity from the HIV LTR is very low and RNA synthesis is 
greatly increased (by more than two logs) when the transcriptional transactivator protein 
Tat is present.
111,149
 When sufficient amounts of Rev protein are produced, Rev binds to 
the the Rev‐responsive element (RRE) of the unspliced or single‐spliced RNAs, leading 
to the formation of a protein complex that interacts with the cellular nuclear export 
machinery, consequently promoting unpliced or partially spliced RNA transport out of 
the nucleus, for translation in the cytoplasm.
111,338
  
Following the synthesis of the full complement of viral proteins, the assembly process 
begins. The major player in virus assembly is the Gag precursor polyprotein, 
Pr55
Gag
.
115,149
 The Gag polyprotein is synthesized in the ribosomes from unspliced 
RNAs and a translation frameshift leads to the formation of smaller amounts of Gag‐Pol 
precursor proteins.
322
 Gag polyprotein is the major responsible for the assembly of new 
immature viral particles. This protein contains determinants that target it to the plasma 
membrane, bind the membrane itself, promote Gag-Gag interactions, encapsidate the 
viral RNA genome, associate with the viral Env glycoproteins, and stimulate budding 
from the cell.
30,41,111
 
The assembly of lentiviruses, including HIV-1, takes place at the plasma membrane of 
the infected cell. During assembly, Gag is targeted to the plasma membrane.  The 
anchored Gag leads to the induction of Gag multimerization and subsequently 
incorporation of the viral genomic RNA, Env glycoproteins and Gag‐pol precursor into 
the viral particle.
41,111,322
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The MA domain is responsible for the targeting of Gag to the plasma membrane and for 
the incorporation of gp120‐gp41 complexes and Gag‐Pol precursor into the viral 
particle, whereas the C‐terminal domain of CA (CA‐CTD) and NC are responsible for 
Gag multimerization.
111
  In addition,NC as part of the Gag polyprotein, speciﬁcally 
binds the genomic RNA via tight interactions between its zinc‐finger motifs and the Psi 
packaging signal located in the 5’ leader sequence. These speciﬁc NC–RNA molecular 
interactions are thought to promote genomic RNA dimerization leading the RNA 
genome for packaging into the virions.
86,236
 Viral enzymes, accessory viral proteins, the 
cellular tRNAlys3 primer and cellular proteins also associate to the immature core for 
incorporation into the viral particle.
3,30,149
 Subsequently, the immature core associated to 
the plasma membrane suffers budding through the plasma membrane. The P6 protein 
helps in this process by recruiting the Endosomal Sorting Complex Required for 
Transport (ESCRT), facilitating fission of virions from the plasma membrane to the 
extracellular medium.
82,221,310
  
In contrast to all the other viral proteins, the Env precursor polyprotein (gp160) is 
synthesized in the endoplasmic reticulum (ER) where CD4 molecules are also present. 
To prevent the premature binding of Env to CD4, the CD4 molecules are targeted for 
removal by Vpu and Vpu signals their degradation via the ubiquitin-proteasome 
pathway.
36,322
 The binding of Env to CD4 in the ER would prevent the translocation of 
Env to the cell membrane and the formation of fully functional  gp120‐gp41 
trimers.
36,322
 Gp160 is translated from the single spliced env mRNA and suffers 
posttranslational modifications in the ER and in the Golgi apparatus. During trafficking 
through the Golgi, gp160 is cleaved by a host cell protease generating the mature gp120 
and gp41 proteins that subsequently form trimeric non-convalent complexes 
(gp120‐gp41). These complexes are transported to the cell surface via the secretory 
pathway and gp41 protein anchors the complexes in the cell membrane for virus 
assembly.
36,322
 
New viral particles can be produced and released through the cell membrane (budding), 
which after suffering a process of maturation become infectious, and can infect new 
cells.  However, when integrated into the host's genetic material, there is the possibility 
of HIV remaining dormant for many years.
322
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1.2  The fusion process: a crucial step in HIV infection 
To initiate a new infection, mature virus particles need to encounter a potential 
target cell that expresses the appropriate receptor structures. In the case of HIV, these 
are the CD4 molecule found primarily on T lymphocytes, macrophages and dendritic 
cells. Although the virus binds to CD4 on the cell surface, this interaction alone is not 
sufficient for entry and productive infection. Expression of other cell-surface molecules, 
designated co-receptors, is required for HIV-1 infection.
176
  
The entry of HIV-1 into a target cell involves three distinct stages: binding of 
gp120 to CD4, binding of gp120 to a co-receptor, and gp41-mediated fusion of the viral 
and host membranes. 
The discovery that CXCR4 and CCR5 serve as co-receptors for HIV-1 on T cells 
and macrophages, respectively, explained why some strains of HIV-1 preferentially 
infect T cells (T-tropic strains) while others prefer macrophages (M-tropic strains). A T-
tropic strain uses CXCR4, while the M-tropic strains use CCR5.
176
 
As previously mentioned the fusion process begins with the binding of gp120 to the 
CD4 cellular receptor. CD4 binding results in a major reorganization of the Env trimer, 
causing an outward rotation and displacement of each gp120 monomer. 
195
 
Since the first step in HIV infection involves both cellular and viral proteins, to 
understand the process it is necessary to identify all the proteins involved and the part 
each protein represents in this crucial step of the virus life cycle. 
 
 
Figure 1.4 – Simplified schematic representation of the current model for the fusion mechanism 
between HIV-1 and the target cell. 
(Adapted with permission from ©Dooms et al., 2000. Originally published in The Journal of Cell 
Biology. 151:9–13).93 
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1.2.1 The CD4 receptor – targets of opportunity 
Cluster determinant 4 (CD4) is a transmembrane glycoprotein of 58 kDa, 
composed of four immunoglobulin-like extracellular domains spanning 370 amino 
acids, a transmembrane segment of 25 amino acids and a cytoplasmic tail of 38 amino 
acids at the C-terminal end (Figure 1.5).
36,201
 The other three domains are less closely 
related to Ig molecules at the level of primary structure but fold similarly to Ig family 
domains, confirming that CD4 is a member of the Immunoglobulin like 
superfamily.
68,201,202,349
 Post-translational modiﬁcations of CD4 include the formation of 
disulﬁde bonds which stabilize the D1, D2, and D4 domains and the addition of two N-
linked glycans between D3 and D4.
201
 
 
Figure 1.5 - Schematic representation of the CD4 molecule.  
The major structural features of the CD4 molecule are shown, including the D1-to-D4 
immunoglobulin-like domains and the two N-glycosylation sites (●——●). The cysteine residues 
involved in disulfide bonds (S– – –S) are indicated by arrows together with their location in the 
amino acid sequence. The T-lymphocyte-specific protein tyrosine kinase p56
lck  
is also partially 
depicted (Reprinted with permission from American Society for Microbiology, copyright (1995)).
36
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As an important component of the immune system, CD4 functions as a co-receptor of 
the T cell receptor (TCR) on the surface of CD4
+
   T cells for stronger association with 
the class II major histocompatibility complex (MHC II) on antigen-presenting cells 
(APCs). This association is sufficient to trigger T-cell signaling transduction resulting in 
activation of the CD4
+ 
 T cells.
64
 The CD4 molecule uses its D1 domain to interact with 
the β2-domain of MHC class II molecules.
53,167
 
More importantly, epitope mapping of CD4 substitution mutants with MAbs showed 
that a small region, containing amino acids 41 to 52 of human CD4 D1, was involved in 
gp120 binding.
288
 Despite extensive homology with human CD4, mouse CD4 (L3T4) 
cannot bind gp120.
36
 
Other studies, performed with substitution of nonconserved amino acids from the mouse 
CD4 D1 domain onto human CD4 showed that residues 38 to 57, located in a region 
analogous to an Ig light-chain variable domain (CDR2), were indispensable for gp120 
binding.
71,185
  Studies, in which CD4 mutants were selected through loss of reactivity 
with MAbs against different CD4 epitopes, showed that binding of gp120, as measured 
by syncytium formation, required residues 42 to 49 in the CDR2 domain.
250
 
  Finally, with the resolution of the atomic structure of the D1 and D2 domains of 
CD4 
282,335
 it was possible to assess that four charged residues (Lys-29, Lys-35, Lys-46, 
and Arg-59) and one hydrophobic phenylalanine at position 43 were essential for gp120 
binding.
66,214,321
 These five amino acids are predicted to form a hydrophobic pocket by 
holding the four charged amino acids around the hydrophobic phenylalanine residue, a 
structure that may be involved in direct contact with gp120.
214,283
   
Several studies have demonstrated that only aminoacids located in the D1 domain of 
hCD4 are required for gp120 binding.
183,282
 Interestingly, a monoclonal antibody that 
blocks HIV-1 entry by binding to D2 domain of human CD4 has been identified.
88,181,301
  
This antibody has the commercial designation of Ibalizumab and is a humanized IgG4 
monoclonal antibody that was engineered from its mouse progenitor (5A8) by grafting 
the mouse complementary-determining region (CDR) onto a human IgG4 construct. 
301
 
This shows that in spite of the fact that only the D1 domain of hCD4 is required for 
gp120 binding, antibodies that bind the D2 domain can impair the CD4-gp120 
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interactions and effectively blocking HIV-1 entry into the target cell.
112
 On the contrary, 
antibodies that bind the D3 domain of hCD4, like the OKT4 clone,
59,116
  do not block 
HIV-1 entry.
269
 
To date only antibodies that target D1 or D2 domains of hCD4 have been found to 
possess the ability to block HIV-1 entry into the target cell, as these domains appear to 
be the ideal targets for an antibody based HIV-1 inhibition strategy that targets the CD4 
receptor. 
 
1.2.2 Viral surface glycoprotein (gp120)  
Env is a heterodimer of a transmembrane glycoprotein (gp41) and a surface 
glycoprotein (gp120) and forms trimers on the surface of the viral membrane. There is, 
however, evidence that other envelope species may also be present on the surface of 
HIV-1.
242
 Although trimers may likely represent the functional envelope spike, both 
functional and nonfunctional forms of the envelope may be present on the virion 
surface. These nonfunctional envelope entities may be monomers, dimers, or tetramers 
and could arise as the result of the dissociation of functional gp120-gp41 complexes, 
perhaps causing gp120 to be shed from the viral surface, or inefficient trimerization of 
the spike in the Golgi.
46,244,356
  
CD4 binding results in a major reorganization of the Env trimer, causing an outward 
rotation and displacement of each gp120 monomer. This appears to be coupled with a 
rearrangement of the gp41 region along the central axis of the trimer, leading to closer 
contact between the viral and target cell membranes.
195
 
In its native state, gp120 is composed of two distinct regions: an inner domain, involved 
in interactions with gp41 and the formation of trimeric envelope spikes, and an outer 
domain that forms a large part of the exposed surface of the spikes and is extensively 
glycosylated (see Figure 1.6 and Figure 1.7).
187,241
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Figure 1.6 - Model of the gp120 component of the trimeric HIV-1 envelope spike based on the 
structure of core gp120, with three gp120 monomers shown in purple, green, and pink. 
Carbohydrate chains are shown in yellow.( Reprinted with permission, Copyright (2010) National 
Academy of Sciences, USA).
95
 
 
The gp120 protein contains five variable regions (V1-V5)
213,304,348
 and five conserved 
regions (C1 –C5). The conserved domains contribute to the core of gp120 (inner 
domain), while the variable domains (and numerous N-linked glycosylation sites) are 
located near the surface of the molecule (outer domain).
315
 
 
Figure 1.7 - Core gp120 showing the inner domain, outer domain, and bridging sheet 
(Reprinted with permission from Elsevier science, copyright (2010)).315 
                                                                                                                                                      Introduction 
16 
 
The gp120 C1 and C5 regions are considered to be the main areas on gp120 for contact 
with gp41, since these regions are accessible to antibody on monomeric gp120 but not 
on gp120-gp41 complexes.
132,218,220
 Major segments of the C2, C3, and C4 regions were 
proposed to form a buried, relatively hydrophobic core within the gp120 molecule. This 
gp120 core harbors several discontinuous neutralizing antibody epitopes that overlap 
the binding sites for CD4, and for the coreceptor.
218,219,235,254
 In contrast to the 
conserved regions, the variable regions (in particular, V1, V2, and V3) are predicted to 
be well exposed on the surface of monomeric gp120.
218,241
 Deletion of V1/V2 and V3 
generally increases the binding affinity of antibodies to epitopes that overlap the 
binding sites for CD4 and the coreceptor, which suggests that these variable regions 
may shield conserved epitopes from efficient antibody recognition.
54,311,354,357
 Regarding 
the V4 and V5 variable regions, no definitive role has been ascribed; although deletion 
of the V4 region has been shown to disrupt gp160 folding,
254,357
 V4 also seems to 
tolerate insertion of foreign antibody epitopes which increase virus neutralization 
efficiency.
270,337
   
The gp120-CD4 interaction induces a conformational change in the V3 loop of gp120 
exposing an envelope epitope that binds a chemokine receptor, inducing conformational 
changes in gp41 that result in an active conformation of the fusion peptide (fusogenic 
conformation).
277,369
 
 
Figure 1.8 – Tridimensional representation of the interaction between CD4 and gp120.  
(Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Microbiol., copyright (2008)). 
154
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Binding of CD4 to gp120 (Figure 1.8) induces significant conformational changes that 
result in the formation of a third domain termed the bridging sheet. This domain 
consists of two pairs of anti-parallel -sheets that link the inner and outer domains, and 
plays a major role in interacting with the viral co-receptors.
273
 
 
1.2.2.1 The CD4 binding site 
The binding site for CD4 on the liganded gp120 structure is formed by the interface 
between the inner domain, bridging sheet, and outer domain.
183,353
 At the center of this 
interface lies a hydrophobic cavity that has been dubbed the Phe43 cavity.
183
 
 However, most of the CD4 contact residues are located on the outer domain of the 
liganded HIV-1 gp120 structures and form a contiguous binding region. The location of 
these conserved residues likely minimizes their immediate recognition by antibodies, 
while preserving the ability to contact CD4. The CD4 binding site (CD4bs) is not 
coherently present on the unliganded structure. It indeed seems likely that gp120 
transiently samples conformations that are reflective of the liganded structure; upon 
interaction with CD4, the gp120 structure is locked in the bound conformation.
242
 
 
1.2.2.2 The co-receptor binding site 
The region that is important for the interaction with the β-chemokine receptor CCR5 has 
been mapped to residues in the bridging sheet and near the V3 stem.
272,274
 Only one 
amino acid change is necessary for co-receptor switch from CCR5 to CXCR4. These 
residues are closer together on the liganded HIV-1 gp120 structure, than in the predicted 
unliganded gp120 structure.
63,336
 These differences are consistent with the notion that 
CD4 binding is required to lock these areas into a contiguous binding site. The fact that 
the coreceptor site is not presented until after CD4 binding suggests that the site may be 
susceptible to antibody recognition.
242
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1.2.3 Viral transmembrane protein gp41    
The viral transmembrane protein gp41 promotes HIV-1 entry by mediating the fusion of 
viral and cellular membranes. The primary structure of gp41 contains an amino-terminal 
domain (ectodomain), a single transmembrane domain (TM) and a cytoplasmic tail 
(Cyto).
114,277,369
  
The gp41 ectodomain consists of an amino-terminal fusion peptide and two segments of 
hydrophobic heptad repeat (HR) sequences.
98
 The fusion peptide is approximately 20 
amino-acid in lenght, rich in glycine and hydrophobic residues and is believed to insert 
into the target cell membrane following receptor activation of Env.
277,285
 
The heptad repeat sequences are designated first heptad repeat (HR1) and second heptad 
repeat (HR2), these are segments with 40 to 60 amino acids and are found immediately 
after the fusion peptide (HR1) and preceding the gp41 transmembrane domain (HR2). 
120,277,369
 
In its native conformation the core of the isolated gp41 ectodomain is a bundle of six -
helices derived from three gp41 ectodomains. The N-peptides (HR1) form a central, 
three-stranded coiled coil. The C-peptides (HR2) pack as -helices in an antiparallel 
direction into hydrophobic grooves formed at the outer interface of two N-peptides.
114
 
When gp41 is in its native conformation most of its extracellular amino-terminal 
domain is “inaccessible” due to the presence of the gp120 surface protein. The gp41 
structural changes that result in the fusogenic conformation start with the extension of 
gp41, exposing the HR1 and HR2 regions and enabling the insertion of the fusion 
peptide into the target cell. Afterwards, this intermediary structure collapses, forming 
the trimer of heterodimers, or six-helix bundle, and the fusion between the viral and 
cellular membranes occurs.
277,369
 
The fusion mechanism (Figure 1.4) is not yet fully understood, it is still unclear if the 
membrane fusion occurs before, concurrent with, or after gp41 collapses into the six-
helix bundle. But it is clear that both the binding to CD4 by gp120 and the gp41 fusion-
mediated structural changes are crucial to the fusion process. 
98,114,369
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1.3 Antiretroviral therapy for treatment of HIV-1 infection  
 
Over the past decades, the growing knowledge of the mechanisms of HIV-1 infection, 
led to the development of antiretroviral drugs that until recently were restricted to 
reverse transcriptase inhibitors and protease inhibitors. The reverse transcriptase 
inhibitors are divided into two groups: nucleoside analogues, which act as alternative 
substrates, being incorporated by reverse transcriptase in the nascent DNA chain, 
interrupting the polymerization reaction, and non-nucleosides, which inhibit the 
functioning of the enzyme by other mechanisms.
222
  
 
Protease inhibitors block the morphogenesis of the virion, inhibiting the 
cleavage of Gag polyproteins and Gag-Pol. The evolution of antiretroviral therapy has 
led to the development of a treatment regimen called HAART (Highly Active 
Antiretroviral Therapy) which is the combination of three or more drugs of the 
following antiretroviral classes: reverse transcriptase inhibitors, protease inhibitors and 
more recently an entry inhibitor. The use of combination HAART can increase the 
therapeutic effectiveness but cannot eradicate HIV-1 from the body which results in 
long-term toxicity and inevitably leads to the emergence of resistant strains, as well as 
being associated with a high level of severe side effects.
222,249,306
  These problems lead 
to the demand and development of new drugs against HIV-1, especially against HIV-1 
strains resistant to currently used drugs. There are several compounds in development 
and in clinical or preclinical trials, acting at various stages of the life cycle of HIV-1: 
the virus adhesion to the cell, the binding of gp120 to the CD4 receptor, gp120 binding 
to the co-receptor, fusion of the viral envelope with the cell membrane, formation of the 
viral particle, reverse transcription, nuclear import of the PIC, integration of proviral 
DNA, among others.
4,104,151,253,263,267,298
  
 
From the demand for new therapeutic approaches emerged a new class of drugs, the 
HIV-1 entry inhibitors (see Section 0). These compounds have a mechanism of action 
different from other classes of antiviral drugs since they act outside the CD4
+
 T cells in 
order to prevent HIV-1 from infecting the cell.
256,277,316
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 Due to the characteristics and nature of HIV-1 infection, including the ability to 
establish reservoirs in various cell lines, progressive and irreversible destruction of the 
immune system associated with an increased prevalence of strains resistant to drug 
therapy, one of the priority areas in the development of new drugs has been the 
development of new molecules, which prevent viral entry into cells, including peptides 
and antibodies that prevent the entry process.  
 
Figure 1.9 - Approved anti-retroviral drugs for the treatment of HIV-1 infection. 
 (Reprinted with permission from Elsevier science, copyright (2010)) 315 
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1.4 Entry inhibitors  
 
Drugs that block HIV-1 entry are collectively known as entry inhibitors, but comprise a 
complex group of drugs with multiple mechanisms of action. Entry inhibitors can target 
the gp120-CD4 interaction, coreceptor binding or the fusion process (Figure 1.10). 
 
Figure 1.10 - Simplified schematic representation of the current model for the fusion mechanism 
between HIV-1 and the target cell, and its inhibition by entry inhibitors. (Adapted with permission 
from Biomed Central, Copyright (2009)). 
211
 
 
1.4.1 Inhibitors of gp120-CD4 interaction 
Several strategies have been pursued in order to block the interaction between gp120 
and CD4. So far none has resulted in a clinically useful anti-HIV drug. One of the first 
strategies was the development of recombinant soluble CD4 (rsCD4) molecules, which 
function as molecular decoys inhibiting the ability of gp120 to attach to cell-associated 
CD4. Despite good activity in vitro against lab-adapted HIV-1 strains, in vivo the levels 
of recombinant sCD4 were too low to inhibit primary isolates.
78,316
 Other attempts were 
made, using variations that mimic the CD4 receptor, like a tetravalent CD4-IgG2 fusion 
protein, comprising human IgG2 in which the Fv portions of both heavy and light 
chains have been replaced by the V1 and V2 domains of human CD4 (PRO-542).
7,363
 
PRO-542 presented only modest reductions in HIV-1 viremia in phase I and II clinical 
trials and it was not persued.
180
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Another entry inhibitor, BMS-488043
105,180,204,281,315
 (a follow-up molecule from BMS-
378806 with improved pharmacokinetic properties) is a small-molecule that binds with 
great affinity to a specific region within the CD4 binding pocket of gp120 and seems to 
prevent the CD4-induced conformational changes in gp120.
194,200
 It has strong antiviral 
activity against HIV-1 subtype B but is less active against other subtypes and inactive 
against HIV-2 
124,200
  and the development of this molecule stopped at phase II trials. 
Ibalizumab (TNX-355) is an anti-CD4 monoclonal antibody that binds to the D2 
domain of CD4.
217
 It acts as a post-attachment inhibitor such that instead of preventing 
gp120-CD4 binding it seems to decrease the flexibility of CD4 and affects gp120 
dissociation.
180
 
 
1.4.2 CCR5 antagonists 
CCR5 antagonists’ development has been actively pursued, since the 32-CCR5 
mutation confers resistance to HIV-1 infection in homozygous individuals (or delayed 
rates of disease progression in heterozygous patients) without significant clinical 
impact. This has encouraged different approaches of pharmacological blockade of the 
gp120-CCR5 interaction in an effort to inhibit HIV infection.
316
 CCR5 antagonists can 
be divided in three groups according to the size of the molecule: large molecules, such 
as the PRO-140, an anti-CCR5 monoclonal antibody; medium size molecules, e.g. 
AOP-RANTES and PSC-RANTES, derivatives of RANTES, a CCR5 natural ligand; 
and small-molecules, like TAK-779, Maraviroc and Vicriviroc.
40,316
 PRO-140 is a 
strong inhibitor of HIV-1 B and non-B subtypes and is currently on phase II clinical 
trials and will be further discussed in Section 1.6.
40,105
  
Vicriviroc (SCH-D) is an orally bioavailable second-generation compound (based in a 
previous molecule, SCH-C) highly active against a large spectrum of HIV-1 primary 
isolates, that made it’s way to phase III clinical trials. However, Vicriviroc didn’t 
achieve the primary efficacy endpoint of these studies and further development of 
Vicriviroc was suspended.
105,309,316
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Of all these, Maraviroc is the only coreceptor antagonist approved for clinical use in 
HIV infection. Maraviroc acts as a functional antagonist of CCR5. It inhibits the 
binding of the CCR5 natural ligands (like, MIP-1, MIP-1and RANTES), blocks 
chemokine-induced signal transducing events and once bound to CCR5 it does not 
trigger the release of intracellular calcium and fails to induce CCR5 internalization.
96
 
Maraviroc interacts with residues lining a cavity formed by the by the 2, 3, 6 and 7 
transmembrane helices of CCR5 ECLs.
57
 Maraviroc is only active against viruses using 
exclusively the CCR5 coreceptor, which limits its therapeutic usefulness. 
96
 
 
1.4.3 CXCR4 antagonists 
The development of CXCR4 inhibitors has proceeded more slowly than that of the 
CCR5 antagonists. Probably because, unlike for CCR5, there are no known naturally 
occurring mutations that lead to the absence of CXCR4. So, while there are numerous 
CCR5 antagonists with very different structures, the number of CXCR4 antagonists 
available is more reduced and their structure is similar to AMD3100, one of the first 
small molecules of this group to enter in clinical trials.
105,134,296
 Despite strong activity 
against X4 strains in vitro, the clinical development of AMD3100 was discontinued due 
to cardiac abnormalities.
133,134
 Subsequent studies resulted in the identification of 
AMD070, a compound orally bioavailable with similar antiviral activity to AM3100.
307
  
However, this molecule is no longer being developed due to results of abnormal liver 
histology in preclinical studies. Toxicities of these two compounds have raised the 
concern of the long-term safety of targeting CXCR4, since this coreceptor seems to be 
important for multiple physiological processes.
181,316
 Like SDF-1, the CXCR4 natural 
ligand, these antagonists are positively charged and of basic nature. They bind strongly 
to the negatively charged surface of the coreceptor, hampering its interaction with the 
gp120 glycoprotein.
97
 Like for CCR5 antagonists, the blockade of CXCR4 results in the 
shift from X4 to R5 phenotype in HIV-1 primary isolates.
103
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1.4.4 Entry inhibitors 
Enfuvirtide (T-20) was the first entry inhibitor to be used in antiretroviral therapy and 
currently no other entry inhibitor has entered the market. It is a 36 amino acid peptide 
that binds to the HR-1 region of the ectodomain of gp41, preventing the transition to a 
conformation critical for the fusion process, the trimer of harpins conformation.
277,313
 
C34 (34 amino acids) is a linear peptide that mimics the HR2 sequence and inhibits 
virus entry by binding to the HR1 core, exposed at prehairpin intermediate state of 
gp41, thereby blocking the subsequent formation of the six-helix bundle structure and 
viral fusion.
99,216
 Both T-20 and C34 inhibit virus-cell fusion and cell-to-cell contact at 
the nanomolar range.
61,346,347
 Although C34 displays stronger antiviral activity than     
T-20, the poor solubility of C34 under physiological conditions hindered its potential as 
a drug candidate.
52
 
Unlike, T-20 and C34, second generation peptides were developed based on the 
consensus sequences of not only HIV-1, but also HIV-2 and SIV strains. T-1249 is a 
representative second generation peptide with 39 amino acids that contains the three 
regions: the pocket-binding domain (PBD), the HR core (3HR) and the lipid-binding 
domain (LBD) and has potent activity against both HIV-1 and HIV-2.
102
 However, the 
clinical development of T-1249 was halted after phase I/II clinical trials apparently due 
to formulation issues, probably due to the production cost and reduced delivery 
efficiency.
205
 
Sifuvirtide, a peptide based in C34, is a good example of the third generation entry 
inhibitors.
131
 Sifuvirtide is now under development and showed promising results in 
phase II clinical studies being active against a broad range of HIV-1 isolates, including 
T-20- resistant strains. Although Sifuvirtide shows a better pharmacokinetic profile than 
T-20, it is still administered as a subcutaneous injection. 
131
 
Enfuvirtide was seen as a therapeutic alternative, particularly for the treatment of 
patients experiencing treatment failure, and despite the high cost of production was 
rapidly introduced in the market.
256,257,281,313
Shortly after the beginning of its clinical 
use cases of resistance to Enfuvirtide were identified.
256,257
 The main mechanism of 
resistance to Enfuvirtide is the appearance of mutations in the HR-1 region of gp41, 
particularly in a field of 10 amino acids located between residues 36 to 
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45.
212,256,257,277,365
  Enfuvirtide also presents problems in terms of bioavailability, 
derivatives of their biophysical properties and removal of many existing mechanisms in 
the human body. It is susceptible to proteolysis, it is immunogenic, and its structure 
allows for it to connect strongly to hydrophobic surfaces, especially to cell membranes. 
These factors contribute to a significant decrease in the levels of Enfuvirtide available to 
inhibit HIV-1 entry into cells and are probably responsible for the rapid emergence of 
resistant viruses.
277
  Despite the rapid emergence of enfuvirtide resistance, it continues 
to represent an important step in developing new therapeutic strategies and their use in 
synergy with other antiretrovirals in many cases continues to be an alternative therapy, 
which emphasizes the need for development of new entry inhibitors.  
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1.5 Antibodies  
1.5.1 The immune system and the origin of antibodies  
Antibodies are produced by B lymphocytes during a humoral immune response and 
play a key role in the immune system. The primary function of the antibody is to bind to 
the antigen. This link may in some cases have a direct effect of a bacterial toxin to 
inactivate or prevent the entry of a virus in a cell. On the other hand, the antibody lacks 
the ability to kill or eliminate an antigen, so it needs to use additional features.  
 
These additional features include effector functions, such as activating the complement 
system or interaction with a variety of cells such as macrophages and auxiliary T 
lymphocytes.
174,177
 Due to its specific binding to the antigen (an antibody is able to 
distinguish between two proteins that differ in only one amino acid), high affinity and 
also due to the fact that these are highly stable molecules and easily manipulated by 
genetic engineering, antibodies have been used in recent decades in various therapeutic 
and diagnostic applications.
172,175
 The ability to generate human antibodies that are not 
accessible by conventional monoclonal or polyclonal approaches has led to the 
development of antibody engineering. The selection of synthetic antibodies using 
techniques such as phage display or ribosome display led to the discovery of molecules 
which have a high potential for use as an alternative to conventional pharmacological 
therapy.
39,123,126,127,142,172
  
 
1.5.2 Structure and genetic organization of the antibodies  
1.5.2.1 Antibody  Structure  
Antibodies or immunoglobulins are composed of one or more monomer units. Each 
monomeric structure consists of a constant region (Fc – Fragment crystallizable) which 
determines the effector function and two antigen-binding fragments (Fab - Fragment 
antigen binding) that include the variable region (Fv) which determines the specificity 
(Figure 1.11).39,177  
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Figure 1.11- Modular structure of immunoglobulins. (Adapted with permission from Macmillan 
Publishers Ltd: Nature Reviews Drug Discovery, copyright (2003)).
39
 
 
Each monomer unit has, in turn, a common structure of four peptide chains. This 
structure is composed of two light chains (L) with an identical molecular weight of 
approximately 25 kDa and two heavy chains (H) with an identical molecular weight of 
50 to 70 kDa (Figure 1.12).
177
  
 
Figure 1.12- Schematic diagram of the structure of immunoglobulin G. 
The sequencing of immunoglobulins has shown that these sequences are composed of about 110 
amino acids, called domains, and these amino acid sequences are either highly conserved (C 
domains) while others are variable (V domains). (Reprinted with permission from: W.H. Freeman 
and Company, copyright (2006)).
177
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Through the analysis of conserved sequences it could be verified that there are two 
types of light chains (L), designated  and , and there are five different types of heavy 
chains (H), , , ,  and .39,177 
The light chains are composed of an amino-terminal variable domain (VL) and a 
constant domain (CL). On the other hand, the heavy chains are composed of an amino-
terminal variable domain (VH) and three constant domains (CH1, CH2 and CH3).
130
 The 
variable domains of light chains and heavy chains form the antigen binding region 
(Fab). Despite being designated variable domains, they do not have a homogeneous 
variability, since within the variable domains there are three segments called 
complementarity determining regions (CDR) 1, 2 and 3, which are highly variable, 
giving a greater degree of definition to the diversity and specificity of the antibody 
binding. The CDRs are in turn located between four very conserved segments, termed 
framework region (FR).  
The Fc region is distinct for each class of immunoglobulins, each composed of a class 
of different types of heavy chain:  (IgG),  ( IgM),  ( IgA),  (IgD) and  (IgE).  The 
Fc region is glycosylated and contains sites of interaction with effector molecules, such 
as the C1 complex of complement and a variety of Fc receptors, including FcRn, as well 
as molecules that determine the biodistribution of the antibody.
39,177
  The heavy chains 
are linked covalently in the Hinge region and light chains are in turn linked to the heavy 
chains by covalent bonds, also established by disulfide bridges and non-covalent bonds, 
such as hydrogen bonds.
177
 Each form, or isotype, of light chain can combine with any 
heavy chain isotype. However, in the same immunoglobulin molecule there is only one 
isotype either for the light chains, or for the heavy chains. Thus, each light chain is 
associated with the amino-terminal region of the heavy chain and form a unity Fab-Fc 
The unit consists of the carboxy-terminal halves of both heavy chains.
38
  
 
1.5.3 Antibodies  - Mechanisms of in vivo action  
The therapeutic methods based on the use of antibodies, aim to remove or neutralize a 
pathogenic infection or the pathogenic agent itself, for example bacterial, viral, or the 
case of oncological targets.
39
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The antibodies used for therapeutic purposes have three principal modes of action:
39
    
 blocking the action of specific molecules;   
 recognizing specific molecules as targets;  
 functioning as signaling molecules.  
The blocking activity of antibodies used for therapeutic purposes is achieved by 
preventing cytokines, growth factors or other cellular mediators to reach their target 
receptors. This blockage can be achieved through antibody binding to the target 
molecule or its receptor.
39
  
Target recognition involves the targeting of antibodies to specific populations of cells. 
The antibodies can be genetically modified to carry specific segments of effector 
molecules such as enzymes, toxins, radionuclides, cytokines or even DNA molecules, to 
the target cells where the effector molecule can exert its function (eg, radionuclides can 
selectively eliminate cancer cells).
39
  
The effector functions of natural antibodies are associated with binding to the Fc 
receptor or binding to complement proteins and induction of complement-dependent 
cytotoxicity (CDC).
39
 Depending on the therapeutic strategy used, antibodies designed 
to recognize specific targets may or may not maintain their effector functions.
39,138,160
  
The signaling effect of antibodies is attributed to the induction of cross-linking of 
receptors that are in turn linked to mediators of cell division or programmed cell death, 
or targeting them to specific receptors in order to act as antagonists for the activation of 
specific cell populations.
39
  
Another approach is the use of antibodies as means to deliver DNA or to deliver 
antigens to certain immune cells  that will process them and will present the antigens to 
T cells, in order to activate a specific immune response against that antigen.
39,160
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1.5.4 Production of polyclonal, monoclonal and recombinant antibodies 
Due to the potential use of antibodies as a low cytotoxicity, highly specific targeted 
therapy, various methods have been developed to obtain and produce antibodies with 
predefined specificities.
39
  
Most antigens have multiple epitopes which means that they induce the proliferation 
and differentiation of various B cell clones, each originating from a B cell that 
recognizes a particular epitope. That is, the resulting serum is composed of a mixture of 
antibodies, each specific to an epitope - a policlonal serum.
177
 
A polyclonal antibody response speeds up the target location, phagocytosis and 
complement-mediated lysis of antigen, and increases the protection that is generated by 
the immune system in vivo.
38,39
 
 For most in vitro uses, whether for diagnostic, therapeutics or research, it is more 
advantageous to use monoclonal antibodies derived from a single clone and specific to 
only one epitope.
38,39
  
In 1975 Georges Kohler and Cesar Milstein developed a method of preparing 
monoclonal antibodies through the fusion of a normal activated antibody producing B 
cell with a myeloid cell, which gave rise to a hybrid cell called a hybridoma, which had 
the growth properties of myeloid cells (immortalization) and excreted the antibody 
produced by the B cell. This method called mouse hybridoma technology was an 
important step in antibody technology and led to the emergence of monoclonal 
antibodies for therapeutic use.
39,177
  
Monoclonal antibodies from mice have proved to be of limited use for therapeutic 
purposes due to low residence times in serum, inability to activate human effector 
functions and production of human anti-mouse antibodies (HAMA response).
39,340
  In 
order to try to reduce the immunogenicity of mouse antibodies, genetic engineering was 
used, taking into account the existing knowledge on the structure of antibodies, to 
produce chimeric antibodies with human Fc regions and mouse Fv regions.
39,340
 While 
chimeric antibodies did not generate such an exacerbated immune response as mouse 
monoclonal antibodies, there continued to be a human anti-chimeric response (HACAs), 
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so it was still necessary to minimize the mouse component present in the 
antibodies.
39,160
 With the mapping of the complementarity determining regions (CDR), 
the mouse component could be restricted solely to the CDRs responsible for binding to 
the antigen. This was achieved by grafting the mouse CDRs into the  human variable 
domain framework.
39,160
  
The ability to manipulate the antibodies in order to maximize the human component 
while maintaining the properties of binding to the antigen provenient from other 
species, allowed for the clinical use of antibodies. The isolation of genes encoding 
human variable regions and their expression in Escherichia coli led to the emergence of 
techniques such as phage display technology which is still the most widely used method 
for selecting and producing antibodies from fully human variable domains.
29,39,207,299
  
 
1.5.5 Recombinant antibody fragments 
Recombinant antibodies that have been used in phage display technology, or other 
recombinant antibodies technologies, can be Fab (fragment antigen binding), scFv 
(single-chain variable fragment) or dAbs (single domain antibody). They have many 
advantages compared to immunoglobulins since:
172
 
• there is no binding / activation of the Fc receptor, which reduces its immunogenicity; 
 • the rate of tissue penetration is higher;  
• Fab, scFv or dAbs antibodies can be produced quickly in prokaryotes, including in E. 
coli. 
The Fab segments consist of VH-CH and VL-CL linked by disulfide bridges, whereas 
scFv are composed only by VL and VH regions joined by a polypeptide linker, usually 
with a sequence of 15 amino acids (GGGGSGGGGSGGGGS) whose function is to 
increase the efficiency of folding and expression.
6,19,100,207
   
A dAb is either the variable domain of an antibody heavy chain (VH domain)
339
 or the 
variable domain of an antibody light chain (VL domain)
248
. Each dAb therefore contains 
three of the six naturally occurring complementarity determining regions (CDRs) from 
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an antibody. Although it might seem surprising that three CDR regions are sufficient to 
confer antigen-binding specificity and high affinity, evolution itself has arrived at that 
very same solution in camelids
125
 but also in sharks
94,308
, which produce antibodies 
comprising only a heavy chain (see Figure 1.13). The antigen binding site of these 
antibodies consists of a single unpaired variable domain (designated VHH for camelid 
and VNAR for shark).
138
 
Currently, almost all FDA approved therapeutic antibodies (except ReoPro, Lucentis 
and Cimzia which are Fabs), and the vast majority of those in clinical trials are full-size 
antibodies mostly in IgG1 format of about 150 kDa size.
90,91
 
A fundamental problem for IgG format antibodies is their poor penetration into tissues 
(e.g., solid tumors) and poor or absent binding to regions on the surface of some 
molecules (e.g., on the HIV envelope glycoprotein) which due to structural features are 
fully accessible only by molecules of smaller size. Therefore, in recent years much work 
has been aimed at developing novel antibody scaffolds of much smaller size and high 
stability
90,138
 
From the recombinant antibody scaffolds available the single chain (scFv) and the 
single domain (VHH, VH, and VNAR) formats are the most widespread for both 
research and industrial applications but their full potential is still to be reached.
168,343
  
After camelid VHH and shark VNAR domains began to be studied, it was found that 
both display long surface loops, often larger than for conventional murine and human 
antibodies. VNAR and VHH domains have the ability to penetrate cavities in large 
antigens and bind to cryptic (immune-evasive) antigens. Unlike mouse VH domains, 
camelid VHH and shark VNAR are in general soluble. This lead to the development and 
increased research of dAbs, either naturally occurring like camelid VHH and shark 
VNAR but also dAbs obtained through recombinant antibody technology from 
conventional antibodies (see Section 1.5.5.1). 
6,11,138
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Figure 1.13 – Schematic representation of different antibody formats.  
(Reprinted by permission from Macmillan Publishers Ltd: Nat. Biotechnol., copyright (2005)). 
138
 
 
The choice of recombinant antibody format depends crucially on the intended 
therapeutic use, although in some cases the choice is also based on avidity and stability 
issues. 
 
1.5.5.1 Single domain antibodies  
Most naturally occurring antibodies are composed of two heavy and two light chains. 
Both chains contribute to the antigen-binding site which is usually flat or concave. In 
addition to these conventional antibodies, llamas, other camelids, and sharks also 
produce antibodies composed only of heavy chains.
94,125,308
 VHH and VNAR are easily 
produced as recombinant proteins, designated dAbs or nanobodies.343 
The CDR3 region of these heavy chain antibodies (hcAbs) possesses the extraordinary 
capacity to form long fingerlike extensions that can extend into cavities on antigens, 
e.g., the active site crevice of enzymes, like lysozyme.
83
  The CDR3 of VHHs and 
VNARs is often much longer than that of conventional VH domains, e.g., 24 and 18 
residues in the case of anti-lysozyme dAbs versus 7 residues in the mouse VH.
128,350
 The 
extended CDR3 is often, but not always, stabilized by an additional disulfide bond 
connecting the CDR3 to the adjacent CDR1 loop (common in camel and shark dAbs) or 
to the CDR2. 
343
 The CDR3 of the heavy chains is the one that displays a higher degree 
of variability in naturally occurring antibodies
178
 and because of that is often used for 
comparison of length variation between species. Furthermore, third complementarity 
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determining region of antibody heavy chains (CDRH3) are unique in defining the fine 
specificities of antibodies, in the sense that any given amino acid sequence of human 
CDRH3 correlates with a defined specificity, and this is also true for most non human 
sequences.
75,152,350
  
For instances sequences of human CDRH3 vary from 2 to 28 amino acids residues, but 
vary less extensively in other species 
75,350
 As an example, mouse antibodies show 
CDRH3 loops ranging from 1–19 residues.75 Common in camel and shark dAbs are 
CDRH3 loops with 20 or more aminoacids.
80,128
 
The length of the CDRs is important because it has been correlated with the type of 
antigens that they recognize, for instances longer CDRH3 loops forming planar or 
concave surfaces tend to recognize large antigens, while shorter loops favor small 
antigens; i.e. a long CDRH3 implies a flat (or protruding) antigen combining site, while 
short loops favor pockets or grooves. Haptens are bound by a cavity between the CDR 
loops, and peptides and DNA antigens by groove–like structures.75,231 
Regarding length distributions in all species for the light chains, we have for the first 
complementarity determining region of antibody light chains (CDRL1) long loops (16 
and 17 residues) that are two to three times more abundant in peptide binders than in 
other classes. For CDRL3 longer loops are seen almost exclusively in viral binders.
75
 
The dAbs have a variety of uses, ranging from simple research tools as diagnostic 
reagents to highly refined biopharmaceutical drugs.
138
 They can be readily cloned into 
various formats by fusion to other proteins or peptides, thereby tailoring their utility for 
certain diagnostic and/or therapeutic applications. For example, fusion to a fluorescent 
protein yields a fluorescent probe (also designated chromobody or fluobody) suitable 
for tracking the target antigen in cells.
234,280
  Tandem cloning of two identical dAbs 
connected by a linker peptide yields a bivalent reagent with higher avidity for the 
antigen, amongst many other applications.
284,343
 
The dAbs are usually generated by PCR cloning of the V-domain repertoire from blood, 
lymph node, or spleen cDNA obtained from immunized animals into a phage display 
vector, such as pComb3X.
19
  Antigen-specific dAbs are commonly selected by panning 
phage libraries on immobilized antigen,
14,142
 e.g., antigen coated onto the plastic surface 
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of an ELISA plate, biotinylated antigens immobilized on Streptavidin beads, or 
membrane proteins expressed on the surface of cells. Several laboratories have also 
constructed semi-synthetic libraries by cassette-mutagenesis of the CDR regions. The 
latter offers the advantage of selecting antibodies against toxic or difficult to express 
antigens. However, dAbs derived from such non-immune libraries often show lower 
affinities for their antigen than dAbs derived from animals that have received several 
immunizations.
128,141,252
 The high affinity of dAbs from immune libraries is attributed to 
the natural selection of variant dAbs during clonal expansion of B-cells in the lymphoid 
organs of the immunized animals. The affinity of dAbs from non-immune libraries can 
often be improved by mimicking this strategy in vitro, i.e., by site directed mutagenesis 
of the CDR regions and further rounds of panning on immobilized antigen under 
conditions of increased stringency.
14,123,160,207
 
Recombinantly expressed dAbs display several advantages as compared to conventional 
antibodies and to the scFv derived from the variable-domains of conventional 
antibodies. Their high thermal stability, high refolding capacity, and good tissue 
penetration in vivo make dAbs ideally suited for various biotechnological and 
therapeutic applications (as previously mentioned). Moreover, dAbs can be readily 
cloned into various formats by fusion to other proteins or peptides, thereby tailoring 
their utility for certain diagnostic and/or therapeutic applications inaccessible to 
conventional antibody formats.
138,284
  
Recombinant antibody scaffolds are based on various human and non-human molecules 
of high stability.
33,138,166
  Of those the dAbs are one of the most promising as therapeutic 
molecules.
140,284
  Firstly, the size (12–15 kDa) of the dAbs is about an order of 
magnitude smaller than the size of an IgG1 (about 150 kDa) and the small size leads to 
relatively good penetration into tissues and the ability to bind into cavities or active sites 
of protein targets which may not be accessible to full size antibodies.
80,138
 This could be 
particularly important for the development of therapeutics against rapidly mutating 
viruses, e.g., HIV. Because these viruses have evolved in humans to escape naturally 
occurring antibodies of large size, some of their surface regions which are critical for 
the viral life cycle may be vulnerable for targeting by molecules of smaller size 
including dAbs. 
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Another important feature of the dAbs is that they can be relatively easy engineered to 
further increase their stability. For example, some dAbs with increased stability could 
be taken orally or delivered via the pulmonary route or may even penetrate the blood-
brain barrier, and retain activity even after being subjected to harsh conditions, such as 
freeze-drying or heat denaturation. In addition, dAbs are typically monomeric, of high 
solubility and do not significantly aggregate or can be engineered to reduce aggregation. 
Their half-life in the circulation can be relatively easy to adjust from minutes or hours to 
weeks. The dAbs for therapeutical applications are in most cases human molecules, but 
can also be humanized molecules, which decreases the likelihood of undesirable 
immune responses. 
67,81,128,139,343
 
Regarding production issues, unlike conventional antibodies, domain antibodies are 
well expressed in bacterial, yeast and mammalian cell systems. Finally, the small size of 
dAbs allows for higher molar quantities per gram of product, which should provide a 
significant increase in potency per dose and reduction in overall manufacturing 
cost.
34,85,141,170
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1.6 Antibody response to HIV-1 
The antibody response to HIV-1 in vivo is directed against several viral proteins. 
However, essentially all neutralizing antibodies are directed toward the viral envelope 
spike, in particular the surface glycoprotein gp120,
245,356
 which is anchored to the viral 
surface by gp41.
356
 Until recently only four broadly neutralizing antibodies had been 
identified (Figure 1.14), B12, and 2G12 that target gp120 and 4E10 and 2F5 that target 
the membrane-proximal external region (MPER) of gp41. In 2007 another broadly 
neutralizing antibody that targets the gp41 (Z13e1)
226
 had been identified. Between 
2009 and 2010 four new broadly neutralizing antibodies that target gp120 (PG9, PG16, 
VRC01 and HJ16) 
76,334,351
 were identified and in 2011 17 new broadly neutralizing 
antibodies  were also described that target gp120.
333
  
In the context of antibody response to HIV-1, it is also worth mentioning the CD4 
receptor targeted antibodies, in particular Ibalizumab, which is not naturally occurring 
but shows great promise for therapeutic use.
217,218
 
 
Figure 1.14 – Tridimensional model of gp120. Location of ENV neutralizing monoclonal antibodies 
is depicted.  
The model is derived from 
292
 with permission from Wolters Kluwer Health–Lippincott Williams 
and Wilkins; from 
332
 with permission from Elsevier; and from 
195
 with permission from Macmillan 
Publishers Ltd./Nature Publishing Group.49  
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1.6.1 Gp120 CD4bs Antibodies: the b12, VRC01 and HJ16 antibodies.  
The b12-IgG1, is a recombinant neutralizing antibody derived from a phage-display 
library that recognizes the CD4-binding site (CD4bs) on gp120.
289
 
The antibody b12, which binds to an epitope that overlaps the CD4bs on gp120,
17,275
 has 
been studied extensively with regard to its antiviral activity both in vitro and in vivo. In 
a comprehensive analysis involving a panel of 90 viruses, the antibody reached a 50% 
inhibitory concentration (IC50) with approximately half of the viruses tested.
32
  Although 
gp120 is the primary target of neutralizing antibodies elicited during natural infection23, 
most gp120-reactive antibodies are ineffective at neutralizing primary HIV-1 isolates.
362
  
As such, b12 was until recently the most potently and broadly neutralizing anti-gp120 
antibody. In vivo studies using macaque models of HIV infection have shown that b12 
can also protect animals against viral challenge.
76,246,328,333,334,351
  
To gain insight into how b12 is able to neutralize broadly, its structure was determined 
and, at the time, docked onto the CD4-liganded structure of gp120.
287
  
The crystal structure of b12 was originally solved as an intact human IgG1 molecule.
287
 
The most prominent feature of the antibody combining site is a heavy-chain 
complementarity-determining region 3 (CDRH3) that extends directly out from the 
surface of the antibody like a finger (Figure 1.15). Computerdocking and mutagenesis 
studies on gp120 and b12 have been used to argue that the finger probes the recessed 
CD4 binding site of gp120.
243,287,367
 The CDRH3 is 18 aa long, which is exceptionally 
long, compared with those typically found in well studied mouse mAbs to protein 
antigens (average CDRH3 length of about 10 residues). It also is relatively long, 
compared with the average in anti-protein human antibody, reported to be about 13 
residues.
74
  This unusually long CDRH3 is responsible for binding to the recessed CD4 
binding site on gp120.
362
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Figure 1.15 - The structure of the b12 monoclonal antibody.  
The structure of Fab b12 as described it has been is shown with the CDRs presented in colors and 
labeled as belonging to the heavy (H) or light (L) chain. The long HCDR3 (H3) is clearly visible as 
an extended finger-like structure. (Reprinted with permission, Copyright (2005) National Academy 
of Sciences, USA).
48
 
 
More recently, the b12 binding epitope on gp120 was identified and it was found that 
b12 binds a conformationally invariant surface that overlaps a distinct subset of the CD4 
binding site.
362
 This b12 binding epitope is constitutively exposed at the gp120 outer 
domain and is involved in the metastable attachment of CD4, before the gp120 
rearrangement required for stable engagement (see Figure 1.16).
362
 
Notably, only the heavy chain of b12 interacted with gp120, with each of the three 
heavy-chain CDRs making extensive contact. Three b12 residues (Asn 31, Tyr 53 and 
Trp 100) from each of the heavy-chain CDRs are depicted in stick representation. 
Together, these three residues combine to form 40% of the b12 contact surface. They 
can be seen gripping the CD4-binding loop, the central focus of the b12 interaction with 
gp120 (Figure 1.16). Although the heavy-chain-only usage is quite unusual, the surface 
areas of interaction were in the range typical for antibody–protein interfaces correlating 
with the strong binding ability of b12.
275,312,362
 Antibody heavy-chain-only interactions 
are rare, although heavy chain interactions predominate in a number of viral Env–
antibody complexes, including those from SARS coronavirus and influenza virus 
haemagglutinin.
107,258
 
362
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When comparing the CD4 cell receptor and b12 interaction with the CD4-binding loop, 
one finds that these interactions are quite different. The b12 antibody uses all three of its 
CDR heavy-chain loops to grasp virtually all surface-exposed portions of the loop. In 
contrast, CD4 only binds to one side of the loop, making anti-parallel hydrogen bonds 
between CD4- and gp120-main-chain atoms. 
362
 
The b12 antibody takes advantage of the backbone reactivity of the outer domain of 
gp120, forming six direct and four water mediated hydrogen bonds with the main-chain 
atoms of two parallel loops—the CD4-binding loop and the outer domain exit loop. 362 
 
Figure 1.16 - Structure of b12 in complex with an HIV-1 gp120 core. 
Polypeptide chains are depicted in ribbon representation, with disordered regions as dashed lines. 
The gp120 inner domain is grey, and the outer domain is red, except for the CD4-binding loop, 
which is purple. The strands and associated loops, which in the CD4-bound conformation 
correspond to the bridging sheet, are blue. The b12 light chain is blue–grey and the b12 heavy 
chain is green, with associated CDRs highlighted in orange (H1), cyan (H2) and dark green (H3). 
(Reprinted by permission from Macmillan Publishers Ltd: Nature, copyright (2007)). 
362
  
 
Due to the unusual characteristic of the b12 heavy chain only interaction with gp120, 
there was some concern was that b12 might be a unique broadly neutralizing antibody 
to the CD4bs, and the CD4bs thus an almost intractable vaccine target. 
49
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Although the mAbs described to date, are able to recognize monomeric gp120, most of 
them cannot do so in the context of gp120 organized in Env spikes on the viral surface. 
It appears that from the antibodies described until 2010 only b12 is able to gain access 
to the CD4 binding site on the Env spike, indicating a strong selection pressures on HIV 
to conceal this crucial and conserved site from antibody recognition.
109,275,290
  The 
recent identification of several broadly neutralizing antibodies to the CD4bs from 
different HIV-infected individuals
76,351
 lays the concerns regarding the lack of  broadly 
neutralizing antibodies against the CD4bs to rest and promotes interest in designing 
immunogens to elicit antibodies to the CD4bs.
49
 
In 2010 two new broadly neutralizing antibodies that target the CD4bs were identified, 
the HJ16 and the VR01 antibodies. The HJ16 recognizes a novel epitope proximal to the 
CD4 binding site on gp120 and selectively neutralized a multi-clade panel of Tier-2 
HIV-1 pseudoviruses, and demonstrated reactivity that was comparable in breadth, but 
distinct in neutralization specificity, to that of the b12 antibody.
76
  The VRC01, was 
identified in a screening where a panel of broadly neutralizing sera was evaluated for 
the presence of antibodies that could preferentially bind to the CD4bs of gp120. This 
antibody was found to neutralize ~90% of nearly 200 viruses of different HIV clades 
tested.
351
 
More recently, in 2011 a study where the neutralizing antibody repertoires of four HIV 
infected donors were probed with remarkably broad and potent neutralizing responses 
and 17 new monoclonal antibodies that neutralize broadly across clades were rescued. 
Many of the newly identified PGT monoclonal antibodies are almost tenfold more 
potent than the recently described PG9, PG16 (see Section 1.6.2) and VRC01 broadly 
neutralizing monoclonal antibodies and 100-fold more potent than the original 
prototype HIV broadly neutralizing monoclonal antibodies. The epitopes recognized by 
the PGT monoclonal antibodies were identified by competition ELISA assays. Most of 
the epitopes recognized by the PGT monoclonal antibodies were in proximity to or 
contiguous with V3, and the epitopes recognized by the remaining PGT antibodies bind 
the gp120 polypeptide backbone (gp120 glycan shield). 
333
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1.6.2 Gp120 V2/V3 Antibodies: the PG9/PG16 antibodies.  
The PG9 and PG16 are antibodies with exceptional neutralizing breadth and potency 
that were identified through a large-scale direct functional screen of B cells from a 
donor with a high broadly neutralizing antibody response.
334
 
These antibodies were found to recognize residues that are primarily located in 
conserved parts of V2 and V3 loops of gp120 with broad isolate reactivity.
334
  The PG9 
and PG16 are somatic variants and seem to recognize the same or overlapping epitopes. 
Like for the CD4bs broadly neutralizing antibodies, PG9 and PG16 do not recognize 
monomeric gp120, and in fact it was demonstrated that the epitope or overlapping 
epitopes targeted by these antibodies is preferentially expressed on trimeric HIV Env. 
49,334
 
1.6.3 Antibodies against gp120 glycans: 2G12 
2G12 is an antibody that recognizes glycans on the surface of gp120. It recognizes the 
dense carbohydrate shield that protects the protein from antibody recognition.
48,242
  
It has been shown that 2G12 does indeed recognize glycans exclusively and a number 
of oligomannose candidates were identified.
291
 2G12 has the unique ability to recognize 
the oligomannose structure on the gp120 surface, because this antibody assembles into a 
previously uncharacterized structure in which the two Fabs of the IgG assemble into an 
interlocked VH domain-swapped dimer – a dimeric configuration. The extraordinary 
configuration of this antibody provides an extended surface consisting of two classical 
binding sites that is responsible for its broad reactivity.
48,291
  In fact, 2G12 has potent in 
vitro and in vivo efficacy, but unfortunately it is unable to neutralize viruses from clade 
C.
32,318,320
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1.6.4 MPER  antibodies : 2F5, 4E10  and Z13e1 
The 2F5 and 4E10 are antibodies that recognize the membrane-proximal external region 
(MPER) of gp41. Although most of the surface of gp41 appears to be occluded from 
antibody binding on Env spikes, a region close to the viral membrane, the MPER,
366
 has 
some accessibility to the neutralizing human mAbs 2F5 and 4E10.
223,224,366
 
Current models suggest that MPER access is achieved after receptor engagement and 
during formation of the putative transitional fusion intermediate. It has also been 
suggested that the transitional intermediate may be required to fully form the MPER 
neutralizing epitopes into the structurally deﬁned “antibody bound” conformations.60,366 
Some evidence has emerged that the epitopes of these two mAbs are accessible, and 
possibly more so, after CD4 binding to gp120.
31
 Both mAbs appear to recognize linear 
gp41 epitopes in that they bind with relatively high affinity to short peptides 
corresponding to cognate gp41 sequences, and their neutralizing activity can be 
effectively inhibited by such peptides. 2F5 and 4E10 may bind directly to free virus or 
they may neutralize virus during the process of receptor-triggered entry.
60
  
A third Ab, Fab Z13, had previously been mapped to an epitope that overlaps those of 
2F5 and 4E10 but only weakly neutralizes a limited set of primary isolates. Because the 
epitope of Z13 at least partially overlaps with those of both 2F5 and 4E10, an attempt to 
improve its affinity for gp41 would possibly also improve its neutralization potency.
366
 
Random mutations were introduced into the CDR L3 of Fab Z13 in a phage display 
library,
19,123,172
 and high-affinity variants of Z13 were selected. From that a new high-
affinity Fab, Z13e1, was identified.  Although its binding site overlaps with those of 
both 2F5 and 4E10, inspite of its increased potency when compared to the original Z13 
Fab, the Z13e1 has only moderate neutralization potency when compared to either 2F5 
or 4E10. Those remain to this date the more potent broadly neutralizing antibodies 
targeting gp41.
226
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1.6.5 CD4 receptor antibodies: Ibalizumab 
Ibalizumab, also known as TNX-355, is a non-immunosuppressive, humanized IgG4, 
monoclonal antibody that blocks HIV-1 entry by binding to domain 2 of human 
CD4.
40,88,148
 
Ibalizumab was engineered from its mouse progenitor (5A8) by grafting the mouse 
complementary-determining region (CDR) onto a human IgG4 construct.
35,42
 The IgG4 
isotype was chosen to minimize the chances for CD4_T-cell depletion by antibody- and 
complement-dependent cytotoxicity, mediated by binding to Fc receptors. Ibalizumab or 
5A8 block CD4-dependent virus entry and inhibit a broad spectrum of both laboratory-
adapted and clinical HIV-1 isolates, including CCR5-tropic and CXCR4-tropic strains 
from multiple subtypes.
301
 
Ibalizumab is currently on phase III clinical trials. 
 
1.6.6 CD4-Induced (CD4i) Antibodies 
CD4i antibodies recognize the coreceptor binding site on gp120. Similarly to the 
trimeric Env, the coreceptor site on monomeric gp120 is revealed by CD4 ligation, 
when it is also then recognized by a set of CD4i antibodies. 
In a stunning demonstration of convergent evolution, a number of CD4i antibodies have 
acquired post-translational modifications in the form of sulfated tyrosines on their 
CDRH3 regions; these tyrosines, in some cases, are important in gp120 binding.
65
 The 
CD4i antibodies fall into two classes, those with long CDRH3s and those with short 
CDRH3s. Only for a subgroup of the long CDRH3 antibodies does tyrosine sulfation 
contribute to antigen binding. Another remarkable feature of CD4i antibodies is the fact 
that their neutralizing activity, as antibody fragments, has an inverse relationship 
between molecular size and neutralization, i.e., single-chain Fv > Fab > IgG in 
neutralizing potency. Thus, it appears that during infection, the virus exposes the 
coreceptor site sufficiently to allow access by CCR5 and antibody fragments but not by 
the physiologically relevant IgG molecule.
48,320
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1.7 Vaccines 
A vaccine is a biological preparation that improves immunity to a particular disease. A 
vaccine typically contains an agent (antigen) that is composed of fragments or by the 
totality of a disease-causing microorganism, and is often made from weakened or killed 
forms of the microorganism or its toxins. The antigen stimulates the body's immune 
system to recognize it as foreign, by stimulating antibody production or cellular 
immunity against the pathogen but being “designed” to be incapable of causing severe 
infection.  
Vaccines can be prophylactic (e.g. to prevent or ameliorate the effects of a future 
infection by any natural or "wild" pathogen), or therapeutic (e.g. vaccines against 
cancer). 
In the case of the AIDS vaccine several approaches have been attempted over the years, 
focusing mainly on developing a safe prophylactic strategy as discussed in section 1.7.1 
1.7.1 AIDS vaccine: Present status and future possibilities 
 Although intensive anti-retroviral therapy has been able to slow or halt expansion of 
the epidemic in some industrialized countries, these treatments are poorly accessible in 
developing countries. Development of a preventive vaccine for HIV is the best hope of 
controlling the AIDS pandemic worldwide. HIV has, however, proved a difficult 
pathogen to vaccinate against. This is largely because HIV has a very high mutation rate 
and can escape immune responses. Recent discoveries in HIV entry and pathogenesis, 
and promising studies of candidate vaccines in animal models have provided reasons to 
hope that developing a safe and effective AIDS vaccine is possible.228  
The first Phase I trial of an HIV vaccine was conducted in the USA in 1987. Since then, 
more than 30 candidate vaccines have been tested in over 80 Phase I/II clinical trials, 
involving more than 10 000 healthy human volunteers.
118,158,345
  
Initially the efforts on developing an HIV-1 vaccine were focused on antibody 
responses elicited by subunit protein (subunit vaccines),
27
 but were later switched to T-
cell responses elicited by a range of viral proteins.
44,189,210
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Early studies reported preliminary data that HIV-specific CD4
+
 T helper cell responses 
were more common in HIV-1 infected individuals who controlled viremia in the 
absence of ART, and that ART given during acute HIV-1 infection could restore HIV-1-
specific CD4
+
 T cell proliferative responses.
279
  These data documented the importance 
of CD4
+
 helper T cells in controlling HIV-infection and also suggested that HIV-
specific T helper responses would be desirable in a vaccine.
203,206,240,278
 
Studies of SIV in animal experiments and studies in humans suggest that CTLs are 
important for control of viral replication, in both acute and chronic disease, suggesting 
that cellular immunity impacts HIV-1 infection and is likely to play a major role in 
clinical outcome.
9,79,122,206
 
Due to the complexity of the interaction between HIV-1 and the human immune system, 
in order to achive immune protection, multiple vaccine concepts are being explored in 
parallel. 
1.7.1.1 Live Attenuated Vaccines 
The finding that nef-deleted mutants of SIV could elicit protection against challenge 
with pathogenic SIV in rhesus macaques triggered the development of a live attenuated 
HIV vaccine approach.
79
 Further research showed that the SIV ∆nef mutants, however, 
establish a lifelong, persistent low grade infection that does not protect the vaccinated 
monkeys against superinfection with wild-type virus, and also is pathogenic in most 
vaccinated adult monkeys, given enough time.
136,143
  In addition, the attenuated virus 
still may cause AIDS when administered orally to infant monkeys.
136
 Further attempts 
to introduce additional deletions or mutations can continue to attenuate the virus but at 
the expense of its protective efficacy. Mostly because of safety concerns, this approach 
was therefore discontinued.
137
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1.7.1.2 Subunit Vaccines 
A subunit HIV vaccine was developed based on monomeric gp120 added with 
aluminium (VaxGen). Two different studies were conducted; in one of them the vaccine 
used a mixture of two subtype B gp120s as the immunogen, and in the other using a 
mixture of a subtype E (CRF_AE) and a subtype B gp120s (AIDSVAX® gp120 B/E). 
None of these studies showed a statistically significant reduction of HIV infection and 
showed no efficacy in Phase III trials.
158,208
  
The same subtype E/B gp120 vaccine was used for booster immunizations in a prime-
boost Phase III trial which was launched in late 2003 in Thailand and uses for priming a 
recombinant canarypox virus (ALVAC) that expresses CRF_AE gp120 and subtype B 
Gag, Pol and Nef antigens (ALVAC-AIDSVAX B/E) this vaccine is also designated 
RV144.
15,158
 The RV144 combination treatment's efficacy ranged from 26.1 to 31.4%, 
which although far from optimal still constitutes a positive result.
271
 
Other approaches aimed at eliciting HIV neutralizing antibodies based on the Env 
proteins, have been develop over the years, initially these were based on monomeric 
gp160.
24,92
 These Env subunit vaccines were shown to induce neutralizing antibodies 
that were mostly directed at the hypervariable V3 loop in gp120 and were able to 
protect chimpanzees against challenge with a homologous or near-homologous HIV-1 
strain, but not against challenge with a distant virus strain.
28,117
  
Since the first attempts to develop an Env subunit vaccine, several other approaches 
have been develop, these have included: 
 trimeric gp140 molecules (gp120 + the ectodomain of gp41) with a deletion of 
the hypervariable V2 loop in order to expose the neutralization epitopes 
overlapping the CD4-binding site;
20,302,303
 
 oligomeric gp140 molecules covalently coupled to synthetic mimics of the CD4 
receptor that should expose neutralization epitopes overlapping the coreceptor 
(CCR5 or CXCR4)-binding site;
84,110
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 gp120/gp41 trimers internally stabilized by disulfide bond formation (SOS 
proteins) which should elicit both neutralizing and fusion-blocking antibodies.
22
 
Another strategy that seems promising is the development of subunit vaccines based on 
the accessory protein Tat, in the hope that immune responses directed at antigens that 
are expressed very early in the virus replication cycle might lead to containment of 
infection. And also because anti-Tat antibodies have been correlated with reduced 
viremia and slow progression to AIDS.
265,359
 Tat is believed to contribute to viral 
pathogenesis and immunosuppression by inducing apoptosis in uninfected 
lymphocytes.
118,191
 
The native Tat protein was tested in a Phase I clinical study and shown to be well 
tolerated and immunogenic in both HIV naive and HIV-infected individuals and is 
currently in a Phase II clinical trial.
23,101
 A Tat–Nef fusion protein that was combined 
with a gp120 subunit vaccine was found to prevent the development of disease in rhesus 
macaques following challenge with SHIV89.6P.
331
  
The same Tat–Nef fusion protein/gp120 combination was tested in Phase I trials119 and 
shown to induce strong and persistant CD4
+
 T-cell responses in human volunteers when 
combined with various adjuvants.
188
 HIV Tat vaccines might therefore show some 
promise specially when combined with other HIV antigens.
55,56
 
 
1.7.1.3 Live Recombinant Vaccines 
Rather than attempting to elicit a protective antibody response, recent HIV vaccine 
approaches have aimed to induce a T-cell response, especially a CD8
+
 CTL response, 
whose role in control of virus load and evolution of disease has been well documented 
in the monkey model.
5,209
 CD8
+
 T-cell secrete antiviral cytokines (IFN-γ), virus entry-
blocking β-chemokines, and other factors that have been correlated with protection 
against SIV infection in the monkey model, as well as associated to asymptomatic  
HIV-1 infection in humans and slower disease protection in HIV-2-infected patients.
118
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 Vaccines that stimulate the T-cell immune response are however not expected to 
protect against infection, but rather to control its course and reduce viral loads, in an 
attempt to prevent or at least delay the occurrence of symptoms.
118
 
Several prime-boost strategies involving priming with a DNA vaccine followed by 
boosting with a live recombinant vector-based vaccine have been tested in monkeys 
against challenge with a lethal dose of simian–human immunodeficiency virus (SHIV) 
that causes AIDS-like illness in the animals. These strategies resulted in reduction in 
virus load but failed in protection against SIV challenge.
129,182
 
A number of recombinant vaccines also have been tested in Phase I/II trials in humans, 
including plasmid DNA and poxvirus vectors (MVA, fowlpox or canarypox viruses) 
expressing a variety of HIV antigens, such as Gag, Env, Pol and Nef. 
25,147,251,314
 
Replication-defective adenovirus type 5 (Ad5) was the base for another HIV-1 vaccine, 
a recombinant Ad5-gag/pol/nef vaccine (Merck). Phase I clinical trial of Ad5 
recombinants induced cell-mediated immune responses against HIV Gag peptides in 
most healthy adult volunteers with baseline Ad5 antibody titers <200, but the response 
was dampened in those volunteers with titers >200.
261
 The vaccine reached Phase II 
trials but in individuals devoid of pre-existing Ad5 neutralizing antibody, an equal 
number of HIV-1 infections was recorded in the vaccinated and placebo groups. In 
volunteers with pre-existing immunity, however, the number of HIV-1 infections in the 
vaccinated group was significantly higher than in the placebo group.  This led to the 
interruption of the trial and the cessation of all Ad5-based vaccine trials.
73,199,297
  
In general, T-cell vaccines for HIV-1 have not elicited the same levels of responses in 
humans as they elicited in nonhuman primates. Also a variety of other vectors have been 
used.
118
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1.7.1.4 Other Vaccinal Approaches 
Other vaccinal approaches are under development like the induction of persistent HIV 
Gag-specific CD8
+
 CTL responses, multi-epitopic combinations of peptides, fusion 
proteins and long lipopeptides also are at an early stage of clinical development, either 
alone or in prime-boost combinations with live vector-based recombinant vaccines. 
Lipopeptides whose sequence corresponds to that of CTL epitopes-rich regions in the 
Gag and Nef viral proteins have undergone Phase II trials in the USA and in France 
(NIAID/ANRS) and many others.
118
 
 
 
Another important aspect to be aware of for the development of a successful AIDS 
vaccine is the type of vaccine formulation. A critical goal of HIV vaccination is the 
induction of mucosal humoral immune responses. Since nanoparticles are an important 
tool for antigen delivery and subsequent induction of cellular and humoral immune 
responses, nanoparticle encapsulation can be a crucial step for the development of AIDS 
vaccines (see Chapter 5).
12,135,156,358
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1.8 Aims  
Given the characteristics and nature of HIV infection, the ability to establish reservoirs 
in various cell lines, progressive and irreversible destruction of the immune system, 
associated with an increased prevalence of strains resistant to drug therapy, one of the 
priority areas in the development of new drugs has been the development of new 
molecules which prevent viral entry into cells, including peptides and antibodies that 
prevent the entry process.  
The objective of the work developed and presented in this Thesis was to evaluate both 
the b12 target sequence and the CD4 binding epitope outside of the gp120 context and 
to explore their potential for CD4 targeting in different therapeutic applications. 
 For that we used a novel approach. Here we used the knowledge of a recent discovery 
that identified in gp120 a conformationally invariant surface that overlaps a distinct 
subset of the CD4-binding site, which is the binding site for the b12 natural antibody.  
We wanted to use both gp120 sequences, the CD4 binding epitope and the b12 target 
sequence, to construct single domain antibodies for independent epitope assessment and 
to evaluate their ability to bind to the hCD4 receptor. 
The strategy developed involved grafting of the b12 target sequence or CD4 binding 
epitope into either CDR1 or CDR3 of a highly stable rabbit single domain VL antibody. 
This grafting process involved the selection of the more stable constructs, their 
expression and development of high yield purification protocols. 
After validating that these constructs can bind specifically to the hCD4 receptor we 
wanted to further explore their potential in three different perspectives: 
1) as HIV-1 entry inhibitors; 
2) as a new therapeutic delivery system using dAb coated nanoparticles; 
3) and VLB12 in particular, as a vaccine antigen.     
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One of the most innovative characteristics of this work is the potential of obtaining a 
uniquely versatile molecule, the VLB12 construct and the ability to distinguish two 
independent regions for binding to the CD4 cell receptor within the gp120 CD4bs 
region each binding to a different  CD4 domain.  
The VLB12 construct has the potential of simultaneously being used as a therapeutic 
molecule that inhibits HIV-1 infection by binding to the CD4 cell receptor and 
preventing HIV from entering the target cell. Furthermore, the VLB12 construct also has 
the potential to be used as a vaccine antigen, since this b12 epitope is the target of a 
natural broadly neutralizing antibody. 
The VLCD4 construct also shows potential for being used as an entry inhibitor molecule 
that inhibits HIV-1 infection by binding to the CD4 cell receptor, but since this gp120 is 
subjected to constant conformational masking its usefulness may be limited.  
Furthermore, the use of gp120 sequences and simply grafting those into an antibody and 
in that manner develop a strategy to prevent the virus from entering the cell, is ironic at 
best. Successfully using a piece of the virus to fight the virus itself maybe one of 
Nature’s ironies. 
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2 A new approach for CD4 targeting – grafted single domain 
antibodies 
2.1 Introduction 
Although gp120 is the primary target of neutralizing antibodies elicited during natural 
infection,
262
 most gp120-reactive antibodies are ineffective at neutralizing primary   
HIV-1 isolates. Only two gp120-reactive antibodies (b12, 2G12) with effective 
neutralization activity against diverse primary HIV-1 isolates had been identified until 
2009 (see Section 1.6).
46,47,319,320,356
 
A recent discovery has identified in gp120 a conformationally invariant surface that 
overlaps a distinct subset of the CD4-binding site, which is a binding site for the b12 
natural antibody. 
362
 This surface is constitutively exposed at the gp120 outer domain 
and is involved in the metastable attachment of CD4, before the gp120 rearrangement 
required for stable engagement.
362
 
The contact surfaces of CD4 and b12 on gp120 have considerable overlap (see Figure 
2.1). However, b12 is able to latch onto this outer domain surface with high affinity, 
without additional gp120 conformational changes. The b12 binding site remains 
accessible to b12 binding since it is not subject to the gp120 conformational changes 
that occur in most of the outer domain (conformational masking), this allows b12 to 
bind and neutralize primary isolates. In this manner, b12 uses the functionally 
conserved initial contact site for CD4 on gp120 to effectively neutralize HIV-1. 
362
 
 
Figure 2.1 – Model of the contact surfaces of CD4 and b12 on gp120.  
Molecular surface of gp120 in red, with the b12- contact surface in green (left) and the CD4-contact 
surface in yellow (right).(Reprinted by permission from Macmillan Publishers Ltd: Nature, 
copyright (2007)).
362
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The identification of the gp120 epitope targeted by the b12 antibody and the fact that 
this epitope partially overlaps the CD4-binding loop has prompted us to graft this gp120 
epitopes, the CD4 and the b12 binding epitopes, into the CDRs of a highly stable VL 
domain antibody (Figure 2.2).
121
  
 
Figure 2.2  – Predicted structure of the single domain VL antibody. 
The model for this structure was performed by us (J Gonçalves Laboratory). The single domain VL 
antibody is derived from the 4BL anti-Vif single chain antibody. 
121
 
 
In this Chapter we wanted to evaluate the ability of both the CD4 binding epitope and 
the b12 target sequence to be stably grafted in the CDRs of a single domain VL antibody 
in order to explore the potential of both gp120 epitopes individually, outside the whole 
gp120 context.  
The reports available on the literature indicate that the gp120 conformation resulting of 
the binding to the CD4 receptor or the binding to the b12 antibody result in a gp120 
conformation where both contact sequences present considerable spatial overlap as 
demonstrated on Figure 2.1. This prompted us to design the VL grafting system in order to 
obtain stable protein expression while maintaining the functionality of both gp120 target 
sequences. In order to evaluate the functionality of both gp120 target sequences the 
recognition of the human CD4 receptor and the characterization of the target epitopes 
also needed to be evaluated. 
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2.2 Materials and methods 
2.2.1 Construction of recombinant single domain antibodies, dAbs 
 The recombinant antibodies developed in this work, were constructed through grafting 
of the b12 target sequence or CD4 binding epitope (Table 2.1) into either CDR1 or 
CDR3 of a highly stable single domain VL antibody.  
Table 2.1– Coding sequences used for CDR grafting of gp120 epitopes. 
Sequence Coding sequence  
B12 target sequence T R D G G N S N N E S E I F R P G G G D M R D 
CD4 binding epitope S S G G D P E I V T  
The original CDR1 or CDR3 sequences of the VL antibody were removed, and the 
gp120 b12 target epitope or CD4 binding epitope were inserted in their places, using an 
overlap PCR. The amplification product was subsequently cloned into the pComb3X 
vector using the Sfi I restriction enzyme.
19
 All the constructs were confirmed by DNA 
sequencing. 
Table 2.2 - Primers used to clone the b12 target sequence, the CD4 binding epitope sequence, or both 
sequences in the CDRs of the VL antibody. 
Primer name Sequence (5’ – 3’) 
RSC -F GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC 
VL-R GGAGGACCAGGAGGAGCCTGNCCGGCCT 
VL-CD4-CDR1-F AGCAGTGGAGGCGACCCAGAAATAGTAACATGGTATCAGCAG 
VL-CD4-CDR1-R TCTGGGTCGCCTCCACTGCTGCAATTGATGGTGACTGTGCCC 
VL-CD4-CDR3-F AGCAGTGGAGGCGACCCAGAAATAGTAACATTTGCTTTCGGCGGAGGG 
VL-CD4-CDR3-R TCTGGGTCGCCTCCACTGCTACAGTAGTAAGTGGCAGCATCGGC 
VL-OL-CDR1-F  ACAAGAGACGGAGGAAACAGCAACAACGAAAGCGAAATATTCAGACCA 
GGAGGCGGAGACATGCGCGACTGGTATCAGCAG 
VL-OL-CDR1-R GTTGCTGTTTCCTCCGTCTCTTGTGCAATTGATGGTGACTGTGCCC 
VL-OL-CDR3-F  ACAAGAGACGGAGGAAACAGCAACAACGAAAGCGAAATATTCAGACCA 
GGAGGCGGAGACATGCGCGACTTTGCTTTCGGCGGAGGG 
VL-OL-CDR3-R GTTGCTGTTTCCTCCGTCTCTTGTACAGTAGTAAGTGGCAGCATCGGC 
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2.2.2 Cloning of the CD4 sequence in the CDR1 of the VL antibody 
For the cloning of the CD4 binding epitope sequence in the CDR1 of the VL antibody, 
two rounds of PCR were performed. The first round of PCR was composed of two 
independent PCR amplifications (see Figure 2.3).  
 
Figure 2.3 – 1st round of PCR for grafting of b12 target epitope or CD4 binding epitope.  
PCR 1 is performed with primers RSC-F and VL-CD4-CDR1-R. This PCR amplifies the N-
terminal region of the VL antibody up to the beginning of CDR1 (not including any of the original 
CDR1 nucleotides). The Primer VL-CD4-CDR1-R includes a tail that codes for part of the CD4 
binding epitope sequence. PCR 2 was performed with primers VL-CD4-CDR1-F and VL-R. The 
Primer VL-CD4-CDR1-F includes a tail that codes for the remaining nucleotides of the CD4 
binding epitope sequence. Both CD4 epitope coding primers (VL-CD4-CDR1-F and VL-CD4-
CDR1-R) possess overlapping sequences that allow for PCR1 and PCR2 amplification products to 
anneal on the 2
nd
 round of PCR and serve as one “unified” template. 
 
PCR1 amplified the N terminal part of the protein, up to the beginning of CDR1 (not 
including any of the original CDR1 nucleotides). PCR 1 was performed with primers 
RSC –F and VL-CD4-CDR1-R (see Table 2.2). The Primer VL-CD4-CDR1-R includes 
a tail that codes for part of the CD4 binding epitope sequence. PCR 2 amplified the C 
terminal part of the protein, from the end of CDR1 (not including any of the original 
CDR1 nucleotides). PCR 2 was performed with primers VL-CD4-CDR1-F and VL-R. 
The Primer VL-CD4-CDR1-F includes a tail that codes for the remaining nucleotides of 
the CD4 binding epitope sequence. Both CD4 epitope coding primers (VL-CD4-CDR1-
F and VL-CD4-CDR1-R) possess overlapping sequences that allow for PCR1 and 
PCR2 amplification products to anneal on the 2
nd
 round of PCR and serve as one 
“unified” template. 
The second round of PCR, uses both of the amplified DNAs from PCR 1 and PCR2 as a 
unique template. The PCR is performed with the flanking primers, RSC-F and VL-R. 
The DNA of the original VL antibody was used as the template for both PCR1 and 
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PCR2. All the PCRs were performed with the phusion DNA polymerase (Finnzymes, 
Finland). 
 
2.2.3 Cloning of the CD4 sequence in the CDR3 of the VL antibody 
The protocol used for the cloning of the CD4 binding epitope sequence in the CDR3 of 
the VL antibody is identical to the protocol described in 2.1.1. PCR1 was performed 
with primers RSC-F and VL-CD4-CDR3-R and PCR2 was performed with primers VL-
CD4-CDR3-F and VL-R. The second round of PCR was identical to 2.2.2. 
 
2.2.4 Cloning of the b12 sequence in the CDR1 of the VL antibody 
The protocol used for the cloning of the B12 binding epitope sequence in the CDR1 of 
the VL antibody is identical to the protocol described in 2.2.2. PCR1 was performed 
with primers RSC-F and VL-OL-CDR1-R and PCR2 was performed with primers VL-
OL-CDR1-F and VL-R. The second round of PCR was identical to 2.2.2. 
 
2.2.5 Cloning of the b12 sequence in the CDR3 of the VL antibody 
The protocol used for the cloning of the B12 binding epitope sequence in the CDR3 of 
the VL antibody is identical to the protocol described in 2.2.2. PCR1 was performed 
with primers RSC-F and VL-OL-CDR3-R and PCR2 was performed with primers VL-
OL-CDR3-F and VL-R. The second round of PCR was identical to 2.2.2. 
 
2.2.6 Cloning of the CD4 sequence in the CDR3 of the VLB12(CDR1) antibody 
The VLB12(CDR1)-CD4(CDR3) was constructed  using as template the VLB12(CDR1) 
and the remaining cloning protocol was as described in 2.2.2. 
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All the VLB12 or VLCD4 constructs were cloned initially in the Escherichia coli 
(E. coli) expression vector pComb3X
19
 and transformed in the E. coli Top10 strain 
(Invitrogen, UK).  
 
2.2.7 Expression and purification of VLB12 or VLCD4 antibodies cloned in 
pComb3X  
To express and purify selected VLB12 or VLCD4 antibodies, phagemid DNA was 
transformed into non-suppressor E. coli strain TOP10. The dAbs optimal expression 
conditions were determined by Western Blot analysis for all the constructs.  
A fresh colony of each clone was grown at 37º C overnight in SB medium containing 
100 g/ml of ampicillin. A 10 ml sample of cells was used to inoculate 1 liter of SB 
medium containing 100 g/ml of ampicillin. Cells were grown at 37º C until A600nm= 
0.9, induced by the addition of 1 mM IPTG and growth was continued for either 6 or 16 
hours, depending on the construct. After induction, bacteria were harvested by 
centrifugation (6,000 × g, 4°C, and 15 min), resuspended in 100 ml equilibration buffer 
(20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole (pH 7.4)), supplemented with 
protease inhibitors (Roche Applied Science, Mannheim Germany)), and lysed by 
sonication or French cell press. Cell debris were removed by centrifugation (6,000 × g, 
4° C, 30 min), and the supernatant was filtered through a 0.45 μm syringe filter.  
All chromatographic steps were performed at 4 ºC. dAb extracts were purified by nickel 
NTA affinity chromatography in a HisTrap HP column (GE Healthcare, UK) using the 
C-terminal His tag. Bound proteins were eluted with a linear imidazole gradient (0-500 
mM imidazole in 20 mM NaH2PO4, 0.5 M NaCl (pH 7.4)). The appropriate fractions 
from affinity chromatography were pooled, and dialyzed against HEPES buffer (20 mM 
HEPES, 100 mM NaCl, 0,1 mM EDTA, 5 % glycerol (pH 7.4)) using Slide-A-Lyzer 
Dialysis Cassettes with a  3,5 K MWCO (Pierce, Rockford, USA) at 4ºC and according 
to the manufacturer’s instructions.  
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2.2.8 Expression and purification of VLB12 or VLCD4 antibodies cloned in 
pET28a 
To express high levels of VLB12 or VLCD4 antibodies (single domain 
antibodies, dAbs), the selected constructs were amplified by PCR using the primers 
listed on Table 2.3. 
Table 2.3 - Primers used to amplify VL B12 or VL CD4 for cloning in the pET28a vector. 
Primer name Sequence (5’ – 3’) 
Primer VL-F CTC GCT AGC GAG CTC GTG CTG ACC CAG 
Primer pComb3 Xho-R CCG CTC GAG TCA TTA AGA AGC GTA GTC CGG AAC GTC 
The amplification product was subsequently cloned into the pET28a vector Novagen, 
Germany) using the Nhe I and Xho I restriction enzymes.
19
 All the constructs were 
confirmed by DNA sequencing. 
 Selected clones were transformed into the E. coli Tuner (DE3) strain (Novagen, 
Germany). The dAb optimal expression conditions have been previously determined for 
the VL framework
286
 and all the CDR grafting variations were expressed and purified in 
these conditions. 
A fresh colony of each clone was grown at 37º C overnight in LB medium containing 
100 g/ml of ampicillin. A 10 ml sample of cells was used to inoculate 1 liter of LB 
medium containing 100 g/ml of ampicillin. Cells were grown at 37º C until A600nm= 
0.4, induced by the addition of 0,2 mM IPTG and growth was continued for 4 hours. 
 After the 4 h expression, bacteria were harvested by centrifugation (10,000 × g, 4°C, 
and 15 min), resuspended in 40 ml buffer A(50 mM HEPES, 1 M NaCl, 10 mM 
imidazole, 5mM CaCl2 (pH 8,0)), and lysed by sonication for 20 min. Cell 
pellet/insoluble fraction was collected by centrifugation (10,000 × g, 4° C, 30 min), 
resuspended in 20 ml buffer A (50 mM HEPES, 1 M NaCl, 10 mM imidazole, 5mM 
CaCl2 (pH 8,0)), and lysed by sonication for 10 min. Cell pellet/insoluble fraction was 
recollected by centrifugation (10,000 × g, 4° C, 20 min), resuspended in 20 ml buffer B 
(50 mM HEPES, 1 M NaCl, 10 mM imidazole, 5mM CaCl2, 1mM -mercaptoethanol, 
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2M urea (pH 8,0)), and lysed by sonication for 20 min. Cell pellet/insoluble fraction 
was once more recovered by centrifugation (10,000 × g, 4° C, 30 min) an resuspended 
in 25 ml buffer C (50 mM HEPES, 1 M NaCl, 10 mM imidazole, 5mM CaCl2, 1mM -
mercaptoethanol, 6 M urea (pH 8,0)).  
The protein pellet ressuspended in buffer C is subjected to a denaturation/solubilization 
step overnight at 4 ºC in a vertical rotator (stuart rotator, Dynalab). The solubilized 
protein (in buffer C) was submitted to centrifugation (12,000 × g, 4° C, 60 min) for 
removal of remaining cell debris and unsolubilized protein. The solubilized protein 
solution (dAb) was filtered through a 0,45 m syringe filter. 
The dAb was applied to a Ni-NTA His GraviTrapTM (GE Healthcare, New York, 
USA) and purified according to the manufacturer’s instructions for purification under 
denaturing conditions. dAb was eluted in 2 x 3 ml buffer D (50 mM HEPES, 1 M NaCl, 
500 mM imidazole, 5mM CaCl2, 1mM -mercaptoethanol, 6 M urea (pH 8,0)).  
The dAb refolding/buffer exchange was performed in Disposable PD-10 Desalting 
Columns (GE Healthcare, UK) according to the manufacturer’s instructions. The dAb 
protein was refolded in 2 x 7 ml buffer HEPES (20 mM HEPES, 100 mM NaCl, 0,1 
mM EDTA, 5 % glycerol (pH 8,0)).  
All the dAbs expression and purification conditions were confirmed by coomassie 
staining for all the constructs.  
 
2.2.9 Western blot 
Protein separation was performed according to the method of Laemmli in 12 % 
polyacrylamide gels (SDS-PAGE). Once separated, the proteins were transferred to onto 
nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK), blotted with anti-
HA-HRP, High Affinity antibody (clone 3F10, Roche Applied Science, Mannheim 
Germany) and developed using the ECL (GE Healthcare, UK). Protein concentration 
was quantified by Bradford colorimetric assay (BioRad, CA, USA). 
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2.2.10    Coomassie staining 
Protein separation was performed according to the method of Laemmli in 12 % 
polyacrylamide gels (SDS-PAGE). Following electrophoresis, the gel was placed in 
staining solution (40% methanol, 10% acetic acid, 0,025% Coomassie Brilliant Blue R-
250
*
).  The gel was incubated for 1 hour to overnight in the staining solution. The gel 
was destained with several changes of destain solution (30% methanol, 10% acetic acid) 
until the background is transparent. All staining destaining steps were done on a rotary 
shaker with gentle mixing. 
 
2.2.11    Enzyme-linked immunosorbent assay (ELISA) to evaluate the dAbs 
binding to human CD4 
Soluble human CD4 (obtained through the NIH AIDS Research and Reference Reagent 
Program, contributor: Progenics) or CD4-IgG2 (obtained through the NIH AIDS 
Research and Reference Reagent Program, contributor: Progenics) at 500 ng or 250 ng 
per well (in phosphate-buffered saline, PBS) was adsorbed onto 96 well flat bottom, 
high binding non-sterile, polystyrene ELISA plates (Corning, NY, USA). The plates 
were then blocked with 3 % bovine serum albumin (BSA) in PBS. The dAbs were 
diluted with 1% BSA in PBS. Amounts used ranged from 1500 ng - 100 ng per well.  
dAbs were added to the wells, and incubated for 1 h. The plates were washed with 
tween 20 (0.05 % in PBS) and incubated with horseradish peroxidase (HRP)-conjugated 
rat monoclonal anti-HA (Roche, Germany), the -HA-HRP antibody was used at a 
1:1000 dilution in 1% BSA (in PBS). All incubations were performed for 1 h at 37 ºC. 
The plates were then washed with PBS and developed with an HRP substrate, ABTS
†
 
solution (citric acid (pH 4.0) with 0,2 % H2O2 and read on an Infinite 200 Microplate 
Reader (Tecan i-control software, version , 1.5.14.0, Tecan, North Carolina, USA)  at an 
optical density (OD) of 405/492 nm.  
 
                                                 
*
 Which has been filtered through Whatman #1 paper 
†
 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt 
                                                                     A new approach for CD4 targeting – grafted single domain antibodies 
63 
 
2.2.12    ELISA assay to evaluate the dAbs binding to b12 mAb 
The ELISA assay to evaluate the dAbs binding to b12 mAb, was performed using as 
antigen either VLCD4 or VLB12 at 500 ng per well (in phosphate-buffered saline, PBS), 
the antigen was adsorbed onto 96 well flat bottom, high binding non-sterile, polystyrene 
ELISA plates (Corning, NY, USA). The plates were then blocked with 3 % bovine 
serum albumin (BSA) in PBS.  The b12 mAb (b12-IgG1, obtained through the NIH 
AIDS Research and Reference Reagent Program, contributor: Dr. Dennis Burton and 
Dr. Carlos Barbas III)
18,45,47,276
 was diluted with 1% BSA in PBS. Amounts used ranged 
from 1000 ng - 50 ng per well.  The b12 mAb was added to the wells, and incubated for 
1 h. The plates were washed with tween 20 (0.05 % in PBS) and incubated with 
horseradish peroxidase (HRP)-conjugated goat anti-Human IgG (Santa Cruz 
Biotechnology, Santa Cruz, USA), the -Human-HRP antibody was used at a 1:1000 
dilution in 1% BSA (in PBS). All incubations were performed for 1 h at 37 ºC. The 
plates were then washed with PBS and developed with an HRP substrate, ABTS 
solution (citric acid (pH 4.0) with 0,2 % H2O2 and read on an Infinite 200 Microplate 
Reader (Tecan i-control software, version , 1.5.14.0, Tecan, North Carolina, USA)  at an 
optical density (OD) of 405/492 nm.  
 
2.2.13 ELISA assay for epitope characterization 
For the epitope characterization ELISA assays were performed using as antigen, native 
conformation soluble hCD4 or denaturated soluble hCD4. Soluble human CD4 
(obtained through the NIH AIDS Research and Reference Reagent Program, 
contributor: Progenics) was used at 500 ng per well (in phosphate-buffered saline, 
PBS). Denaturated soluble hCD4 was obtained by submitting the protein to heat 
denaturation for 10 minutes at 95 ºC. Either native conformation soluble hCD4 or 
denaturated soluble hCD4 was adsorbed onto 96 well flat bottom, high binding non-
sterile, polystyrene ELISA plates (Corning, NY, USA). The plates were then blocked 
with 3 % bovine serum albumin (BSA) in PBS. 3 % BSA (in PBS) was also used and as 
negative control. The dAbs were diluted with 1% BSA in PBS. Amounts used ranged 
from 1500 ng - 100 ng per well.  dAbs were added to the wells, and incubated for 1 h. 
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The plates were washed with tween 20 (0.05 % in PBS) and incubated with horseradish 
peroxidase (HRP)-conjugated rat monoclonal anti-HA (Roche, Germany), the -HA-
HRP antibody was used at a 1:1000 dilution in 1% BSA (in PBS). All incubations were 
performed for 1 h at 37 ºC. The plates were then washed with PBS and developed with 
an HRP substrate, ABTS solution (citric acid (pH 4.0) with 0,2 % H2O2 and read on an 
Infinite 200 Microplate Reader (Tecan i-control software, version , 1.5.14.0, Tecan, 
North Carolina, USA) at an optical density (OD) of 405/492 nm.  
 
2.2.14 Production of HEK293T expressing mCD4, hCD4 or hCD4mD1 
Human embryonic kidney 293T (HEK293T) (ATCC, VA, USA) cells were transfected, 
by calcium phosphate method, with either human CD4 (original plasmid pMX hCD4, 
Addgene, Cambridge MA, USA)
185
 for the purpose of this work the hCD4 was cloned 
in pcDNA 3.1 (Invitrogen, UK), human CD4 with mouse Domain1 (hCD4mD1) 
(pEYFP-N1-hCD4mD1, a kind gift from Dr. Alexandra Trkola)
295
 or mouse CD4 
(mCD4) (pCMV-Sport6-mCD4, a kind gift from Dr. Alexandra Trkola).
295
 Briefly, 240 
000 HEK293T cells were transfected with one of the plasmids in order to produce 
HEK293T cells expressing hCD4, hCD4mD1 or mCD4. After 48 h, the transfected cells 
were stained (see 2.2.15.3) and submitted to the Flow Cytometry assay to identify the 
hCD4 domain recognized by VLB12 and VLCD4. 
 
2.2.15     Flow cytometry analysis  
2.2.15.1 VLB12 (CDR1) specific binding to the CD4 receptor 
For each assay condition, 200 000 cells, either HEK293T or HeLa‐P4 
(HeLa‐CD4‐LTR‐β‐gal, obtained through the NIH AIDS Research and Reference 
Reagent Program, MD, USA, contributor Dr. Richard Axel) were stained. Cells were 
detached from the flasks with cell dissociation buffer (Gibco, NY, USA), washed with 
PBS and incubated with either 10 nmol of VLB12(CDR1)  or 2,5 l of fluorescein 
isothiocyanate (FITC) Mouse Anti-Human CD4 (clone RPA-T4; BD Pharmingen, San 
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Diego, CA) and diluted in 1% BSA (in PBS). Afterwards, cells were washed with PBS 
and cells stained with VLB12(CDR1)  were incubated with 2,5 l anti-HA-FITC-
conjugated (Clone BMG-3F10; Roche, Germany) diluted in 1% BSA (in PBS). Cells 
were washed with PBS and fixated with 1 % p-formaldehyde (in PBS). 
 
2.2.15.2 VLB12 (CDR1), VLB12 (CDR3) and VL CD4 (CDR3) binding to CD4 in 
Jurkat cells 
For each assay condition, 200 000 Jurkat E6‐1 T‐cells obtained through the NIH AIDS 
Research and Reference Reagent Program (MD, USA, contributor Dr. Arthur Weiss). 
were stained. Cells were washed with PBS and incubated with different concentrations 
of either VLB12 (CDR1), VLB12 (CDR3), VLCD4 (CDR3)  or 2,5 l of FITC Mouse 
Anti-Human CD4 and diluted in 1% BSA (in PBS). Afterwards, cells were washed with 
PBS and cells stained with the dAbs were incubated with 2,5 l anti-HA-FITC diluted 
in 1% BSA (in PBS). Cells were washed with PBS and fixated with 1 % p-
formaldehyde (in PBS). 
 
2.2.15.3 Flow cytometry assay to identify the hCD4 domain recognized by 
VLB12 and VLCD4  
For each assay condition, 200 000 (HEK293T) transfected cells were stained. HEK293T 
cells were stained 48h after Calcium phosphate transfection of mouse CD4 (mCD4), 
human CD4 (hCD4) or human CD4 with mouse Domain1 (hCD4mD1). For each assay 
condition 200 000 transfected cells were washed with PBS and incubated with 10 nmol 
or 25 nmol of either VLB12 or VLCD4 and also with 2,5 l of FITC Mouse Anti-Human 
CD4 (-CD4-FITC), all diluted in 1% BSA (in PBS). Afterwards, cells were washed 
with PBS and cells stained with the dAbs were incubated with 2,5 l anti-HA-FITC 
diluted in 1% BSA (in PBS). Cells were washed with PBS. All the cells stained with 
either VLB12, VLCD4 or -CD4-FITC were again washed with PBS and stained with 
goat anti-mouse-DyLight 405 (1:5000). Cells were washed with PBS and fixated with   
1 % p-formaldehyde (in PBS). 
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All flow data were acquired on a BD Calibur (BD Bioscience, Franklin Lakes, NJ 
USA), 10 000 gated cells were acquired for each assay condition and data analysis was 
performed using Flowjo software 6.4.7 (BD Biosciences, Franklin Lakes, NJ USA). 
 
2.2.16 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, 2007, San Diego, California, USA, www.graphpad.com) with a 
level of significance of 5%. 
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2.3 Results 
2.3.1 Construction, expression and purification of the recombinant domain 
antibodies, dAbs  
The recombinant antibodies developed in this work, were constructed through grafting 
of specific sequences into either CDR1 or CDR3 of a highly stable single domain VL 
antibody. The single domain VL antibody used as a framework in this Thesis was 
originally cloned in the pComb3X vector. This vector was originally designed for Phage 
Display and has an N terminal peptide leader sequence that targets the expressed 
proteins to the periplasm, and also a C terminal 6 His Tag followed by a Hemagglutinin 
Tag (HA Tag). The peptide leader sequence minimizes the formation of inclusion 
bodies and allows the recovery of soluble dAbs. The optimal expression conditions 
were determined by Western Blot for all the dAbs (Table 2.4). 
Table 2.4 - Optimal expression conditions for the dAbs cloned in pComb3X.  
Protein expression was performed at 30 ºC with shaking at 220 rpm.  
Protein (dAb) Expression 
time (h) 
Induction with 
IPTG (mM) 
Cell lysis method 
VL CD4 (CDR1) 4 1,0 French cell press 
VL CD4 (CDR3) 6 0,6 Sonication 
VL B12 (CDR1) 16 1,0 French cell press 
VL B12 (CDR3) 6 1,0 French cell press 
VL B12 (CDR1)CD4(CDR3) 4 1,0 French cell press 
 
From the expression assays it was possible to verify that for the CD4 binding epitope 
(hereafter designated CD4 loop) the antibody expression was much higher when the 
loop was placed in the CDR3 that in CDR1. In fact, from 12 positive clones tested for 
VLCD4 (CDR1) all presented very low expression (in the soluble fraction) that was 
undetectable after 4 h, as opposed to VLCD4 (CDR1) clones that presented much higher 
expression levels that peaked at 6 hours post induction. 
It seemed that the CD4 loop could only be inserted in the CDR3 of the VL antibody 
since almost no soluble protein could be recovered from VLCD4 (CDR1). Either the 
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protein is insoluble or expression levels are very low. Therefore the only VL CD4 
(CDR3) was selected for further studies. 
 
Figure 2.4 – Western blot analysis of the expression levels (soluble fraction) of the dAbs.  
Equal amounts of protein were loaded onto the gel. The dAbs detection was performed with -HA-HRP. 
Regarding VLB12, both constructs VLB12 (CDR1) and VLB12 (CDR3) presented fair 
expression rates in the soluble fraction, with the CDR1 construct only peeking 
expression 16 hours post induction and the CDR3 construct peeking expression at 6 
hours post induction (see Figure 2.5). 
 
Figure 2.5 - The VL B12 (CDR1) and VL B12 (CDR3) protein expression assays were compared by 
ELISA assay. 
Assay was performed using 500 ng per well of protein extract as antigen. 3 % BSA (in PBS) was 
used for blocking and as negative control. The antibody used for detection was -HA-HRP (1: 
1000) and the colorimetric substrate used was ABTS (0,2 % H2O2). Assay was performed in 
triplets. 
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After the protein expressions of the single CDR replaced loop were compared and due 
to the very low expression of soluble VLCD4 (CDR1), only the VLB12 
(CDR1)CD4(CDR3) construct was developed. As for the VLCD4 (CDR1) all the VLB12 
(CDR1)CD4(CDR3) clones tested (12) had very low soluble protein expression. This is 
an indicator that not all CDR combinations will be supported by the VL framework and 
that the sequence present in the CDRs plays an important role in antibody 
stability/solubility and that this is not directly correlated to the size of the CDR 
sequence (see Table 2.5). 
Table 2.5 – Comparison between the CDR1 and CDR3 sequences of the original VL and the CD4 and b12 
epitopes. 
Single domain antibody CDR1 sequence CDR3 sequence 
VL (original) Q A S Q S V Y N N N N L A Q G E F S C V G G D C 
VLCD4 (CDR1) S S G G D P E I V T   
VLCD4 (CDR3)   S S G G D P E I V T  
VLB12 (CDR1) T R D G G N S N N E S E I F R P G G G D M R D  
VLB12 (CDR3)  T R D G G N S N N E S E I F R P G G G D M R D 
 After the optimization of the expression conditions it was necessary to purify the 
proteins. The proteins were purified by affinity chromatography (see Section 2.2.7) with 
a linear gradient of Imidazol and afterwards were submitted to buffer exchange. The 
results are shown on Table 2.6. 
Table 2.6 - Results of the dAbs purifications per liter of bacteria culture. 
dAb Total amount of dAb Purity (%)
‡
 
VLCD4 (CDR3) 386 g      90 
VLB12 (CDR1) 315 g 20 
VLB12 (CDR3) 92,8 g 20 
 
                                                 
‡
 Purity was determined by densitometry using the Chemidoc software version 4.6 (Bio-Rad, USA) 
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The total amounts of purified protein are very low, in part because the pComb3X vector 
is not designed for high levels of protein expression; it does not possess a strong 
promoter like the T7 promoter. This system was designed for soluble expression of 
recombinant antibodies (mainly for antibody library screening)
100
 and the C terminal 6 
His tag is followed by an HA tag. This limits the access of the His tag to Ni
2+
 and 
greatly diminishes the amount of protein recovered from the affinity chromatography. 
 
2.3.2 ELISA assays to evaluate the dAbs binding to human CD4 
After purification it was necessary to verify if the constructs could bind to the human 
CD4 receptor. Preliminary binding assays were performed by ELISA (see 2.2.11) using 
as antigen soluble human CD4 (Full-length extracellular domain of human CD4). 
Results showed that both the VLCD4 and the VLB12 constructs could bind specifically 
to hCD4 (see Figure 2.6). 
 
Figure 2.6 - ELISA assays to evaluate the dAbs binding to hCD4.  
Assay was performed using 500 ng per well of hCD4 as antigen. 3 % BSA (in PBS) was used for 
blocking and as negative control. Equal amounts of dAbs were used (500 ng per well). The antibody 
used to detect the binding of the dAbs was -HA-HRP (1: 1000) and the colorimetric substract used 
was ABTS (0,2 % H2O2). Results are expressed as mean ± SD of at least 3 independent experiments 
performed in triplicate. ** corresponds to P < 0,001,  *** corresponds to P < 0,0001. 
 
                                                                     A new approach for CD4 targeting – grafted single domain antibodies 
71 
 
Both the VLCD4 and the VLB12 constructs could bind specifically to hCD4. 
Surprisingly, although VL CD4 is the construct that possess the gp120 epitope that, 
according to the literature
362
 binds the CD4 receptor, both the VLB12 constructs show 
higher binding to hCD4 that the VLCD4.    
With this results we wanted to see if VLB12 constructs could in fact bind hCD4 in a 
“cell context”, so we performed FACS assays in HeLa-P4 cells and used as an 
additional negative control a cell line that does not express the CD4 receptor (293T). 
The results are discussed in the next section.  
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2.3.3 Flow cytometry assay to evaluate VLB12 binding to CD4 
  293T HeLA-P4 
a) Cells +   IgG-FITC 
b) Cells + -HA-FITC 
c) Cells + -CD4-FITC 
d) Cells + 10 nmol VL B12 (CDR1) 
+ -HA-FITC 
e) Cells + 10 nmol VL B12 (CDR3) 
+ -HA-FITC 
a) 
 
  
b) 
 
 
 
 
 
c) 
 
 
% of CD4 positive cells  
 293T HeLA-P4 
a) 
1,02 0,32 
b) 
1,86 3,96 
d) 
  
c) 
3,26  15,2 
d) 
1,04 (20,7-3,96) 
e) 
2,09 (16,1-3,96) 
 
  
 
e) 
 
 
Figure 2.7 – Flow cytometry assay to evaluate that VLB12 (CDR1) binds specifically to the CD4 
receptor.  
For each assay condition, 200 000 cells, either Human embryonic kidney 293T (HEK293T) or 
HeLa‐P4 were stained. Cells were detached from the flasks with cell dissociation buffer (Gibco, NY, 
USA), washed with PBS and incubated with either 10 nmol of VLB12(CDR1)  or 2,5 l of 
fluorescein isothiocyanate (FITC) Mouse Anti-Human CD4 and diluted in 1% BSA (in PBS). 
Afterwards, cells were washed with PBS and cells stained with VLB12(CDR1)  were incubated with 
2,5 l anti-HA-FITC-conjugated diluted in 1% BSA (in PBS). Cells were washed with PBS and 
fixated with 1 % p-formaldehyde (in PBS). Shown is one representative experiment out of three. 
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The VLB12 constructs can in fact bind specifically to hCD4. With the VLB12 (CDR1) 
presenting a higher binding ability than VLB12 (CDR3), and also higher than the 
commercial -CD4 at the conditions tested. The actual number of CD4 positive cells 
was 14,9 % (15,2 – 0,32) for the commercial -CD4-FITC, 16,7 % (20,7-3,96) for the 
VLB12 (CDR1) and 12,1 % (16,1-3,96) for VLB12 (CDR3). 
The VLB12 (CDR1) is also expressed at higher amounts that the VLB12 (CDR3) 
indicating that the structure of the VL framework supports the B12 loop better in the 
CDR1 than in the CDR3 and that this loop can bind specifically to the hCD4 receptor 
integrated in a dAb structure.  
Furthermore, the original CDR1 of this rabbit VL is 13 amino acids long and the CDR3 
is 11 amino acids long (see Table 2.5). For most antibodies the CDR3 possesses the 
bigger loop since the variability is higher for CDR3. But contrary to that, in this rabbit 
VL the CDR1 loop is bigger so probably that is related to the fact that the B12 loop, that 
is 23 amino acids long, is more stable in the CDR1 than in CDR3. 
After validating that the B12 loop can bind specifically to the CD4 receptor without the 
presence of the gp120 CD4 binding epitope, we wanted to compare this VLB12 results 
with the VLCD4, but this time using an immortalized line of T lymphocyte cells, Jurkat 
cell line. 
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2.3.4 Flow cytometry assay to evaluate VLB12 (CDR1), VLB12 (CDR3) and VL 
CD4 (CDR3) binding to CD4 in Jurkat cells 
               Controls  VLB12 (CDR1) VLB12 (CDR3) VLCD4 (CDR3) 
a) 
 
d) 
   
b) 
 
e) 
   
c) 
 
f) 
  
 
 
Legend 
 
a) Jurkat + IgG-FITC 
b) Jurkat + -HA-FITC 
c) Jurkat + -CD4-FITC 
d) Jurkat + 1,0 nmol dAb + -HA-FITC 
e) Jurkat + 2,5 nmol dAb + -HA-FITC 
f) Jurkat + 5,0 nmol dAb + -HA-FITC 
g) Jurkat + 10 nmol dAb + -HA-FITC 
h) Jurkat + 25 nmol dAb + -HA-FITC 
i) Jurkat + 50 nmol dAb + -HA-FITC 
g) 
   
h) 
   
i) 
   
Figure 2.8 - Flow cytometry assay to evaluate VLB12 (CDR1), VLB12 (CDR3) and VLCD4 (CDR3) 
binding to CD4 in Jurkat cells.  
For each assay condition, 200 000 Jurkat cells were stained. Cells were washed with PBS and 
incubated with different concentrations of either VLB12 (CDR1), VLB12 (CDR3), VLCD4 (CDR3)  
or 2,5 l of FITC Mouse Anti-Human CD4 and diluted in 1% BSA (in PBS). Afterwards, cells were 
washed with PBS and cells stained with the dAbs were incubated with 2,5 l anti-HA-FITC diluted 
in 1% BSA (in PBS). Cells were washed with PBS and fixated with 1 % p-formaldehyde (in PBS). 
Shown is one representative experiment out of three. 
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Table 2.7 - % of  CD4 positive cells 
 
Controls VLB12 
(CDR1) 
VLB12 
(CDR3) 
VLCD4 
(CDR3) 
a) 3,7    
b) 0,65    
c) 69,0    
d)  21,7 14,7 21,2 
e)  25,5 14,7 23,2 
f)  35,5 17,8 20,6 
g)  47,8 23,1 20,9 
h)  64,6 26,6 20,2 
i)  72,9 31,8 16,8 
The percentage of CD4 positive cells for the Flow cytometry assay presented on Figure 
2.8 is listed on Table 2.7. The percentage of CD4 positive cells for the three 
independent Flow cytometry assays are presented in a graphic format (see Figure 2.9).  
 
Figure 2.9 - Graphical representation of the percentage of CD4 positive cells obtained for the three 
independent Flow cytometry assays performed. Single domain Ab amounts range from 1,0 nmol to 50,0 
nmol. 
Mouse Anti-Human CD4 FITC conjugated (clone RPA-T4) was used as a positive 
control. The -CD4-FITC antibody was used to correlate the percentage of positive 
CD4 Jurkat cells between independent assays.  
This results correlate to the results obtained in HeLa-P4 cells, where VLB12 (CDR1) 
also presents a higher binding ability than VLB12 (CDR3). So the VLB12 (CDR1) 
construct is not only expressed in higher amounts, and the purification yield is also 
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higher than for VLB12 (CDR3) (see Figure 2.5 and Table 2.6), but this also correlates 
with a higher binding ability do hCD4. The results obtained for binding to soluble hCD4 
were consistent between the ELISA assays and the Flow cytometry assays (see Figure 
2.6, Figure 2.7 and Figure 2.8) so all subsequent experiments were performed with only 
one of the VLB12 constructs, VLB12 (CDR1). 
The range of dAb amounts used in the Flow cytometry assays is limited to 50 nmol, 
because due to the low concentration of the dAbs obtained after the purification process, 
the volume of dAbs necessary to stain the cells is so big that higher amounts of dAbs 
result in higher percentage of cell death and the same percentage of CD4 positive cells 
(data not shown). 
The average number of CD4 positive cells stained with 50 nmol of dAbs was 72,2 % for 
VLB12 (CDR1), 30,1 % for VLB12 (CDR3) and  15,3 % for VLCD4 (CDR3). 
 
 
Figure 2.10 - Graphical representation of the percentage of CD4 positive cells obtained for the three 
independent Flow cytometry assays performed.(continues on the next page) 
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a) Graphical representation of the percentage of CD4 positive cells stained with VLB12 (CDR1) 
showing both linear and logarithmic function adjustments and respective R
2
. b) Graphical 
representation of the percentage of CD4 positive cells stained with VLCD4 (CDR3) showing both 
linear and logarithmic function adjustments and respective R
2
. 
 
The graphical representation of the percentage of CD4 positive cells obtained for the 
three independent Flow cytometry assays performed shows an logarithmic (R
2
 = 
0,9697) increase in the percentage of cells stained with VLB12 (CDR1) up to 50 nmol as 
opposed to the percentage of CD4 positive cells stained with VLCD4 (CDR3) that 
present a linear fit (R
2
 = 0,9055) with a slope of -0,0855, meaning that the percentage of 
CD4 positive cells is almost constant, with an optimum of 2,5 nmol, afterwich  the 
percentage of CD4 positive cells decreases this if due to the dilution factor previously 
mentioned. 
Form this point forward only VLB12 (CDR1) and VLCD4 (CDR3) will be submitted to 
further study and characterization. These domain antibodies are subsequently designated 
by the abbreviations, VLB12 and VLCD4. 
Because the method being used to express and purify the proteins gave very low protein 
yields. It was necessary to develop an alternate method to express and purify large 
amounts of the proteins. 
 
2.3.5 Alternate expression and purification method of recombinant domain 
antibodies, dAbs  
The method optimized in our laboratory to produce and purify large amounts of purified 
VL proteins (see Section 2.2.8) involves the use of the pET system.  
The VLB12 and VLCD4 proteins were cloned in the pET28a vector, and four clones 
from each construct were tested for optimal expression conditions. These dAbs can only 
be found in the insoluble fraction of the bacteria cell extract (Figure 2.11). 
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Figure 2.11 - Optimized expression conditions for VL B12 in the pET-28a vector.  
Both the soluble and insoluble fractions were analyzed. E. coli Tuner cells were grown at 37º C 
until A600nm= 0.4, induced by the addition of 0,2 mM IPTG and growth was continued for 4 hours 
at 30ºC. Bacteria were harvested by centrifugation (6,000 × g, 4°C, and 15 min), resuspended in 
PBS, and lysed by sonication. The proteins in both the soluble and insoluble fractions were 
separated by SDS-PAGE and stained with coomassie staining solution. 
 
Unlike for the dAbs expressed in pComb3X, the pET-28a vector expresses very large 
amounts of protein, but all in the insoluble fraction (Figure 2.11). Insoluble proteins 
require a completely different purification protocol (see Section 2.2.8), so it was 
necessary to develop a new purification protocol for the purification of the dAbs. 
Legend: 
1) Protein Ladder 
2) Purification step 1 
3) Purification step 2 
4) Purification step 3 
5) Purification step 4 – O/N 
solubilization 
6) Affinity chromatography 
7) Protein refolding/dialysis 
 
Figure 2.12 - VLB12 protein recovered after each purification step using the protocol for 
purification of insoluble dAbs .  
Proteins were separated by SDS-PAGE and stained with coomassie staining solution; equal 
volumes of sample were loaded in each well, in order to evaluate the dAb protein recovery after 
each step. 1) PageRuler™ Prestained Protein Ladder; 2) proteins present in the insoluble fraction 
after the first sonication step; 3) Proteins recovered after the second sonication step; 4) Proteins 
recovered after the third sonication step; 5) Proteins present in the soluble fraction after the 
overnight solubilization step; 6) Proteins recovered after the affinity chromatography step; 7) 
Proteins recovered after the protein refolding/dialysis step. 
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The protein recovery profile after each purification step is depicted in Figure 2.12 for 
the VLB12 protein, using the protocol for purification of insoluble dAbs. It is interesting 
to highlight the fact that the amount of contaminants diminishes greatly on the overnight 
solubilization step, and that after the affinity chromatography almost no contaminants 
are present and the protein concentration is greatly enhanced. The factor that greatly 
enhanced the protein recovery in the affinity chromatography step is the presence of an 
N-terminal Histidine tag. In the proteins produced from the pComb3X vector there was 
a single C-terminal Histidine tag followed by an HA tag, and the presence of the HA tag 
limits the binding of the Histidines to the matrix of the affinity chromatography column 
and greatly reduces the amount of purified protein recovered. 
Although the amount of protein produced in the pET system is much higher than in the 
pComb3X system, without the presence of the second Histidine tag (N-terminal) the 
amount of purified protein recovered was also low. As it can be perceived from Figure 
2.12, the limiting step in this purification protocol is the refolding/dialysis step. 
 The amount of dAb recovered in the refolding/dialysis step is drastically lower, when 
compared to the amount of protein recovered after the affinity chromatography 
purification, because most of the protein does not refold properly and precipitates in the 
refolding/dialysis column. 
Table 2.8 - Results of the dAbs purifications per liter of bacteria culture, using 
the insoluble dAb purification protocol. 
  dAb dAb concentration Total amount of dAb Purity (%)
§
 
VL CD4  75 ng/l 3,92 mg      95 
VL B12  140 ng/l 1,96 mg 95 
 
Although a very large amount of the purified dAb is lost in the refolding process, the 
total amount obtained for each dAb, per liter (Table 2.8), is almost ten times higher the 
the amount obtained in the soluble form (see Table 2.6). 
                                                 
§
 Purity was determined by densitometry using the Chemidoc software version 4.6 (Biorad, USA) 
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The concentrations for the dAbs, as indicated on Table 2.8, are actually the highest 
concentrations at which each of the dAbs is soluble in HEPES buffer. All attempts to 
achieve higher concentrations resulted in protein precipitation and loss of function. 
 
2.3.6 VLB12 and VLCD4 binding to hCD4 – characterization and domain 
identification 
After the purification of the VLB12 and VLCD4 dAbs using the protocol for purification 
of insoluble dAbs, further characterization of the interaction between the dAbs and the 
hCD4 was pursued.  
The specificity of VLB12 and VLCD4 to the human CD4 receptor had already been 
established by the ELISA assays performed to evaluate the dAbs binding to soluble 
hCD4 (see Figure 2.6) and by the Flow cytometry assays that validated that the binding 
was specific to CD4 (see Figure 2.7) and that both VLB12 and VLCD4 had a strong 
affinity to the CD4 receptor (see Figure 2.8) in a cell context. 
The next step was to identify the domain where VLB12 and VLCD4 bind to the human 
CD4 receptor. It has been described that the HIV-1 gp120 binds domain 1 of the CD4 
receptor
36,288,305,362
, so it was expected that VLCD4 would bind the same CD4 epitope. 
As for VLB12, since the grafted loop is also an HIV-1 gp120 highly conserved sequence 
that overlaps the gp120 CD4 binding sequence, we were also expecting binding in the 
domain 1 of the CD4 receptor. 
VLB12, VLCD4 and the original VL were submitted to ELISA assays to compare 
binding to soluble hCD4 and to CD4-IgG, a tetrameric fusion protein comprising human 
IgG2 in which the Fv portions of both heavy and light chains have been replaced by the 
V1 and V2 domains of human CD4 (Figure 2.13). 
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Figure 2.13 - ELISA assays were performed to evaluate VLB12, VLCD4 and the original VL binding 
to either soluble hCD4 or a CD4-IgG.  
(Continues on the next page) 
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a) VL B12 binding to either soluble hCD4 or a CD4-IgG on ELISA, using decreasing amounts of 
dAb. b) VL CD4 binding to either soluble hCD4 or a CD4-IgG on ELISA, using decreasing 
amounts of dAb. c) Original VL antibody binding to soluble hCD4 and to CD4-IgG on ELISA, 
using decreasing amounts of dAb. Assay was performed using 500 ng per well of soluble hCD4 or 
CD4-IgG as antigen. 3 % BSA (in PBS) was used for blocking and as negative control.  
A range of decreasing amounts of dAb was used (1500 ng, 1250 ng, 1000 ng, 500 ng, 250 ng, 100 ng, 
50 ng and 0 ng per well). The antibody used to detect the binding of the dAbs was -HA-HRP (1: 
1000) and the colorimetric substract used was ABTS (0,2 % H2O2). All incubation steps were 
performed at 37 ºC for 1 h. Results are expressed as mean ± SD of at least 3 independent 
experiments performed in triplicate. *** corresponds to P < 0,0001. 
 
The ELISA assays presented on Figure 2.13, were performed to compare binding to 
soluble hCD4 and to CD4-IgG, using 500 ng of each antigen per well and using 3 % 
BSA (in PBS) as a negative control and also as a blocking agent. A range of decreasing 
amounts of dAb was used (1500 ng, 1250 ng, 1000 ng, 500 ng, 250 ng, 100 ng, 50 ng 
and 0 ng per well).  From these assays it is possible to verify that both VLB12 and 
VLCD4 bind specifically to soluble hCD4 and to CD4-IgG, and that the binding to 
soluble hCD4 is proportional to the amount of dAb used. When analyzing the binding of 
both VLB12 and VLCD4 to CD4-IgG we see an increase in binding to CD4-IgG in the 
250 ng – 50 ng range, this is probably due to the fact that each CD4-IgG molecule 
possesses two binding sites, duplicating the amount of epitopes available e probably 
these are more readily accessible in an IgG format than in the full-length extracellular 
domain of human CD4 and as the dAb amount decreases, there is no excess of dAb and 
these differences are more readily noticed. 
Original VL antibody binding to soluble hCD4 and to CD4-IgG as also assessed to 
confirm that after the protein refolding step, VLB12 and VLCD4 produced using the 
insoluble dAb purification protocol, maintained their binding specificity. This can be 
confirmed when comparing either VLB12 or VLCD4 to the original VL antibody, where 
the original VL antibody presents no specific binding to either soluble hCD4 or CD4-
IgG as determined by the ELISA assays presented on Figure 2.13. 
These results also indicate that both VLB12 and VLCD4 bind to either domain 1 or 
domain 2 of the CD4 receptor, since all four domains are present in soluble hCD4 but 
only domain 1 and domain 2 are present in CD4-IgG. 
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2.3.7 ELISA assay to evaluate the dAbs binding to b12 mAb 
The ELISA assays presented on Figure 2.14 were also performed to evaluate the dAbs 
binding to b12 mAb. Since VLB12 was constructed by grafting of the gp120 b12 target 
sequence into the CDR1 of the original VL framework. We wanted to evaluate if b12 
target sequence is recognized by the b12 mAb antibody in the context of the VLB12 
grafting. The binding of b12 mAb to VLCD4 was also evaluated.  
 
 
Figure 2.14 - ELISA assays were performed to evaluate b12 mAb binding to VLB12 and VLCD4.  
a) b12 mAb binding to either VLB12 or BSA on ELISA, using decreasing amounts of b12 mAb.     
b) b12 mAb binding to either VLCD4 or BSA on ELISA, using decreasing amounts of b12 mAb.  
Assay was performed using 500 ng per well of VLB12 or VLCD4 as antigen. 3 % BSA (in PBS) was 
used for blocking and as negative control. A range of decreasing amounts of b12 mAb was used 
(1000 ng, 500 ng, 250 ng, 100 ng, 50 ng and 0 ng per well). The antibody used to detect the binding 
of the b12 mAb was a goat -Human IgG-HRP (1: 1000) and the colorimetric substract used was 
ABTS (0,2 % H2O2). All incubation steps were performed at 37 ºC for 1 h. Results are expressed as 
mean ± SD of at least 3 independent experiments performed in triplicate. *** corresponds to P < 
0,0001. 
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From these results (see Figure 2.14) it is possible to verify that b12 mAb binds 
specifically to VLB12, and this binding is proportional to the amount of b12 mAb 
present. Furthermore, it was also found that b12 mAb does not bind to VLCD4. These 
results confirm that VLB12 maintains the characteristics of the original gp120 epitope 
allowing it to be recognized by its specific antibody, b12 mAb, outside the gp120 
context and that the VLCD4, also retains the characteristics of the original gp120 
epitope and is not recognized by b12 mAb.  
 
2.3.8 VL B12 and VL CD4 binding to hCD4 – epitope characterization  
Another important feature is epitope characterization, and in particular determining if 
the epitopes recognized by VL B12 and VL CD4 are linear or conformational. 
 
 
Figure 2.15 - VLB12 and VLCD4 binding to soluble hCD4 – Epitope characterization. 
(Continues on the next page)  
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ELISA assays were performed using as antigen native conformation soluble hCD4 or denaturated 
soluble hCD4. For each assay, 500 ng of antigen (in PBS) were used per well. Denaturated soluble 
hCD4 was obtained by submitting the protein to heat denaturation for 10 minutes at 95 ºC. 3 % 
BSA (in PBS) was used for blocking and as negative control. a) A range of decreasing amounts of 
VLB12 was used (1500 ng, 1250 ng, 1000 ng, 500 ng, 250 ng, 100 ng, 50 ng and 0 ng per well).  
b) A range of decreasing amounts of VLCD4 was used (1500 ng, 1250 ng, 1000 ng, 500 ng, 250 ng, 
100 ng, 50 ng and 0 ng per well). For both assays the antibody used to detect the binding of the 
dAbs was -HA-HRP (1: 1000) and the colorimetric substract used was ABTS (0,2 % H2O2). All 
incubation steps were performed at 37 ºC for 1 h. Results are expressed as mean ± SD of at least 3 
independent experiments performed in triplicate. *** corresponds to P < 0,0001. 
 
To determine if the epitopes recognized by VLB12 and VLCD4 are linear or 
conformational, ELISA assays were performed (Figure 2.15) using as antigen native 
conformation soluble hCD4 or denaturated soluble hCD4. For each assay, 500 ng of 
antigen (in PBS) were used per well. Denaturated soluble hCD4 was obtained by 
submitting the protein to heat denaturation for 10 minutes at 95 ºC. When comparing 
both VLB12 and VLCD4 bindings to native conformation soluble hCD4 (Figure 2.15) it 
was observed a strong and specific binding, in agreement with the results obtained 
previously (Figure 2.13). On the other hand, both VLB12 and VLCD4 presented very 
low binding to denaturated soluble hCD4, meaning that the dAbs did not recognize the 
denaturated (linearized) epitopes. This proved that both VLB12 and VLCD4 recognized 
conformational epitopes. 
 
2.3.9 Flow cytometry assay to identify the hCD4 domain recognized by 
VLB12 and VLCD4  
The results obtained by the ELISA assays performed to evaluate the VLB12 and VLCD4 
binding to either soluble hCD4 or a CD4-IgG indicated that both VLB12 and VLCD4 
bind to either domain 1 or domain 2 of the CD4 receptor. To distinguish between 
binding to domain 1 or domain 2, another assay was designed, where by comparison of 
the binding to either mouse CD4 (mCD4), human CD4 (hCD4) or to a construct where 
the domain 1 of the human CD4 has been replaced by a mouse domain 1(hCD4mD1) 
we aimed to specifically identify the exact domain recognized by VLB12 and VLCD4 
(see Figure 2.16).  
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Figure 2.16 - Schematic representation of the HEK293T cells transfected with mCD4, hCD4 or 
hCD4mD1.  
Human embryonic kidney 293T (HEK293T) (ATCC, VA, USA) cells were transfected, by calcium 
phosphate method, with either human CD4 (hCD4), human CD4 with mouse Domain1 (hCD4mD1) 
or mouse CD4 (mCD4). Briefly, 240 000 HEK293T cells were transfected with one of the plasmids 
in order to produce HEK293T cells expressing hCD4, hCD4mD1 or mCD4. After 48 h, the 
transfected cells were stained and submitted to the Flow Cytometry assay to identify the hCD4 
domain recognized by VLB12 and VLCD4. This figure was designed through the Protein lounge 
software: Copyright www.proteinlounge.com, 2011. 
 
Figure 2.16 presents a schematic representation of the HEK293T transfection assay with 
the different CD4 receptors. The dAbs, VLB12 and VLCD4 have already been identified 
as binding to either domain 1 or domain 2. If one of the dAbs does not bind to mCD4, 
binds to hCD4 and it does not bind to hCD4mD1, this means that the dAb is binding to 
the only domain that is not present in the hCD4mD1, the human domain 1. On the other 
hand, if one of the dAbs does not bind to mCD4, binds to hCD4 and also binds to 
hCD4mD1, this means that the dAb is binding to a domain that is still present in the 
hCD4mD1, the human domain 2. 
The HEK 293T cells transfected with each of the CD4 plasmids were afterwards 
submitted to the Flow cytometry assays (see Figure 2.17).  
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               Controls  mCD4 hCD4    hCD4mD1 
a) 
 
e) 
   
b) 
 
f) 
   
c) 
 
g) 
 
  
d) 
 
h) 
   
 
 
 
Legend 
 
a) 293T   
b) 293T mCD4 
c) 293T hCD4 
d) 293T hCD4mD1 
e) cells+ -HA-FITC 
f) cells+ + -HA-FITC + * 
g) cells + 2,5ul -CD4-FITC + * 
h) cells +10 nmol VLB12+-HA-FITC+* 
i) cells+25 nmol VLB12+-HA-FITC+* 
j) cells +10 nmol VLCD4+-HA-FITC+* 
k) cells+25 nmol VLCD4+-HA-FITC+* 
 
*indicates that samples were also 
stained with -mouse-DyLight 
 
i) 
 
  
j) 
   
k) 
   
Figure 2.17 - Flow cytometry assay to identify the hCD4 domain recognized by VLB12 and VL CD4  
(continues on the next page) 
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For each assay condition, 200 000 (293T) transfected cells were stained. 293T cells were stained 48h 
after Calcium phosphate transfection of mouse CD4 (mCD4), human CD4 (hCD4) or human CD4 
with mouse Domain1 (hCD4mD1). For each assay condition 200 000 transfected cells were washed 
with PBS and incubated with 10 nmol or 25 nmol of either VLB12 or VL CD4 and also with 2,5 l 
of FITC Mouse Anti-Human CD4 (-CD4-FITC), all diluted in 1% BSA (in PBS). Afterwards, cells 
were washed with PBS and cells stained with the dAbs were incubated with 2,5 l anti-HA-FITC 
diluted in 1% BSA (in PBS). Cells were washed with PBS. All the cells stained with either VLB12, 
VL CD4 or  -CD4-FITC were again washed with PBS and stained with a-mouse-DyLight 405 
(1:5000). Cells were washed with PBS and fixated with 1 % p-formaldehyde (in PBS). Shown is one 
representative experiment out of three. 
 
As previously mentioned, HEK293T cells were transfected with mCD4, hCD4 or 
hCD4mD1 (see 2.2.14) and a Flow cytometry assay was performed to identify the 
hCD4 domain recognized by VLB12 and VLCD4, as positive control it was used the 
FITC Mouse Anti-Human CD4 (-CD4-FITC, clone RPA-T4) which binds to the D1 
domain (CDR1 and CDR3 epitopes) of the hCD4 antigen.
164,294
   
The results from the Flow cytometry assay are presented on Figure 2.17 and also on 
Table 2.9 (Shown is one representative experiment out of three.) 
 
Table 2.9 - % of binding to CD4 transfected cells 
 Controls mCD4 hCD4 hCD4mD1 
a) 0,052    
b) 0,11    
c) 0,077    
d) 0,8    
e)  0,064 0,11 0,41 
f)  22,7 31,3 33 
g)  18,3 72,4 29,7 
h)  19,5 60,6 41,4 
i)  30,3 76,64 53 
j)  34,5 31,5 29 
k)  26,8 56,3 28,1 
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Table 2.10 - % of binding to CD4 transfected cells.  
Relative values, where the background fluorescence from unspecific -HA-FITC-mouse-
DyLight 405 binding (condition f) is subtracted to the % of total CD4 positive cells for each 
condition under evaluation. 
 mCD4 hCD4 hCD4mD1 
f)  cells+ + -HA-FITC-mouse-DyLight    
g) cells + 2,5ul -CD4-FITC -mouse-DyLight -4,4 41,1 -3,3 
h) cells +10 nmol VLB12+-HA-FITC-mouse-DyLight 
-3,2 29,3 8,4 
i) cells +25 nmol VLB12+-HA-FITC-mouse-DyLight 
7,6 45,1 20,0 
j) cells +10 nmol VLCD4+-HA-FITC-mouse-DyLight 
11,8 0,2 -4,0 
k)   cells +25 nmol VLCD4+-HA-FITC-mouse-DyLight 
4,1 25,0 -4,9 
 
From the results obtained from the Flow cytometry assays performed to identify the 
hCD4 domain recognized by VLB12 and VLCD4, we can conclude that the -CD4-
FITC (clone RPA-T4) performed according to what has been described in the literature, 
since the -CD4-FITC binds to the domain 1 of the hCD4. In the Flow cytometry assay 
the -CD4-FITC did not bind to the mCD4 and neither to the hCD4mD1, indicating that 
an antibody that specifically recognizes the domain 1 of the hCD4 will not bind to the 
mCD4 and neither to the hCD4mD1 since in the hCD4mD1 the domain 1 present is the 
same as in the mCD4. 
As for VLB12, it presented no binding to mCD4 at 10 nmol (-3,2 %), but presented a 
slight binding (7,6 %) at 25 nmol. When comparing the binding of VLB12 at 25 nmol to 
hCD4 (45,1 %) and to hCD4mD1 (20%), the binding to mCD4 can be considered 
unspecific. Regarding binding to hCD4 at 10 nmol VLB12 presented a specific binding 
of 29,3 % and at 25 nmol the specific binding increased to 45,1 %, similar to the 
specific binding of the -CD4-FITC to the hCD4. This also correlates with the results 
obtained for both the -CD4-FITC and the VLB12 (this is the CDR1 grafting) that at 25 
nmol also presented almost the same specific binding to hCD4, that was also the case n 
the Flow cytometry assays performed to evaluate the binding of the dAbs in Jurkat cells 
(see 2.3.4). VLB12 can be considered to present no specific binding to mCD4, and 
specifically recognizes the hCD4. VLB12 also presents specific binding to hCD4mD1 
with a 8,1 % binding at 10 nmol and a 20,0 % binding at 25 nmol. The fact that VLB12 
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presents specific binding to hCD4mD1 indicates that VLB12 is not binding to the 
domain 1 of the CD4 receptor, but instead is binding to the domain 2.  
VLCD4, like VLB12 presents some unspecific binding to mCD4, this binding can also 
be considered unspecific since it is higher at a lower concentration and it does not 
correlate to the previously determined specific binding to hCD4 (see 2.3.4 and 2.3.6) 
that is higher at 25 nmol (25,0 %) than at 10 nmol (0,2 nmol). Contrary to VLB12, 
VLCD4 does not bind to hCD4mD1 indicating that VLCD4 binds specifically to the 
domain 1 of hCD4. The fact that VLCD4 binds to domain 1 of the hCD4 is in agreement 
with what has been described in the literature regarding the interaction between gp120 
and the CD4 receptor, where gp120 binds to the domain 1 of hCD4.
183,282,288
 Since 
VLCD4 was constructed by grafting of the gp120 CD4 binding epitope into the CDR3 
of the original VL framework, it was expected that VLCD4 would behave in the same 
manner as what has been described for gp120.   
 
2.4 Discussion 
From the results obtained from the expression and purification yields of the dAbs 
produced in the pComb3X vector it is possible to conclude that not all CDR 
combinations will be supported by the VL framework and that the sequence present in 
the CDRs plays an important role in antibody stability/solubility and that this is not 
directly correlated to the size of the CDR sequence. 
Although VLCD4 presents a higher expression and purification yields in the pComb3X 
system, than both VLB12 constructs (CDR1 and CDR3), this does not translate into 
antigen binding ability. In fact, both VLB12 constructs presented a higher binding to the 
human CD4 receptor than VLCD4, as determined by ELISA assays and by Flow 
cytometry analysis. 
The fact that the B12 target sequence presents a higher binding ability to the CD4 
receptor than the CD4 binding epitope itself, it is probably due to the context of 
antibody grafting. In the VLCD4 construct the CD4 binding epitope (10 amino acids) 
may not be sufficiently exposed to achieve optimal binding to the CD4 receptor, 
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contrary to what happens in the gp120 context. The larger B12 target sequence (23 
amino acids) allows for a higher exposure of the epitope that may facilitate binding to 
the antigen. 
When both proteins, VLCD4 CDR3 and VLB12 CDR1 were expressed in the pET 
system, due to the very high insoluble protein expression, the limiting step for the yield 
of purified protein was the refolding/dialysis step. Because most of the protein does not 
refold properly and precipitates in the refolding/dialysis column, the amount of protein 
recovered is drastically lower, when compared to the amount of protein recovered after 
the affinity chromatography purification. In fact, the maximum concentrations that we 
were able to obtain were 140 ng/l for VLB12 and 75 ng/l for VLCD4, because when 
in refolding/dialysis the recovered proteins were at higher concentrations, both proteins 
precipitated. As previously mentioned all attempts to achieve higher concentrations 
resulted in protein precipitation and loss of function. 
This proves that the VLB12 construct has a higher stability than VLCD4 since it 
maintains its function at higher concentrations than VLCD4, when subjected to 
refolding. 
After establishing that for both constructs, VLCD4 and VLB12, the binding was specific 
to CD4 and that both VLB12 and VLCD4 had a strong affinity to the CD4 receptor, the 
next step was to identify the domain where VLB12 and VLCD4 bind to the human CD4 
receptor.  
It has been described that the HIV-1 gp120 binds domain 1 of the CD4 
receptor
36,288,305,362
, so it was expected that VLCD4 would bind the same CD4 epitope. 
As for VLB12, since the grafted loop is also an HIV-1 gp120 highly conserved sequence 
that overlaps a conformationally invariant surface that overlaps a distinct subset of the 
gp120 CD4 binding site, we were also expecting binding in the domain 1 of the CD4 
receptor.  
The ELISA assays performed to compare binding to soluble hCD4 and to CD4-IgG 
confirmed that both VLB12 and VLCD4 bind to either domain 1 or domain 2 of the CD4 
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receptor, since all four domains are present in soluble hCD4 but only domain 1 and 
domain 2 are present in CD4-IgG. 
Further analysis of the CD4 domains involved in the dAbs binding to the CD4 receptor 
were performed in the Flow cytometry assays designed to identify the hCD4 domain 
recognized by each of the dAbs (Section 2.3.9) and it was possible to identify that 
VLCD4 binds to domain 1, but VLB12 on the other hand binds domain 2 of the CD4 
receptor. These findings reinforce the fact that although these regions have a similar 
spatial distribution at the gp120 surface after binding to either the CD4 receptor (for the 
CD4 binding epitope, VL CD4) or to b12 mAb (for the B12 target sequence, VL B12) 
they are in fact two independent regions with different roles in the interaction between 
gp120 and the CD4 receptor. 
Regarding epitope characterization, as previously mentioned both VLB12 and VLCD4 
presented very low binding to denaturated soluble hCD4, meaning that the dAbs did not 
recognize the denaturated (linearized) epitopes. This proved that both VLB12 and 
VLCD4 recognized conformational epitopes. 
 
In conclusion, both VLCD4 and VLB12 bind specifically to the hCD4 cell receptor and 
recognize conformational epitopes in respectively, domain 1 and domain 2 of the CD4 
receptor. Both domain 1 and domain 2 of the CD4 receptor are targeted by HIV-1 
neutralizing antibodies.
112,150
 So, the next step was to evaluate the VL B12 and VL CD4 
ability to inhibit HIV-1 infection. 
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3 HIV-1 Inhibition by single domain antibodies  
 
3.1 Introduction 
Due to the characteristics and nature of HIV infection, including the ability to establish 
reservoirs in various cell lines and progressive and irreversible destruction of the 
immune system associated with an increased prevalence of strains resistant to drug 
therapy, one of the priority areas in the development of new drugs has been the 
development of new molecules which prevent viral entry into cells, including peptides 
and antibodies that prevent the entry process.  
The antibody response to HIV-1 in vivo is directed against several viral proteins, 
however, essentially all neutralizing antibodies are directed toward the viral Envelope 
spike, in particular the surface unit glycoprotein (gp) 120.
245,356
 No naturally occurring 
anti HIV-1 antibodies are directed against the CD4 cell receptor, although there is a  
nonimmunosuppressive, humanized IgG4 monoclonal antibody, derived from a mouse 
antibody, 5A8, which binds domain 2 of CD4. This monoclonal antibody that blocks 
HIV-1 entry by binding to domain 2 of human CD4 (Ibalizumab), blocks HIV-1 
infection in vitro and  is currently on phase III clinical trials.
40,43,87,88,148,268
  
Ibalizumab is the first from a new class of entry inhibitors, the inhibitors of gp120-CD4 
interaction, this paves the way for a new approach to HIV-1 inhibition. Entry inhibitors 
are broadening, the so far limited number of viable alternative strategies to contain the 
virus without recourse to antiretroviral drug cocktails. 
In this chapter we wanted to evaluate the ability of our anti-CD4 antibodies, VLB12 and 
VLCD4, to inhibit HIV-1 infection, by binding to either domain 2 or domain 1 of the 
CD4 cell receptor, respectively. For that we performed inhibition assays against the 
HIV-1 NL4-3 subtype B molecular clone and two non B primary isolates, a subtype J 
and a subtype H primary isolates.  The effect of both dAbs on cell viability was also 
evaluated.  
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3.2 Materials and Methods 
3.2.1 Cell Lines and culture conditions 
Human embryonic kidney 293T (HEK293T) (ATCC, VA, USA), and TZM-bl (obtained 
through the NIH AIDS Research and Reference Reagent Program, MD, USA, 
contributors Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.) cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS) here on designated DMEM‐10. 
All cell cultures were maintained at 37 °C in 5 % CO2. All cell culture media and 
reagents, otherwise indicated, were from Lonza (Basel, Switzerland). 
 
3.2.2 NL4-3 Viral production 
HEK293T cells were transfected, by calcium phosphate method, with pHIV‐1NL4‐3 
plasmids (AIDS reagent, contributor Dr. Malcolm Martin) in order to produce 
HIV‐1NL4‐3 virions. After 48 h, virions were collected from supernatant cultures, the 
amount of viral particles released in the supernatant was measured by p24CA ELISA 
(AIDS & Cancer Research Program, NCI Frederick, MD, USA) and HIV‐1NL4‐3 virions 
were used to infect TZM-bl cells. 
 
3.2.3 Primary isolates viral production 
Primary isolates were obtained from HIV-1-infected Angolan patients, all naïve to 
therapy with entry inhibitors, by cocultivation with PBMCs and stimulated with 
phitohemagglutinin from seronegative subjects. Cultures were maintained and expanded 
until the amount of viral particles released in the supernatant was measured by p24CA 
ELISA and the results obtained gave overflow. Virions were then collected from 
supernatant cultures, and the amount of infectious viral particles released in the 
supernatant was measured by performing infection assays with serial dilution in TZM-bl 
cells.
58
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Briefly, 10,000 cells per well were seeded in a 96-well plate in 100 l/well of 
DMEM‐10 and incubated overnight at 37°C. The next day, the media was removed and 
200 l of serial diluted primary isolate (subtype J or H) were prepared, in DMEM‐10, 
and added to the cells.  
The cells were incubated for 48 h at 37 °C in 5 % CO2. Assay medium was removed 
from each well, cells were washed with 200 l of PBS and 50 l of Passive Lysis Buffer 
reagent (Promega, Madison, WI) were added. This was followed by a freeze-thaw step 
(-20 ºC – 37 ºC) afterwhich 10 l cell lysates from each sample (in Passive Lysis 
Buffer) were placed in a 96 well Luminescence Plate (BD Falcon 96 Flat Bottom White 
Opaque Polystyrene Plate, BD Biosciences, USA). 50 l Luciferase Assay Reagent II 
(LAR II) were added to each sample and luminescence was measured using an Infinite 
200 Microplate Reader (Tecan i-control software, version 1.5.14.0, Tecan, North 
Carolina, USA).  
 
3.2.4 Virus inhibition assay using TZM-bl cells. 
 An inhibition assay was performed based on the methods of Wei et al. 
341
 with 
modification.
192,215
 TZM-bl cells were derived from a HeLa cell line (JC.53) that stably 
expresses CD4 and CCR5. TZM-bl cells also express luciferase and -galactosidase 
under the control of the HIV-1 promoter.  
Briefly, 10,000 cells per well were seeded in a 96-well plate in 100 l/well of 
DMEM‐10 and incubated overnight at 37°C. The next day, the media was removed and 
100 l of serial diluted VLB12 or VLCD4 was added to the cells and incubated for 1 h at 
37°C.  Then, 100 l of HIV‐1 were prepared, in DMEM‐10, for a multiplicity of 
infection (MOI) of 0,5 (NL4-3) or MOI of 10 (subtype J and H primary isolates) and 
added to the cells. 
**
 
                                                 
**
 For the T20 assays the incubation step with the inhibitor was performed with virus and not with the 
cells. 
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The cells were incubated for 48 h at 37 °C in 5 % CO2. Assay medium was removed 
from each well, cells were washed with 200 l of PBS and 50 l of Passive Lysis Buffer 
reagent (Promega, Madison, WI) were added. This was followed by a freeze-thaw step 
(-20 ºC – 37 ºC) afterwhich 10 l cell lysates from each sample (in Passive Lysis 
Buffer) were placed in a 96 well Luminescence Plate (BD Falcon 96 Flat Bottom White 
Opaque Polystyrene Plate, BD Biosciences, USA). 50 l Luciferase Assay Reagent II 
(LAR II) were added to each sample and luminescence was measured using an Infinite 
200 Microplate Reader.  
 
The 50 % inhibitory concentration (IC50) was calculated based on the antibody dilution 
that caused a 50% reduction in relative luminescence units (RLU) compared to the virus 
control wells after subtraction of cell control RLUs. 
 
3.2.5 Assessment of cell viability in the presence of the recombinant 
antibodies 
Briefly, 10,000 TZM-bl cells per well were seeded in a 96-well plate in 100 l/well of 
DMEM‐10 and incubated overnight at 37°C. The next day, the media was removed and 
100 l of serial diluted VLB12, VLCD4 or HEPES buffer alone, were added to the cells 
and incubated for 1 h at 37°C.  Then, 100 l of DMEM‐10 was added to the cells. The 
cells were incubated for 48 h at 37°C in 5 % CO2. 100 l assay medium was removed 
from each well and 10 l AlamarBlue cell viability reagent (Invitrogen, UK) was added. 
The cells were incubated for 2 h at 37°C in 5 % CO2. Cell viability was assessed by 
fluorescence emission intensity at 570 nm in an Infinite 200 Microplate Reader (Tecan i-
control software, version , 1.5.14.0, Tecan, North Carolina, USA). 
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3.2.6 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, 2007, San Diego, California, USA, www.graphpad.com) with a 
level of significance of 5%. IC50s were estimated by the sigmoidal dose-response 
(variable slope) equation - GraphPad Prism version 5.00. 
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3.3 Results 
 
3.3.1 HIV-1 inhibition assays 
HIV‐1 inhibition assays were performed in TZM-bl cells, a HeLa cell line that was 
engineered to express CD4 and CCR5 and contains integrated reporter genes for firefly 
luciferase and E. coli β-galactosidase under the control of the HIV-1 LTR. 
In order to evaluate the VL B12 and VL CD4 ability to inhibit HIV-1 infection, 
inhibition assays were performed with the HIV‐1 NL4‐3 subtype B molecular clone2  in 
in TZM-bl cells in a single cycle infection assay. The HIV‐1NL4‐3 inhibition assays were 
performed with an MOI = 0,5 and the Luciferase activity was measured after 48 h of 
incubation and is directly proportional to the number of infectious virus particles that 
entered the cell.  
The HIV‐1NL4‐3 inhibition assays performed to evaluate VLB12 entry inhibitor capability 
were performed with a starting concentration of 21 M. TZM-bl cells were incubated 
for 1 h with nine serial dilutions of VLB12, afterwich HIV‐1NL4‐3 was added at the 
indicated MOI.  As shown in Figure 3.1, VLB12 was able to inhibit HIV‐1NL4‐3 with an 
IC50 = 3,89 M.  
 
In the case of VLCD4, the HIV‐1NL4‐3 inhibition assays were performed with a starting 
concentration of 10,5 M. TZM-bl cells were also incubated for 1 h with nine serial 
dilutions of VLCD4, afterwich HIV‐1NL4‐3 was added at the indicated MOI.  As shown in 
Figure 3.1, VLCD4 was able to inhibit HIV‐1NL4‐3 with an IC50 = 6,57 M. 
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Figure 3.1 – HIV‐1NL4‐3 inhibition assays performed in TZM-bl cells. 
 a) HIV‐1NL4‐3 inhibition assays using VLB12 in TZM-bl cells. TZM-bl cells were incubated for 1 h 
with nine serial dilutions of VLB12, afterwich HIV‐1NL4‐3 was added at an MOI = 0,5 (200 l final 
volume).  Assay was performed with a VLB12 starting concentration of 21 M. A sigmoidal dose 
response curve was calculated and an IC50 = 3,89 M was obtained. b) HIV‐1NL4‐3 inhibition assays 
using VLCD4 in TZM-bl cells. . TZM-bl cells were incubated for 1 h with nine serial dilutions of 
VLCD4, afterwich HIV‐1NL4‐3 was added at an MOI = 0,5 (200 l final volume). (Continues on the 
next page) 
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Assay was performed with a VLCD4 starting concentration of 10,5 M. A sigmoidal dose response 
curve was calculated and an IC50 = 6,57 M was obtained. c) HIV‐1NL4‐3 inhibition assays using T20 
in TZM-bl cells. HIV‐1NL4‐3 was incubated for 1 h with eight serial dilutions of T20, afterwich 
HIV‐1NL4‐3 incubated with the T20 were added at an MOI = 0,5 (200 l final volume) to TZM-bl 
cells. Assay was performed with a T20 starting concentration of 1 M. A sigmoidal dose response 
curve was calculated and an IC50 = 0,0694 M was obtained.  Results are expressed as mean ± SD of 
at least 3 independent experiments performed in triplicate. 
 
The starting concentrations for both VLB12 and VLCD4 were dependent on the 
maximum concentrations at which the purified dAbs are stable (see section 2.3.5). Since 
VLCD4 is only stable at a maximum of 42 pmol/l in HEPES buffer, and VLB12 is 
stable at a maximum of 84 pmol/l in HEPES buffer, this translated into different 
starting concentrations for both dAbs. 
Although the obtained IC50 for VLB12 was 3,89 M and the IC50 obtained for VLCD4 
was 6,57 M, the maximum percentage of inhibition achieved with VLB12 was 92,0 % 
but for VLCD4 was only 57,5 %. Moreover at 10,5 M the percentage of inhibition 
achieved with VLB12 was 89,4 % as opposed to the 57,5 % for VLCD4. This shows that 
VLB12 is a more potent entry inhibitor that VLCD4 when tested against HIV-1NL4‐3 
(subtype B molecular clone). T20 inhibition assays of HIV-1NL4‐3 were also performed 
and the IC50 obtained for T20 was 0,0694 M. 
While performing HIV-1 inhibition assays it was also necessary to evaluate the effect of 
the dAbs and also of the HEPES buffer solution in cellular viability for the TZM-bl cell 
line in the concentration range used for the inhibition assays. TZM-bl cell viability 
assay was performed in the same conditions as the HIV-1 inhibition assays, only instead 
of HIV-1NL4‐3 only DMEM-10 medium was added to the cells after the 1h incubation 
with either HEPES buffer or the dAbs. 
The effect of T20 on TZM-bl cellular viability was not evaluated since T20 is a 
compound already approved for clinical use and therefore does not affect cellular 
viability. 
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Figure 3.2 – TZM-bl cell viability was evaluated using alamarBlue.  
TZM-bl cells were incubated with either HEPES buffer alone or with each dAb. Assay was 
peformed with a) VL B12  and HEPES buffer or b) VL CD4 and HEPES buffer.  TZM-bl cells were 
incubated for 1 h with nine serial dilutions of each dAb,  afterwich DMEM-10 was added to a final 
volume of 200 l.  Cell viability was evaluated 48 h after dAbs were added to the cells. 100 l of cell 
media were removed and 10 l of alamarBlue cell viability reagent were added to the cell medium. 
After 2 h of incubation at 37 ºC cell viability was assessed by fluorescence spectrophotometry. 
Results are expressed as mean ± SD of at least 3 independent experiments performed in triplicate. 
The results shown on Figure 3.2 prove that both VLB12 and VLCD4 do not decrease 
TZM-bl cell viability, this indicates that the dAbs do not possess a cell toxicity effect as 
far as analysis of cell proliferation and cytotoxicity is measurable by AlamarBlue.  
After performing the inhibition assays for HIV-1NL4‐3 it was important to evaluate the 
inhibitory capability of both VLB12 and VLCD4 on HIV-1 primary isolates, and in 
particular for other HIV-1 subtypes. 
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In order to evaluate the VLB12 and VLCD4 ability to inhibit HIV-1 non B subtypes, 
inhibition assays were performed with two HIV‐1 primary isolates, a subtype J primary 
isolate and a subtype H primary isolate. T20 inhibition assays were also performed. 
 
HIV‐1 primary isolates inhibition assays were performed using TZM-bl cells in a single 
cycle infection assay. Since these subtypes are not as infectious as NL4‐3, infection 
assays were performed with an MOI = 10. 
 
VLB12 entry inhibitory capability for a subtype J and a subtype H primary isolates were 
performed with a starting concentration of 21 M. TZM-bl cells were incubated for 1 h 
with nine serial dilutions of VLB12, afterwich either subtype J or subtype H was added 
at the indicated MOI.  As for HIV-1NL4‐3 inhibition assays, VLCD4 starting 
concentration was 10,5 M. TZM-bl cells were also incubated for 1 h with nine serial 
dilutions of VLCD4, afterwich either subtype J or subtype H was added at the indicated 
MOI. T20 inhibition assays for subtype J and subtype H primary isolates were 
performed with a starting concentration of 8,5 M. Either HIV-1 subtype J or subtype H 
were incubated for 1 h with eight serial dilutions of T20, and afterwards the virus 
incubated with the T20 were added at the indicated MOI to TZM-bl cells.  
 
As shown in Figure 3.3, VLB12 was able to inhibit HIV‐1 subtype H with an IC50 = 3,97 
M and HIV‐1 subtype J with an IC50 = 3,86 M. VLCD4 was not able to inhibit either 
subtype J or subtype H primary isolates. As for T20, it was able to inhibit HIV‐1 
subtype H with an IC50 = 1,33 nanoM and HIV‐1 subtype J with an IC50 = 0,42 nanoM. 
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Figure 3.3 – HIV‐1 primary isolates inhibition assays using TZM-bl cells. 
 a) HIV‐1 primary isolates, subtypes H and J, neutralization assays using VLB12 in TZM-bl cells. 
Assay was performed with a VLB12 starting concentration of 21 M. (continues on the next page) 
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 A sigmoidal dose response curve was calculated and an IC50 = 3,97 M was obtained for HIV‐1 
subtype  H and IC50 = 3,86 M was obtained for HIV‐1 subtype  J. b) HIV‐1 primary isolates, 
subtypes H and J, neutralization assays using VLCD4 in TZM-bl cells. Assay was performed with a 
VLCD4 starting concentration of 10,5 M. No sigmoidal dose response curve was calculated 
because no inhibition was obtained for HIV‐1 subtype  H or subtype  J. . c) HIV‐1 primary isolates, 
subtypes H and J, neutralization assays using T20 in TZM-bl cells. Assay was performed with a T20 
starting concentration of 8,5 M. A sigmoidal dose response curve was calculated and an IC50 = 
1,33 nanoM was obtained for HIV‐1 subtype  H and IC50 = 0,42 nanoM was obtained for HIV‐1 
subtype  J. Results are expressed as mean ± SD of 3 independent experiments performed in 
duplicate. 
 
3.4 Discussion 
The HIV‐1NL4‐3 inhibition assays performed to evaluate VLB12 and VLCD4 entry 
inhibitory capability demonstrated that VLB12 was able to inhibit HIV‐1NL4‐3 with an 
IC50 = 3,89 M and VLCD4 was able to inhibit HIV‐1NL4‐3 with an IC50 = 6,57 M. 
While the maximum percentage of inhibition achieved with VL B12 was 92,0 %, for 
VLCD4 was only 57,5 %. Moreover at 10,5 M the percentage of inhibition achieved 
with VLB12 was 89,4 % as opposed to the 57,5 % for VLCD4. This shows that VLB12 is 
a more potent entry inhibitor that VLCD4 when tested against HIV-1NL4‐3 (subtype B 
molecular clone).  
When compared to T20 (IC50 = 0,0694 M) both dAbs present a much higher IC50, 
indicating that the dAbs are less potent entry inhibitors than T20 against HIV-1NL4‐3.  
With regard to the VLB12 and VLCD4 ability to inhibit HIV-1 non B subtypes, 
inhibition assays were performed with two HIV‐1 primary isolates, a subtype J primary 
isolate and a subtype H primary isolate. VLB12 was able to inhibit HIV‐1 subtype H 
with an IC50 = 3,97 M and HIV‐1 subtype J with an IC50 = 3,86 M but VLCD4 was 
not able to inhibit either subtype J or subtype H primary isolates. 
VLB12 presented an IC50 almost identical for either HIV‐1NL4‐3, subtype J or subtype H 
primary isolates that could indicate a potent broad spectrum of both laboratory-adapted 
and clinical HIV-1 isolates inhibitory capability. 
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Since VLCD4 was unable to inhibit neither of the HIV-1 non B subtypes tested and due 
to its poor performance, when compared to VLB12, it is reasonable to assume that 
VLB12 is a much more promising entry inhibitor, with no cell toxicity effect as far as 
analysis of cell proliferation and cytotoxicity was measurable in the conditions tested. 
Regarding the primary isolates inhibition assays, T20 was able to inhibit HIV‐1 subtype 
H with an IC50 = 1,33 nanoM and HIV‐1 subtype J with an IC50 = 0,42 nanoM. So, as 
for HIV-1NL4‐3 inhibition assays T20 presents a much lower IC50 and is also a more 
potent entry inhibitor against the primary isolates tested, but T20 has a different target 
than the dAbs. T20 targets gp41 and due to the virus high frequency of mutation many 
strains show broad cross-resistance to antiretroviral drugs, including T20.
184,212,257
 
It is also important to compare the VLB12 with the only entry inhibitor that targets the 
gp120-CD4 interaction. Ibalizumab blocks CD4-dependent virus entry and inhibits a 
broad spectrum of both laboratory-adapted and clinical HIV-1 isolates, including 
CCR5-tropic and CXCR4-tropic strains from multiple subtypes, with 50% inhibitory 
concentrations (IC50s) of 0.0004 to 0.152 g/ml (0,0027 to 1,026 nM).301 The IC50 for 
VLB12 is much higher than Ibalizumab’s, when comparing the IC50 for HIV‐1NL4‐3, 
Ibalizumab has an IC50 of 0,73 g/ml (4,93 nM)
360
 and VLB12 was only able to inhibit 
HIV‐1NL4‐3 with an IC50 = 3,89 M which is almost 1000 times higher.  
It has already been reported in vitro studies that demonstrate the synergistic activity of 
Ibalizumab (TNX-355) and enfuvirtide (T20) against HIV-1.
360
 Implying that an entry 
inhibitor that targets the gp120-CD4 interaction, like VLB12, can also prove to be useful 
as a therapeutic aid in improving the therapeutic response of enfuvirtide and other entry 
inhibitors treated patients. Although it is not as potent as Ibalizumab, VL B12 may prove 
to be another non pharmacological therapeutical alternative in the treatment of HIV-1 
infection, since entry inhibitors that target CD4 hopefully will be less susceptible to 
broad cross-resistance than antiretroviral drugs that target the virus itself. 
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4 VL B12 coated nanoparticles - A new therapeutic delivery 
system  
4.1 Introduction 
4.1.1 Nanoparticles  
The efficacy of many drugs is often limited by their potential to reach the site of 
therapeutic action. In most of the conventional dosage forms, only a small amount of 
administered dose reaches the target site, while the majority of the drug distributes 
throughout the rest of the body in accordance with its physicochemical and biochemical 
properties. Therefore, developing a drug delivery system that optimizes the 
pharmaceutical action of a drug while reducing its toxic side effects in vivo is a 
challenging task. 
One approach is the use of synthetic nonviral vectors such as cationic liposomes and 
cationic polymers that can provide site specific or targeted drug delivery combined with 
optimal drug release profiles. Liposomes present some technological limitations 
including poor reproducibility and stability, and low drug entrapment efficiency. 
Nevertheless, several low molecular weight drugs are now commercially available 
which employ this technology. 
198,229
 
Polymeric nanoparticles, which possess a better reproducibility and better stability 
profiles than liposomes, have been developed as alternative drug carriers that overcome 
many of the liposome formulation problems. These polymeric nanoparticles are 
composed of polysaccharides that are derived from natural sources, and therefore they 
are expected to be nontoxic, biocompatible, and biodegradable.
198,229
 
Nanoparticles are solid colloidal particles with diameters ranging from 1-1000 nm. 
They consist of macromolecular materials and can be used therapeutically as drug 
carriers or as adjuvant in vaccines in which the active ingredient is dissolved, entrapped, 
encapsulated, adsorbed or chemically attached. 
There are two types of nanoparticles depending on the preparation process: nanospheres 
and nanocapsules. Nanospheres have a monolithic-type structure (matrix) in which 
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drugs are dispersed or adsorbed onto their surfaces. Nanocapsules exhibit a membrane-
wall structure and drugs are entrapped in the core or adsorbed onto their exterior.
8
  
Nanoparticles not only have potential as drug delivery carriers as they offer non-
invasive routes of administration such as oral, nasal and ocular routes, but also show to 
be good adjuvant for vaccines.
77,186
 
Nanoparticles being compact are well suited to traverse cellular membranes to mediate 
drug or gene delivery. It is also expected that due to smaller size, nanoparticles will be 
less susceptible to reticuloendothelial system clearance and will have better penetration 
into tissues and cells, when used in in vivo therapy.
361
 
 
4.1.2 Chitosan (CS) nanoparticles 
Chitosan is a modified natural carbohydrate polymer prepared by the partial N-
deacetylation of chitin, a natural biopolymer derived from crustacean shells such as 
crabs, shrimps and lobsters. Chitosan is also found in some microorganisms, yeast and 
fungi.
145,198,225
 
Among water-soluble polymers available, chitosan is one of the most extensively 
studied. This is because chitosan possesses some ideal properties of polymeric carriers 
for nano- and microparticles for controlled drug release, such as biocompatible, 
biodegradable, nontoxic, inexpensive, and providing versatile routes of administration. 
Chitosan nanoparticles also avoid the use of hazardous organic solvents while 
fabricating particles since they are soluble in aqueous acidic solution.
225
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4.1.3  Polyethylenimine (PEI) nanoparticles 
Recently, the use of non-viral vectors such nanoparticles to deliver plasmid DNA 
(pDNA) have been highlighted. Poly(ethylenimine) (PEI) has been revealed to be the 
most effective nonviral vector based on cationic polymers owing to its high pH 
buffering capacity that is believed to enhance the exit of vectors from the endosomal 
compartment for  subsequent release of DNA–PEI complex.229 Different types of 
polyethylenimine (PEI), branched (25 and 800 kDa) and linear (25 kDa), have been 
successfully used.
247
 
Polycationic polymers, particularly polyethylenimine (PEI), have the ability to bind 
with pDNA easily, and can be applied to a wide variety of cells. PEI condenses DNA 
into positively charged particles, which bind to anionic cell surface residues and these 
condensed particles can enter  the cell via endocytosis.
153,157,229,361
 
These unique characteristics make PEI nanoparticles uniquely suited for delivery of 
DNA to a target cell, however, a major disadvantage of using PEI nanoparticles is that a 
considerable toxicity associated with PEI at the cellular level is widely demonstrated.
229
 
 
4.1.4 Nanoparticle formulations with VL B12 for FUGW-dsRed delivery to 
CD4 positive cells. 
Bearing in mind both the advantages and disadvantages of either CS or PEI 
nanoparticles, in this Chapter we wanted to evaluate both nanoparticles formulations for 
VLB12 coated nanoparticles delivery to CD4 positive cells. In order to evaluate 
nanoparticles delivery to the cells, we encapsulated in either CS or PEI nanoparticles a 
pDNA, FUGW-dsRed , that is a lentiviral vector that once it successfully enters the cell 
expresses the DsRed red fluorescent protein. The DsRed fluorescence can be detected 
either by immunofluorescence or by Flow cytometry. 
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4.2 Materials and Methods 
4.2.1 Cell Lines and culture conditions 
Jurkat E6‐1 T‐cells obtained through the NIH AIDS Research and Reference Reagent 
Program (MD, USA, contributor Dr. Arthur Weiss) were cultured in Roswell Park 
Memorial Institute medium (RPMI)‐1640, supplemented with 10 % of fetal bovine 
serum (FBS) (RPMI‐10). 
 Cell cultures were maintained at 37 °C in 5 % CO2. All cell culture media and reagents, 
otherwise indicated, were from Lonza (Basel, Switzerland). 
 
4.2.2 Determination of the optimal pDNA/nanoparticle ratio for CS/DS and 
PEI nanoparticles 
The optimal pdna/nanoparticle ratio for nanoparticle encapsulation was determined by 
agarose gel electrophoresis. CS/DS and PEI nanoparticle formulations we ran in a 1 % 
agarose gel (in tris-borate- EDTA buffer (TBE buffer)) in order to determine if the 
plasmid DNA was properly encapsulated in the nanoparticles in the presence of VLB12 
or in the absence of VLB12. The DNA ladder used was a 1 kb DNA ladder (New 
England Biolabs, MA, USA) and was ran as a control for DNA migration in the agarose 
gel.  
 
4.2.3 Preparation of chitosan-sodium deoxycholate (CS/DS) nanoparticles 
The Low molecular weight chitosan (CS, 75-85% degree of deacetylation) and sodium 
deoxycholate (DS) were obtained from Sigma-Aldrich. CS/DS nanoparticles were 
prepared using an ionic gelation technique as previously described. 
230
 Briefly, CS and 
DS were separately dissolved in ultra-pure water in order to obtain 1 mg/ml solutions. 
CS/DS nanoparticles were formed on a 1:1 (weight:weight, w/w) ratio, when DS 
solution was added to a CS solution. For the nanoencapsulation, FUGW-dsRed plasmid 
was added to DS solution before the addition to the CS solution, at a proportion of 
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weight: weight of 20% pDNA: chitosan. The plasmid adsorption to the nanoparticles 
surface was done at 4ºC for 24 hours. 
Table 4.1 -VLB12 coated CS/DS nanoparticle formulations with encapsulated FUGW-dsred plasmid 
Formulation Amount of VLB12 
(g/ml) 
Amount of FUGW-dsREd 
(g/well) 
b) 0 0 
c) 105 0 
d) 84 0 
e) 47 0 
f) 0 1 
g) 105 1 
h) 84 1 
i) 47 1 
 
4.2.4 Preparation of PEI based nanoparticles 
Polyethyleneimine (PEI 25 kDa; branched) was obtained from Sigma. A stock PEI 
solution was prepared in water at a final concentration of 1 mg/mL (pH 7.0) and 
sterilized by filtration. For each 2.5 µg of DNA and the amount of PEI necessary to   
have a ratio DNA:PEI 1:5 (W/W), were added separately to 50 µL of 150 mM NaCl. 
Prior to transfection, the PEI/NaCl solution was added to the DNA/NaCl solution and 
allowed to stand at room temperature for 10 min before addition to the culture.  
Table 4.2 - VLB12 coated PEI nanoparticle formulations with encapsulated FUGW-dsred plasmid 
Formulation Amount of VLB12 
(g/ml) 
Amount of FUGW-dsREd 
(g/well) 
b) 0 0 
c) 48 0 
d) 29 0 
e) 11 0 
f) 0 0,5 
g) 48 0,5 
h) 29 0,5 
i) 11 0,5 
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4.2.5 Transfection assays for immunofluorescence assays 
For transfection assays Jurkat E6‐1 T‐cells were grown at 37 ºC with 5% CO2 in a 
humidified atmosphere in RPMI-10 medium supplemented with 100 U penicillin, and 
0.1 mg streptomycin (Invitrogen, UK) per millilitre. Cells were grown in 96-well white 
clear bottom plates (Greiner-Bio One, Frickenhausen, Germany) to approximately 50-
60% confluence and transfected using CS/DS, containing 1 g of FUGW-dsRed  
plasmid per well at optimal amount of adsorbed antibody, controls of cells without 
nanoparticles and with empty nanoparticles were also run. 24h after transfection, the 
medium was changed. The fluorescence of cells was measure directly on plate, 24 h and 
72 hours after transfection. The fluorescence was measured at an excitation wavelength 
of 554 nm and emission wavelength of 591 nm, using an Infinite 200 Microplate Reader 
(Tecan i-control software, version 1.5.14.0, Tecan, North Carolina, USA).  
 
4.2.6 Immunofluorescence 
The fluorescence of Jurkat cells was measure at an excitation wavelength of 554 nm and 
emission wavelength 591 nm. Cells were recovered and counted with trypan blue and 
fixed for microscope fluorescence picture. The fluorescence of the cells that were 
transfected was subtracted from the controls and normalized by cell number and per 
24h.  
For fixation cells were rinsed twice with PBS and fixed for 30 min in a 4% (v/v) p-
formaldehyde (PFA) (Merck, Darmstadt, Germany) and 4% (w/v) sucrose (Applichem, 
Darmstadt, Germany) solution, in PBS (Merck, Germany). After two washes with PBS, 
free aldehyde groups were quenched for 15 min with 50 mM NH4Cl (Merck, Germany) 
in PBS. Cell slides were mounted in fluorescent mounting medium (S3023; Dako, 
Glostrup, Denmark) or ProLong® Gold antifade reagent with DAPI and their 
fluorescence was observed and recorded on an Axiovert 40CFL fluorescence 
microscope (Carl Zeiss, Jena, Germany) equipped with an Axiocam MRc5 (Carl Zeiss) 
camera. Images were processed with the software AxioVision Rel. 4.6.3 (Carl Zeiss).  
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4.2.7 VLB12 coated nanoparticles targeting CD4 cell receptor for FUGW-
dsred plasmid delivery to Jurkat cells 
Briefly, 20,000 Jurkat cells per well were seeded in a 96-well plate in 100 l/well of 
RPMI‐10 and incubated at 37°C in 5 % CO2. 24h latter, 50 l/well of RPMI‐10 were 
added. 48 h after cells were seeded; each nanoparticle formulation (see Table 4.1 and 
Table 4.2) was added to the media and incubated at 37°C in 5 % CO2.  Cell culture media 
(RPMI-10 supplemented with gentamicin) was replaced at 24h and 48h. Cells were 
recovered 72 h post nanoparticle delivery. 
 
4.2.8 Flow cytometry analysis of nanoparticle delivery to Jurkat cells 
For each assay condition, of the VLB12 coated nanoparticles targeting CD4 cell receptor 
for FUGW-dsred plasmid delivery to Jurkat cells (see 4.2.7), cells were washed with 
PBS and fixated with 1 % p-formaldehyde (in PBS). 
All flow data were acquired on a BD Calibur (BD Biosciences, Franklin Lakes, NJ 
USA), 10 000 gated cells were acquired for each assay condition and data analysis was 
performed using Flowjo software 6.4.7 (BD Biosciences, Franklin Lakes, NJ USA). 
. 
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4.3 Results 
In this chapter we wanted to evaluate the ability to use VLB12 as a vehicle for target 
specific drug delivery, using as carriers either CS/DS or PEI nanoparticles. To validate 
the ability of VLB12 to specifically deliver CS/DS or PEI nanoparticles to CD4 positive 
cells we used as a reporter gene dsRed, a red fluorescent protein chromophore cloned in 
the FUGW lentiviral vector (Addgene plasmid repository, Cambridge, MA, USA).
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Cells with positive nanoparticles delivery of the dsRed reporter gene, will express the 
dsRed red fluorescent protein. The dsRed fluorescence is detectable either by 
immunofluorescence or by Flow cytometry. 
4.3.1 Determination of the optimal pDNA/nanoparticle ratio for CS/DS and 
PEI nanoparticles 
The optimal pdna/nanoparticle ratio (W/W) is usually between 20 to 40 % in order for a 
proper nanoparticle packaging to occur. Several pdna/nanoparticle ratios were tested 
either for CS/DS or PEI. The optimal pdna/nanoparticle ratio for nanoparticle 
encapsulation was determined by agarose gel electrophoresis. 
 
 
 
Legend 
 
lane 1- DNA Ladder 
lane 2- CS/DS nanoparticles  
lane 3- CS/DS nanoparticles + VL B12  
lane 4- PEI nanoparticles  
lane 5- PEI nanoparticles + VL B12 
lane 6- FUGW-dsRed plasmid 
 
Figure 4.1 – Nanoparticle encapsulation as determined by agarose gel electrophoresis. 
CS/DS and PEI nanoparticle formulations we ran in a 1 % agarose gel in order to determine if the 
plasmid DNA was properly encapsulated in the nanoparticles in the presence of VLB12 ( lanes 3 
and 5) or in the absence of  VLB12 ( lanes 2 and 4). The DNA ladder (1 kb DNA ladder, New 
England Biolabs, MA, USA) was ran in Lane 1 as a control for DNA migration in the agarose gel. 
The plasmid FUGW-dsRed was ran on lane 6 as a control for free plasmid migration profile. 
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The results obtained (Figure 4.1) indicate an optimal proportion of 20% (W/W) FUGW-
dsRed: chitosan and a FUGW-dsRed:PEI ratio of 1:5 (W/W). There is no plasmid DNA 
migration in the agarose gel electrophoresis in the lanes where pDNA was encapsulated 
in the nanoparticles formulations (lanes 2 to 5), this is a measure of the degree of DNA 
packaging in the nanoparticles. The smaller the amount of free DNA the less DNA is 
visible migrating in the agarose gel, the more DNA is encapsulated in the nanoparticles. 
As a control for the migration profile of the FUGW-dsRed plasmid on agarose gel 
electrophoresis the plasmid alone was ran on lane 6, confirming that on lanes 2 to 5 
there was no free plasmid present.  
 
4.3.2 Immunofluorescence 
To evaluate the ability to use VLB12 as a vehicle for target specific drug delivery, using 
as carriers either CS/DS or PEI nanoparticles, and as a reporter gene the FUGW-dsRed, 
both nanoparticle systems were optimized for FUGW-dsRed packaging (see section 
4.3.1) and the therapeutic delivery system was evaluated by immunofluorescence. 
 
Based on the VLB12 concentration obtained after the purification and followed by the 
protein refolding/dialysis step (see section 2.3.5) and based on the characteristics of 
either CS/DS or PEI nanoparticles formulation the optimal theoretical amount of VLB12 
was adsorbed to either CS/DS or PEI nanoparticles. The specificity of the VLB12 coated 
nanoparticle drug delivery systems was evaluated by measuring the expression of the 
dsRed protein by immunofluorescence (Figure 4.2). 
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 a) 
 
 
b) 
 
c) 
 
d) 
 
e) 
 
f) 
 
g) 
 
Figure 4.2 – Immunofluorescence staining of FUGW-dsRed/CS/DS nanoparticle complexes using 
VLB12 for specific delivery to Jurkat cells. 
a) Jurkat cells observed with a magnification of 40X (visible) for CS/DS nanoparticle delivery to 
Jurkat cells; b) Jurkat cells targeted by empty CS/DS nanoparticles (magnification 40X) stained 
with DAPI Nuclear Counterstain; c) Jurkat cells targeted by empty CS/DS nanoparticles 
(magnification 40X) dsRed fluorescence; d) Jurkat cells targeted by FUGW-dsRed/CS/DS 
nanoparticles for delivery of the dsRed reporter gene (magnification 100X), stained with DAPI 
Nuclear Counterstain; e) Jurkat cells targeted by FUGW-dsRed/CS/DS nanoparticles for delivery of 
the dsRed reporter gene (magnification 100X), dsRed fluorescence; (continues on the next page) 
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f) Jurkat cells targeted by VLB12 coated CS/DS nanoparticles for delivery of the dsRed reporter 
gene (magnification 100X), stained with DAPI Nuclear Counterstain; g) Jurkat cells targeted by 
VLB12 coated CS/DS nanoparticles for delivery of the dsRed reporter gene (magnification 100X), 
dsRed fluorescence. Fluorescence of the cells was measured at an excitation wavelength 554 nm and 
emission wavelength of 591 nm. Fluorescence was observed and recorded on an Axiovert 40 CFL 
fluorescence microscope (Carl Zeiss, Jena, Germany) equipped with an Axiocam MRc5 (Carl Zeiss) 
camera. Images were processed with the software AxioVision Rel. 4.6.3 (Carl Zeiss).  
  
                                                                  VL B12 coated nanoparticles - A new therapeutic delivery system  
121 
 
 a) 
 
 
b) 
 
c) 
 
d) 
 
 
e) 
 
 
f) 
 
g) 
 
Figure 4.3 – Immunofluorescence staining of FUGW-dsRed/PEI nanoparticle complexes using 
VLB12 for specific delivery to Jurkat cells. 
a) Jurkat cells observed with a magnification of 40X (visible) for PEI nanoparticle delivery to 
Jurkat cells; b) Jurkat cells targeted by empty PEI nanoparticles (magnification 40X) stained with 
DAPI Nuclear Counterstain; c) Jurkat cells targeted by empty PEI nanoparticles (magnification 40X) 
dsRed fluorescence; d) Jurkat cells targeted by FUGW-dsRed/ PEI nanoparticles for delivery of the 
dsRed reporter gene (magnification 100X), stained with DAPI Nuclear Counterstain; e) Jurkat cells 
targeted by FUGW-dsRed/ PEI nanoparticles for delivery of the dsRed reporter gene 
(magnification 100X), dsRed fluorescence; (continues on the next page) 
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f) Jurkat cells targeted by VL B12 coated PEI nanoparticles for delivery of the dsRed reporter gene 
(magnification 100X), stained with DAPI Nuclear Counterstain; g) Jurkat cells targeted by VLB12 
coated PEI nanoparticles for delivery of the dsRed reporter gene (magnification 100X), dsRed 
fluorescence. Fluorescence of the cells was measured at an excitation wavelength 554 nm and 
emission wavelength of 591 nm. Fluorescence was observed and recorded on an Axiovert 40 CFL 
fluorescence microscope (Carl Zeiss, Jena, Germany) equipped with an Axiocam MRc5 (Carl Zeiss) 
camera. Images were processed with the software AxioVision Rel. 4.6.3 (Carl Zeiss).  
 
As it is perceivable from Figure 4.2 and Figure 4.3, the presence of VLB12 greatly 
increases the amount of the dsRed protein present in the cells for both CS/DS and PEI 
nanoparticle formulations. The normalized
††
 immunofluorescence results for the VLB12 
specific targeting to the CD4 receptor vs the endocytosis of the nanoparticles are listed 
on Table 4.3, the same data are also represented in a graphical format in Figure 4.4. 
Table 4.3 - Normalized results from the fluorescence assay, with CS/DS nanoparticles and PEI Nanoparticles. 
Assays are representative of n = 4 
Nanoparticle 
formulation 
 FU
‡‡
/10
5
 cells  
24 h post transfection 
FU/10
5
 cells  
72 h post transfection 
CS/DS Nanoparticles  DsRed 1.530   5.353  
CS/DS Nanoparticles  DsRed+VL B12 3.701  10.333  
PEI Nanoparticles  DsRed 7.475  26.163  
PEI Nanoparticles  DsRed+VL B12 105.229  293.763  
 
The FU value/105 cells for the VLB12 specific nanoparticle/FUGW-dsRed delivery to 
Jurkat cells can be obtained as the difference between VLB12 coated CS/DS 
nanoparticle fluorescence and the CS/DS uncoated nanoparticles, and the same applies 
for PEI nanoparticles. The calculations for the VLB12 specificity for both CS/DS and 
PEI nanoparticles are compiled in Table 4.4. 
 
                                                 
††
 The fluorescence results were normalized against the background fluorescence from the control Jurkat 
cells. 
 
‡‡
 FU-Relative Fluorescence Units 
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Figure 4.4 - Normalized fluorescence units/10
5
 cells for CS/DS and PEI VLB12 coated nanoparticles 
delivery of FUGW-dsREd. 
For transfection assays Jurkat E6‐1 T‐cells were grown at 37 ºC with 5% CO2 in a humidified 
atmosphere in RPMI-10 medium supplemented with 100 U penicillin, and 0.1 mg streptomycin 
(Invitrogen, UK) per millilitre. Cells were grown in 96-well white clear bottom plates (Greiner-Bio 
One, Frickenhausen, Germany) to approximately 50-60% confluence and transfected using CS/DS, 
containing 1 g of FUGW-dsRed  plasmid per well at optimal amount of adsorbed antibody, 
controls of cells without nanoparticles and with empty nanoparticles were also run. 24h after 
transfection, the medium was changed. The fluorescence of cells was measure directly on plate, 24 h 
and 72 hours after transfection. The fluorescence was measured at an excitation wavelength of 554 
nm and emission wavelength of 591 nm, using an Infinite 200 Microplate Reader (Tecan i-control 
software, version 1.5.14.0, Tecan, North Carolina, USA). Assays are representative of n = 4. 
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Table 4.4 - Calculations from the fluorescence assay, with CS/DS nanoparticles and PEI Nanoparticles 
Nanoparticle 
formulation 
FU
§§
/10
5
 cells 
24 h post transfection 
FU/10
5
 cells 
72 h post transfection 
CS/DS Nanoparticles    2 171 (58,7 %)     4 980 (48,2 %) 
PEI Nanoparticles  97 754 (92,9 %)           267 600 (91,1 %)  
 
For the CS/DS nanoparticles the increase in dsRed fluorescence due to VLB12 specific 
CD4 targeting increases by 58,7 % at 24 h post transfection and still presents a 48,2 % 
increase in fluorescence at 72 h post transfection. In the case of the PEI nanoparticles 
the VLB12 specific CD4 targeting increases dsRed fluorescence by 92,9 % at 24 h post 
transfection and maintains a 91,1 % of increase in fluorescence at 72 h post transfection. 
When comparing both nanoparticle systems in terms of FU/10
5
 cells only, PEI 
nanoparticles present a much more effective pDNA delivery system than the CS/DS 
nanoparticles.  
CS/DS nanoparticles show a 10 % decrease in VLB12 specific dsRed fluorescence from 
the 24 h time point to the 72 h time point although the normalized FU increased over 
time. Since the goal is to evaluate not only the increase in dsRed fluorescence due to 
VLB12 specific CD4 targeting but also the correlation with maintained cell viability 
over time, other methods should be used to complement the immunofluoresce assays. In 
order to obtain more detailed information on specific dsRed fluorescence/cell viability 
these nanoparticle CD4 targeted delivery systems were also evaluated by Flow 
cytometry analysis. 
 
 
  
                                                 
§§
 FU-Relative Fluorescence Units 
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4.3.3 VLB12 coated nanoparticles for delivery of FUGW-dsREd plasmid to 
CD4 positive Jurkat cells. 
Controls Chitosan nanoparticles 
a) 
 
b) 
 
f) 
 
 c) 
 
g) 
 
% of dsREd positive cells 
a) 1,84   
b) 6,72 f) 5,25 
c) 6,84 g) 7,01 d) 
 
h) 
 
d) 7,38 h) 23,5 
e) 7,65 i) 7,58 
Legend 
a) cells only 
b)CS/DS nanoparticles only 
c) CS/DS +105g/ml VLB12+ 0g dsRed  
d) CS/DS +84g/ml VLB12+ 0g dsRed 
e) CS/DS +47g/ml VLB12+ 0g dsRed 
f) CS/DS +0g/ml VLB12+ 1g dsRed 
g) CS/DS +105g/ml VLB12+ 1g dsRed 
h) CS/DS +84g/ml VLB12+ 1g dsRed 
i) CS/DS +47g/ml VLB12+ 1g dsRed 
e) 
 
i) 
 
 
Figure 4.5 – Flow cytometry analysis of chitosan nanoparticles coated with VLB12 for delivery of 
FUGW-dsREd plasmid to CD4 positive Jurkat cells. 
 80 000 Jurkat cells were incubated with each nanoparticle formulation. Cell culture media (RPMI-
10 supplemented with gentamicin) was replaced at 24h and 48h. Cells were recovered 72 h post 
nanoparticle delivery. Cells were washed with PBS and fixated with 1 % p-formaldehyde (in PBS). 
Condition a) displays the cells only control. Conditions b to i) correspond to the VLB12/CS/DS 
nanoparticles/FUGW-dsREd combinations listed on Table 4.1. Shown is one representative 
experiment out of three. 
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After the CS/DS formulation for specific delivery of the FUGW-dsRed plasmid to 
Jurkat cells was optimized and evaluated by immunofluorescence (see 4.2.6), optimal 
adsorbed amount of VLB12 was also evaluated by FACS analysis. From the results 
displayed on  
Figure 4.5 it is possible to conclude that background fluorescence is the same for empty 
particles (condition b), as for particles with FUGW-dsREd plasmid only (condition f).  
CS/DS nanoparticles coated with either 105 or 47 g/ml (conditions c and e) without 
FUGW-dsREd encapsulated, present approximately the same percentage of dsRed 
positive cells as CS/DS nanoparticles coated with either 105 or 47 g/ml (conditions g 
and i) with encapsulated FUGW-dsREd meaning that there was no FUGW-dsREd 
delivery to the cells. 
Only the formulation with 84 g/ml of VLB12 (condition h) is expressing the dsRed 
gene. Therefore this is the only combination of VLB12/CS/DS nanoparticles/ FUGW-
dsREd where there is a successful delivery of the plasmid expressing the red fluorescent 
protein. The percentage of effective dsRed positive cells is 16,1 % (23,5 - 7,38) which 
represents a good performance value for this type of nanoparticles. 
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Controls PEI nanoparticles 
a) 
 
b) 
 
f) 
 
 C) 
 
g) 
 
% of dsREd positive cells 
a) 1,84   
b) 17,7 f) 19,4 
c) 26 g) 8,17 d) 
 
h) 
 
d) 19,5 h) 7,87 
e) 15 i) 11,3 
Legend 
a) cells only 
b)PEI nanoparticles only 
c) PEI +48g/ml VLB12+ 0g dsRed  
d) PEI +29g/ml VLB12+ 0g dsRed 
e) PEI +11g/ml VLB12+ 0g dsRed 
f) PEI +0g/ml VLB12+ 0,5g dsRed 
g) PEI +48g/ml VLB12+0,5g dsRed 
h) PEI +29g/ml VLB12+ 0,5g dsRed 
i) PEI +11g/ml VLB12+ 0,5g dsRed 
e) 
 
i) 
 
Figure 4.6 – Flow cytometry analysis of PEI nanoparticles coated with VLB12 for delivery of FUGW-dsREd 
plasmid to CD4 positive Jurkat cells.  
80 000 Jurkat cells were incubated with each nanoparticle formulation. Cell culture media (RPMI-10 
supplemented with gentamicin) was replaced at 24h and 48h. Cells were recovered 72 h post nanoparticle 
delivery. Cells were washed with PBS and fixated with 1 % p-formaldehyde (in PBS). Condition a) displays the 
cells only control. Conditions b to i) correspond to the VL B12/PEI nanoparticles/FUGW-dsREd 
combinations listed on Table 4.2. Shown is one representative experiment out of three. 
The results depicted on Figure 4.6 represent a maximum of approximately 900 gated 
cells acquired. In the presence of the PEI nanoparticles, most of the conditions depicted 
present a percentage of dsRed positive cells higher in the controls without the FUGW-
dsREd plasmid than in the corresponding VLB12/PEI nanoparticles/FUGW-dsREd 
conditions, this is the result of a very high autofluorescence due to the very low 
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numbers of live cells as opposed to very high amounts of dead cells present in all the 
samples containing PEI nanoparticles. From approximately 6,4 x 10
5
 cells per well 
expected to be present at the end of the assay (all the cells from each well were 
collected for Flow cytometry analysis) less than 1 x 10
3
 live cells per well could be 
acquired. This represents that less than 0,15 % of the expected number of cells were 
alive, on average, at the end of the assay.  
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4.4 Discussion 
The VLB12 has proved to be an efficient method for specific delivery of nanoparticle 
encapsulated drugs to CD4 positive cells. When comparing the CS/DS nanoparticles to 
the PEI nanoparticles we reach the conclusion that PEI nanoparticles although present a 
good dsRed delivery as obtained by immunofluorescence are very toxic and cause very 
high levels of cell death. 
The results obtained by immunofluorescence indicated that PEI was a much more 
effective system for drug delivery, and both CS/DS and PEI nanoparticle systems 
allowed us to validate VLB12 as an efficient method for specific delivery of 
nanoparticle encapsulated drugs to CD4 positive cells. 
When VLB12 amounts different from the amount previously optimized by 
immunofluorescence assays, were used in the Flow cytometry assays no specific 
targeting could be achieved, this could be due to the fact that process used for coating 
the nanoparticles with VLB12 was a not controlled adsorption method, that may not 
work in all formulations and also the dilution factor associated with this process also 
interferes in the particle’s superficial charge. These may be the reasons why only one of 
the VLB12 amounts worked for specific CS/DS nanoparticle formulation and 
subsequent cell targeting. 
In this Chapter we wanted to evaluate the VLB12 potential for specific delivery of 
nanoparticle encapsulated drugs to CD4 positive cells and its subsequent use for gene 
therapy. Consequently, although CS/DS nanoparticles present a much more modest 
pDNA delivery to the target cells than PEI nanoparticles, PEI’s high toxicity limits its 
application in gene therapy.229,361 
So, in conclusion the VLB12/CS/DS nanoparticles is a promising system for specific 
delivery of nanoparticle encapsulated drugs to CD4 positive cells. 
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5 VL B12 as a vaccine antigen 
5.1 Introduction 
In order to use VLB12 as a vaccine antigen some considerations must be taken into 
account, like the type of formulation and the route of administration. Regarding the type 
of formulation several methods can be addressed, as for the route of administration 
these range from the classical parenteral routes to the mucosal membranes delivery as 
well as different delivery systems.
10,77
 
 
5.1.1 Vaccine formulations and vaccine administration 
The rout for vaccine administration is of great importance in the development of 
protective immunity and the choice is most of the times a matter of pharmacokinetics. 
The pharmacokinetics is of course related with the location of the target effect of active 
substances. In the case of HIV-1 vaccines, vaccine administration is clearly associated 
with parenteral routes or with mucosal membranes administration. 
Among the non-parenteral routes of administration, mucosal membranes, which possess 
associated lymphoid tissue with all of the immunocompetent cells required for the 
induction of antigen specific immune responses, are emerging as attractive routes for 
vaccination.
161,227
  
There are two main administration routes for mucosal vaccine delivery, oral and nasal. 
The main targeted for oral delivery vaccine are Peyer ’s patches. By incorporating 
vaccine into nanoparticles systems, the vaccine is protected against enzymatic 
degradation on its way to the mucosal tissue and efficiently taken up by M-cells. In 
contrast to oral administration, nasal administered vaccines have to be transported over 
a very small distance, remain only about 15 minutes in the nasal cavity, and are not 
exposed to low pH values and degradative enzymes. Thus, nasally delivery vaccines 
may not necessary be formulated as nanoparticles.
146,324-326
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Since the nasal cavity has been investigated as a promising site for nanoparticle vaccine 
administration, different delivery systems have been explored by the nasal route, 
including CS-based nanoparticles incorporating soluble antigens, and plasmid DNA, 
which have shown to be efficient for intranasal vaccination, inducing important and 
long-lasting immune responses.
329,330
 
 
5.1.2 Nanoparticles for delivery of vaccines 
Nanoparticles often exhibit significant adjuvant effects in parenteral vaccine delivery 
since they may be readily taken up by antigent presenting cells.
173
  Moreover, oral and 
nasal delivery of nanoparticles are thought to have the potential to provide mucosal 
protective immune responses, one of the most desired goals of modern vaccinology. 
The submicron size of nanoparticles allows them to be taken up by M-cells, in mucosa 
associated lymphoid tissue (MALT) i.e. gut-associated, nasal-associated and bronchus-
associated lymphoid tissue,
146,324-326
 initiating sites of vigorous immunological 
responses. Immunoglobulin A (IgA), a major immunoglobulin at mucosal surface, and 
the generation of B-cell expressing IgA occur primarily inMALT. The B-cell then 
leaves the MALT and reaches systemic circulation where they clonally expand and 
mature into IgA plasma cells. Therefore, providing not only protective IgA at the 
pathogen entered sites, but also systemic immunity. 
 
5.1.3 Antiviral activities of antibodies in vivo – their role in vaccine 
development 
In principle, antibodies can act against both free virus and infected cells. Probably the 
most marked antiviral activity of antibody and the activity that is most important for 
antibody-mediated protection in vivo is the neutralization of free virus particles.
44
 
Animal models provide direct evidence that mechanisms other than neutralization can 
be important for protection by neutralizing antibodies. In some cases, protection is 
found to be as effective with F(ab)2 fragments as with the corresponding whole IgG 
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molecule. However, in other cases, F(ab)2 fragments that are as effective as whole IgG 
molecules at neutralization in vitro are ineffective at protection in vivo. It has been 
shown that neutralizing mouse IgG1 antibodies (which are poor activators of effector 
functions) are ineffective at protection, whereas IgG2a molecules (which are good 
activators) of the same specificity are effective.
293
 In many examples in mouse models, 
protection requires the Fc part of IgG, but is independent of complement. This implies 
that, in these cases, protection by neutralizing antibodies probably requires activity 
against infected cells and involves ADCC or phagocytosis.
44
 
Also, for viruses whose primary route of entry are also mucosal surfaces, antibodies that 
are present in the mucosal compartments at the time of exposure may protect against 
viral challenge.
155,232
 Both mucosal secretory IgA (sIgA) and systemic IgG have been 
shown to be effective. And may play an important role in the development of an 
efficient protective AIDS vaccine.
44
 
In summary, a vaccine may generate antibodies that are are ineffective in in vitro 
neutralization assays, but may simply require the activation of the effector functions, 
involving ADCC or phagocytosis and may also trigger mucosal secretory IgA that may 
protect against viral challenge. In order to properly evaluate the potential of a particular 
antigen as a vaccine candidate, several different markers should be evaluated, like IgA 
and IgG titers, and also IgG1 versus IgG2a titers.  
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5.2 Materials and Methods 
5.2.1 Cell Lines and culture conditions 
Human embryonic kidney 293T (HEK293T) (ATCC, VA, USA), and TZM-bl (obtained 
through the NIH AIDS Research and Reference Reagent Program, MD, USA, 
contributors Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.) cell lines were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (FBS) here on designated DMEM‐10. 
All cell cultures were maintained at 37 °C in 5 % CO2. All cell culture media and 
reagents, otherwise indicated, were from Lonza (Basel, Switzerland). 
 
5.2.2 Viral production 
HEK293T cells were transfected, by calcium phosphate method, with pHIV‐1NL4‐3 
plasmid (AIDS reagent, contributor Dr. Malcolm Martin) in order to produce HIV‐1NL4‐3 
virions. After 48 h, virions were collected from supernatant cultures; the amount of viral 
particles released in the supernatant was measured by p24CA ELISA (AIDS & Cancer 
Research Program, NCI Frederick, MD, USA) and HIV‐1NL4‐3 virions were used to 
infect TZM-bl cells. 
 
5.2.3 Virus neutralization assay using TZM-bl cells. 
 A neutralization assay was performed based on the methods of Wei et al. (28)
341
 with 
modification.
192,215
 TZM-bl cells were derived from a HeLa cell line (JC.53) that stably 
expresses CD4 and CCR5. TZM-bl cells also express luciferase and -galactosidase 
under the control of the HIV-1 promoter.  
Briefly, 10,000 cells per well were seeded in a 96-well plate in 100 l/well of 
DMEM‐10 and incubated overnight at 37°C. The next day, 200 l of HIV‐1NL4‐3 were 
prepared, in DMEM‐10, for a multiplicity of infection (MOI) of 0,1 and serial diluted 
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serum from each mice group (1/40 – 1/81920 dilution) was added to the virus solution 
and incubated for 1 h at 37°C. The media was removed and the virus solution added to 
the cells. 
The cells were incubated for 48 h at 37°C in 5 % CO2. Assay medium was removed 
from each well, cells were washed with 200 l of PBS and 50 l of Passive Lysis Buffer 
reagent (Promega, Madison, WI) were added. This was followed by a freeze-thaw step 
(-20 ºC – 37 ºC) afterwhich 10 l cell lysates from each sample (in Passive Lysis 
Buffer) were placed in a 96 well Luminescence Plate (BD Falcon 96 Flat Bottom White 
Opaque Polystyrene Plate, BD Biosciences, USA). 50 l Luciferase Assay Reagent II 
(LAR II) were added to each sample and luminescence was measured using an Infinite 
200 Microplate Reader (Tecan i-control software, version 1.5.14.0, Tecan, North 
Carolina, USA).  
 
5.2.4 Preparation of CS/DS  
The Chitosan/Deoxycholate (CS/DS) nanoparticles were prepared using an ionic 
gelation technique as described.
50
 Briefly, chitosan (Chitosan low molecular weight 
(LMW) with degree of deacetylation (DD) 75-85%, Sigma-Aldrich, UK) and sodium 
deoxycholate (Sigma-Aldrich, UK) were separately dissolved in ultra-pure water in 
order to obtain 1 mg/ml solutions. Empty nanoparticles were formed when 1mL DS 
solution was added to a 1mL CS solution. For protein VLB12 encapsulation, protein was 
first liofilized in order to concentrate and ressuspended in DS solution before the 
addition to CS solution. CS/DS nanoparticles were prepared using an ionic gelation 
technique as previously described. 
51
 
The encapsulation efficiency of nanoparticle formulations was determined as 
described,
50
 after centrifugation of the samples at 29,000 × g for 30 min. Supernatants 
were analyzed by the BCA protein assay (Pierce, USA) to determine the free protein 
concentration. Calibration curves were made with corresponding solutions of blank 
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nanoparticles, and all samples were measured in triplicate. The encapsulation efficiency 
was determined by difference as follows:  
                             
                              
                
     
The percentage of protein encapsulation efficiency was 68 ± 10%.  
 
5.2.5 Nanoparticles Physicochemical Characterization 
Mean particle size and polydispersion index (PI) were determined by photon 
correlation spectroscopy (Zetasizer Nano-S, Malvern Instruments, UK). Samples were 
diluted with 0.22 m filtered ultra-pure water. The zeta potential was measured through 
electrophoresis mobility (Zetasizer 2000; Malvern Instruments, UK) using samples 
diluted with ultra-pure water. In all cases, mean values were obtained from the analysis 
of three different batches, each of them measured three times. Results were expressed as 
mean ± standard deviation (SD).  
 
5.2.6 Mice immunisation schedule 
Female BALB/c mice obtained from Charles River (Spain) (n=5/group), 6–8weeks old 
provided with food and drink ad libitum, were used in the in vivo studies, which were 
performed in strict accordance with Directive of 24 November (nº 86/609 EEC), the 
Portuguese laws D.R. nº 31/92, D.R. 153 I-A 67/92, and all following legislations. 
Seven groups (25 g; n 5/group) were immunised by intranasal (i.n.) and subcutaneous 
(s.c.) routes on day 1 and boosted on day 21, for i.n. route a micropipette tip was used to 
administer 20 µl of sample (10 µl in each nostril) containing 50 µg of VLB12 protein. 
The formulations were delivered slowly onto nares, so that the mice could inhale it i.n. 
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Controls consisted of free antigen or empty nanoparticles. All formulations were freshly 
and aseptically prepared by particles dispersion in PBS pH 7.4 in a biological safety 
cabinet, immediately prior dosing. A group was vaccinated by s.c. route with protein 
adsorbed to gel of aluminium hydroxide (Sigma-Aldrich, UK): the protein was mixed 
with a solution of gel of aluminium hydroxide in a proportion in order that the dose of 
the vaccine did not exceed the 0.2 mg of aluminium containing 50 µg of protein. 
Blood samples were collected from the tail vein after 2, 4, 6, 8, 10, 12, 14 and 16 weeks 
of immunization and sera was separated by centrifugation (18000 x g, 5min at 4 ºC, 
Allegra 64R, Beckman, USA) and stored at −20 ºC until tested by antigen specific 
enzyme-linked immunosorbent assay (ELISA) for IgG, IgG subclass 1 (IgG1) and IgG 
subclass 2 (IgG2a). 
 
5.2.7 Quantification of antigen-specific IgG and subtypes by ELISA 
The antibody responses (IgG, IgG1 and IgG2a) to VLB12 cell extracted proteins were 
determined based on a previously reported method.
13
 
Plates (Microlon®, High binding flat bottom plates, Greiner, Germany) were coated 
overnight with 5.0 µg/ml VLB12 protein in 100mM sodium carbonate buffer (pH 9.6), 
washed and afterwards blocked with a 5% (w/v) skimmed milk powder (Merck KGaA, 
Germany) dissolved in 10mM PBS at pH 7.4 containing 0.05% (v/v) of Tween
® 
20 
(PBST; Sigma Aldrich, Co., Germany). Plates were again washed and sera were tested 
by serial two-fold dilutions. Sera obtained from naive mice were used as a control. 
Horseradish peroxide conjugate goat anti-mouse IgG, (Sigma, Pool Dorset, UK), IgG1 
and IgG2a (Serotec, UK) (diluted 1:1000) were applied as secondary antibody. Finally, 
the substrate OPD (SigmaFAST™ OPD Kit, Sigma Aldrich, Germany) was used to 
develop the plates, the color reaction was stopped after 15 min, by adding 2.5N H2SO4 
to the wells, and absorbance was read on an Infinite 200 Microplate Reader (Tecan i-
control software, version , 1.5.14.0, Tecan, North Carolina, USA) at 490 nm. The titters 
reported are the reciprocal of serum dilutions that gave an optical density 5% higher 
than the strongest negative control reading. 
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5.2.8 ELISA assay for mice serum IgG specificity to gp120  
For the mice serum IgG specificity to gp120, ELISA assays were performed using as 
antigen, recombinant HIV-1BaL gp120 (obtained through the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1BaL gp120 from 
DAIDS, NIAID) was used at 500 ng per well (in phosphate-buffered saline, PBS). 
Recombinant HIV-1BaL gp120 was adsorbed onto 96 well flat bottom, high binding non-
sterile, polystyrene ELISA plates (Corning, NY, USA). The plates were then blocked 
with 3 % bovine serum albumin (BSA) in PBS. 3 % BSA (in PBS) was also used and as 
negative control. The serums from the immunized mice groups were diluted with 1% 
BSA in PBS. The mice serums were used at a 1:100, 1:1000 or 1:10000 dilutions.  The 
b12-IgG (obtained through the NIH AIDS Research and Reference Reagent Program, 
contributor: Dr. Dennis Burton and Dr. Carlos Barbas III)
18,45,47,276
 was used as a 
positive control. b12-IgG was used at 1000 ng, 100 ng or 10 ng per well. The G1 to G7 
serums and b12-IgG were added to the wells, and incubated for 1 h. The plates were 
washed with Tween 20 (0.05 % in PBS) and incubated with either horseradish 
peroxidase (HRP)-conjugated goat anti-Human IgG (Santa Cruz Biotechnology, Santa 
Cruz, USA) or HRP-conjugated goat anti-Mouse IgG (Bio-Rad Laboratories, CA, 
USA), the -Human-HRP and the -Mouse-HRP antibodies were used at a 1:1000 
dilution in 1% BSA (in PBS). All incubations were performed for 1 h at 37 ºC. The 
plates were then washed with PBS and developed with an HRP substrate, ABTS 
solution (citric acid (pH 4.0) with 0,2 % H2O2 and read on an Infinite 200 Microplate 
Reader (Tecan i-control software, version 1.5.14.0, Tecan, North Carolina, USA)  at an 
optical density (OD) of 405/492 nm.  
 
5.2.9 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, 2007, San Diego, California, USA, www.graphpad.com) with a 
level of significance of 5%.  
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5.3 Results 
BALB/c mice were immunized by intranasal (i.n.) and subcutaneous (s.c.) routes on day 
1 and boosted on day 21 according to the immunization conditions described on section 
5.2.6.  Mice were divided in seven groups as described on Table 5.1. 
 
Table 5.1 – Mice groups used for the immunization assay of the VL B12 antigen. 
Group   
I 
CONTROL 
II 
i.n. protein encapsulated in CS/DS nanoparticles 
III 
i.n. empty CS/DS nanoparticles 
IV 
s.c. protein encapsulated in CS/DS nanoparticles 
V 
s.c. protein + gel of aluminium hydroxide 
VI 
i.n. free antigen  
VII 
s.c. free protein  
    
To evaluate the vaccine antigen properties of VLB12 serum was collected from each 
group at 2, 4, 6, 8, 10 and 12 weeks (Bleed 1, 2, 3, 4, 5 and 6 respectively) and antigen 
specific enzyme-linked immunosorbent assay (ELISA) was determined for total IgG, 
IgG subclass 1 (IgG1) and IgG subclass 2 (IgG2a). The results for antigen specific 
ELISA determined for total IgG are summarized in Figure 5.1.  
 
Figure 5.1 – ELISA assay performed to determine antigen specific total IgG titers.  
(Continues on the next page). 
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Plates (Microlon®, High binding flat bottom plates, Greiner, Germany) were coated overnight with 
5.0 µg/ml VLB12 protein in 100mM sodium carbonate buffer (pH 9.6), washed and afterwards 
blocked with a 5% (w/v) skimmed milk powder (Merck KGaA, Germany) dissolved in 10mM PBS 
at pH 7.4 containing 0.05% (v/v) of Tween
® 
20 (PBS-T; Sigma Aldrich, Co., Germany). Plates were 
again washed and sera were tested by serial two-fold dilutions. Sera obtained from naive mice were 
used as a control. Horseradish peroxide conjugate goat anti-mouse IgG (Sigma, Pool Dorset, UK) 
(diluted 1:1000) were applied as secondary antibody. Finally, the substrate OPD (SigmaFAST™ 
OPD Kit, Sigma Aldrich, Germany) was used to develop the plates, the color reaction was stopped 
after 15 min, by adding 2.5N H2SO4 to the wells, and absorbance was read at 490 nm. The titters 
reported are the reciprocal of serum dilutions that gave an optical density 5% higher than the 
strongest negative control reading. Results are expressed as mean of a pool of five mice. *** 
corresponds to P < 0,0001. 
 
Group II doesn’t appear to have a significant increase in total specific IgG overtime, but 
the total specific IgG titer rose on week 8 which might indicate that the immune 
response is starting to develop. Group III is only starting to develop an increase in total 
specific IgG at week 8, but since group III are intranasaly delivered empty CS/DS 
nanoparticles it is not expected a significant increase in total IgG since CS/DS 
nanoparticles are not immunogenic.  
Groups IV, V and VII were the firsts to present a significant rise in total specific IgG 
titters with is related to the rout of administration since subcutaneous delivery usually 
triggers a much faster immune response that an intranasal administration. 
Group VI is also only starting to present high IgG titer at week 8, which also correlates 
with intranasal administration. 
 From week 8 onword the total specific IgG titters present a slight drop but titer 
proportions between groups remain constant. 
The results for antigen specific ELISA determined for IgG1 and IgG2a are summarized 
in Figure 5.2. This subclass titers were only determined from week 8 onword. 
Regarding specific IgG1 only Groups IV, V, VI and VII present elevated titers of IgG1, 
in particular Group V presents the highest specific IgG1 titer which correlates with the 
extremely high total specific IgG titer. This is particularly significant at week 10 
Regarding specific IgG2a only Groups IV and V present IgG2a, indicating that these are 
starting to develop a Th2 response that could significantly improve the vaccine’s 
protective immunity. 
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Figure 5.2 – ELISA assay performed to determine antigen specific IgG1 and IgG2a titres. 
Plates (Microlon®, High binding flat bottom plates, Greiner, Germany) were coated overnight with 
5.0 µg/ml VLB12 protein in 100mM sodium carbonate buffer (pH 9.6), washed and afterwards 
blocked with a 5% (w/v) skimmed milk powder (Merck KGaA, Germany) dissolved in 10mM PBS 
at pH 7.4 containing 0.05% (v/v) of Tween
® 
20 (PBS-T; Sigma Aldrich, Co., Germany). Plates were 
again washed and sera were tested by serial two-fold dilutions. Sera obtained from naive mice were 
used as a control. Horseradish peroxide conjugate goat anti-mouse IgG1 and IgG2a (Serotec, UK) 
(diluted 1:1000) were applied as secondary antibody. Finally, the substrate OPD (SigmaFAST™ 
OPD Kit, Sigma Aldrich, Germany) was used to develop the plates, the color reaction was stopped 
after 15 min, by adding 2.5N H2SO4 to the wells, and absorbance was read at 490 nm. The titters 
reported are the reciprocal of serum dilutions that gave an optical density 5% higher than the 
strongest negative control reading. Results are expressed as mean of a pool of five mice. *** 
corresponds to P < 0,0001. 
 
From week 8 to week 10 there is a decrease in the titter of IgG2a and this lower values 
of the titter of IgG2a were maintained at week 12. 
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Figure 5.3 - Inhibition assay performed with serial dilutions of G1 to G7 serum from Bleed 6 for 
HIV-1NL4-3 inhibition. 
10,000 TZM-bl cells per well were seeded in a 96-well plate in 100 l/well of DMEM‐10 and 
incubated overnight at 37°C. The next day, 200 l of HIV‐1NL4‐3 were prepared, in DMEM‐10, for 
a multiplicity of infection (MOI) of 0,5 and serial diluted serum from each mice group (1/40 – 
1/81912 dilution) was added to the virus solution and incubated for 1 h at 37°C. The media was 
removed and the virus solution added to the cells. The cells were incubated for 48 h at 37°C in 5 % 
CO2. Assay medium was removed from each well, cells were washed with 200 l of PBS and 50 l 
of Passive Lysis Buffer reagent (Promega, Madison, WI) were added. This was followed by a freeze-
thaw step (-20 ºC – 37 ºC) afterwhich 10 l cell lysates from each sample (in Passive Lysis Buffer) 
were placed in a 96 well Luminescence Plate (BD Falcon 96 Flat Bottom White Opaque Polystyrene 
Plate, BD Biosciences, USA). 50 l Luciferase Assay Reagent II (LAR II) were added to each 
sample and luminescence was measured using an Infinite 200 Microplate Reader (Tecan i-control 
software, version 1.5.14.0, Tecan, North Carolina, USA). Results are expressed as mean ± SD of two 
independent experiments performed in duplicate. 
 
Surprisingly although the specific IgG titers were very high, particularly for Group V 
(subcutaneous protein with aluminium adjuvant), none of the serums from the different 
immunization groups presented a specific inhibitory effect on HIV-1NL4-3 (see Figure 5.3) . 
Groups II and IV seem to increase HIV-1NL4-3, while groups V, VI and VII presented a 
fluctuating inhibition pattern, that decreases as the serial dilution increases, only to 
increase again at lower concentrations. The overall conclusion is that no group presents 
an inhibitory effect on HIV-1NL4-3. These results are in agreement with the results 
obtained for bleed 5 (data not shown). 
Since there was no inhibitory effect detected for the antibodies generated by each of the 
different mice groups used in the VLB12 immunization assay, the need to arrive at an 
explanation for these facts prompted us to perform an ELISA assay in order to confirm 
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if the high levels of specific total IgG were recognizing the gp120 glycoprotein (see 
Figure 5.4). 
 
Figure 5.4 - ELISA assay for serum binding to gp120. 
ELISA assays were performed using as antigen, recombinant HIV-1BaL gp120 (obtained through 
the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-
1BaL gp120 from DAIDS, NIAID) was used at 500 ng per well (in phosphate-buffered saline, PBS). 
Recombinant HIV-1BaL gp120 was adsorbed onto 96 well flat bottom, high binding non-sterile, 
polystyrene ELISA plates (Corning, NY, USA). The plates were then blocked with 3 % bovine 
serum albumin (BSA) in PBS. 3 % BSA (in PBS) was also used and as negative control. The serums 
from the immunized mice groups were diluted with 1% BSA in PBS. The mice serums were used at 
a 1:100, 1:1000 or 1:10000 dilutions.  The b12-IgG was used as a positive control. b12-IgG was used 
at 1000 ng, 100 ng or 10 ng per well. The G1 to G7 serums and b12-IgG were added to the wells, 
and incubated for 1 h. The plates were washed with tween 20 (0.05 % in PBS) and incubated with 
either -Human-HRP or -Mouse-HRP, the antibodies were used at a 1:1000 dilution in 1% BSA 
(in PBS). All incubations were performed for 1 h at 37 ºC. The plates were then washed with PBS 
and developed with an HRP substrate, ABTS solution (citric acid (pH 4.0) with 0,2 % H2O2 and 
read on an Infinite 200 Microplate Reader at an optical density (OD) of 405/492 nm. Results are 
expressed as mean ± SD of three independent experiments performed in triplicate. *** corresponds 
to P < 0,0001. 
 
 
The ELISA assay for serum binding to gp120 determined that the mice serum 
antibodies were not recognizing gp120, and that this was true for all the groups in the 
immunization assay. Even more so since the G1 is the one that at a 1:100 dilution 
presents some binding to gp120, but this group is the control were the mice received no 
treatment. This confirms that the high total specific IgG titers obtained are not targeting 
the b12 epitope, but must be targeting the remaining regions of the VL framework. The 
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usage of b12-IgG as a positive control validates the assay confirming that the 
recombinant HIV-1BaL gp120 protein used as antigen is being recognized by ELISA 
assay by antibodies targeting gp120, and the b12 epitope in particular. In conclusion, 
the VL framework, which is of rabbit origin,
121
 is apparently highly immunogenic and 
since the b12 epitope is only 23 amino acids long this is not being sufficient for the 
development of high titers of b12 specific antibodies.  
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5.4 Discussion 
To evaluate the vaccine antigen properties, of VLB12 the mucosal immunity was tested 
by using encapsulated VLB12 in nanoparticles of chitosan in comparison with 
subcutaneous routes with aluminium adjuvant and without adjuvant. Th1 or Th2 
responses were evaluated by the ratio of antigen-specific IgG2a-IgG1 in the serum 
samples.  
 
All groups presented an increase in total specific IgG over time until week 8. From 
week 8 onword the total specific IgG titters present a slight drop but titer proportions 
between groups remain constant. 
The groups where the antigen was encapsulated in CS nanoparticles and particularly 
where the antigen was delivered intra nasally present lower titers of total specific IgG as 
was expected since mucosal response develops more slowly than when the antigen is 
delivered subcutaneously. 
Th2 response was also present in the groups that presented the highest specific IgG 
titers indicating a possibility of development of a cellular immunity component. And 
since the immune response elicited by a successful vaccine likely will require both 
antibodies and T cells that recognize, neutralize and/or inactivate diverse strains of HIV 
and that reach the site of infection before the infection becomes irreversibly established 
this may reveal a global effect different than the one obtained from the HIV-1 
neutralization assay alone.158 
Surprisingly although the specific IgG titers were very high, particularly for Group V 
(subcutaneous protein with aluminium adjuvant), none of the serums from the different 
immunization groups presented inhibitory effect on HIV-1NL4-3. This may be caused by the 
fact that the VL framework is highly immunogenic and the majority of the antibodies are 
being generated against the VL framework and not our sequence of interest that is present in 
the CDR1 of the antigen. This was confirmed by the ELISA assay for serum binding to 
gp120, where none of the immunized mice groups serum could bind to the gp120, 
confirming the fact that the antibodies are only being generated against the framework and 
not to the b12 epitope present in the CDR1. This would explain the fact that the groups 
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where the antigen is encapsulated in CS nanoparticles that reduces the exposure of the 
framework to the mice immune system, are developing lower specific IgG titers.  
The effect caused by the presence of the rabbit framework may be minimized by 
introducing key amino acid substitutions in the framework in order to make the 
framework less immunogenic to the mouse immune system, a process similar to 
“antibody humanization”.144,196,259,260 By using a framework less immunogenic to the 
mouse immune system it may be possible to have a higher prevalence of antibodies 
generated that target our sequence of interest and therefore this VLB12 construct may 
yet be a useful vaccine antigen. 
The occurrence of an epitope that is targeted by a broadly neutralizing mAb (2F5) and 
when engrafted onto a different protein scaffold to serve as an immunogen, while 
possessing high structural fidelity, but eliciting antibodies that lack HIV-1 neutralizing 
activity has also been reported.
159
 This indicates that an antigen-driven B cell selection 
of HIV-1 neutralizing antibodies may require a complementary immunization strategy. 
Interestingly both the b12 mAb and 2F5 possess long CDRH3. For instances sequences 
of human CDRH3 vary from 2 to 28 amino acids residues, but mouse antibodies only show 
CDRH3 loops ranging from 1–19 residues and the b12 mAb CDRH3 is 18 amino acids 
long 
368
 that may prove to be difficult to achieve in mice and therefore b12 like mAbs 
may not be reproducible in the mouse system. 
In conclusion, the eliciting of b12 like mAbs may not be reproducible in the mouse 
system although the introduction of key amino acid substitutions in the framework to 
reduce immunogenicity to the mouse immune system should still be evaluated. If this 
strategy fails, another animal model that does not possess the same CDR length 
constraints as the mouse should be used to evaluate VLB12 as a vaccine antigen. 
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6 General Discussion 
 
The work presented on this Thesis is divided in four parts; the first part was the 
construction of single domain antibodies that target the hCD4 cell receptor, through 
grafting of the b12 target sequence or CD4 binding epitope into either CDR1 or CDR3 
of a highly stable rabbit single domain VL antibody and the selection of the antibodies 
with the highest binding ability to the CD4 receptor. 
In the second part of the Thesis we wanted to evaluate the VLB12 and VLCD4 ability to 
inhibit HIV-1 infection, and for that inhibition assays were performed with the 
HIV‐1NL4‐3 subtype B molecular clone and with HIV‐1 subtypes J and H primary 
isolates. 
In the third part of the Thesis we wanted to take advantage of VLB12’s high binding 
affinity to the CD4 receptor and to evaluate the potential of VLB12 coated nanoparticles as 
a new therapeutic delivery system. For that, two different types of nanoparticle formulations 
were tested, Chitosan and PEI nanoparticles, for the delivery of FUGW-dsRed plasmid 
DNA to Jurkat cells. 
And finally, in the fourth part of the Thesis we wanted to evaluate the VLB12 in another 
perspective. Taking into account the fact that the B12 target sequence is a gp120 highly 
conserved and constitutively exposed region we wanted to evaluate its potential as a 
vaccine antigen. 
From the results obtained in the first part of the work (Chapter 2) it was possible to 
obtain a large amount of information. From the results obtained from the expression and 
purification yields of the dAbs produced in the pComb3X vector it is possible to 
conclude that not all CDR combinations will be supported by the VL framework and 
that the sequence present in the CDRs plays an important role in antibody 
stability/solubility and that this is not directly correlated to the size of the CDR 
sequence. 
The fact that the B12 target sequence presents a higher binding ability to the CD4 
receptor than the CD4 binding epitope itself, it is probably due to the context of 
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antibody grafting. In the VLCD4 construct the CD4 binding epitope (10 amino acids) 
may not be sufficiently exposed to achieve optimal binding to the CD4 receptor, 
contrary to what happens in the gp120 context. The larger B12 target sequence (23 
amino acids) allows for a higher exposure of the epitope that may facilitate binding to 
the antigen. 
After establishing that for both constructs, VLCD4 and VLB12, the binding was specific 
to CD4 and that both VLB12 and VLCD4 had a strong affinity to the CD4 receptor, the 
next step was to identify the domain where VLB12 and VLCD4 bind to the human CD4 
receptor and it was possible to determine that VLCD4 is binding to domain 1 and VLB12 
is binding to the CD4 domain 2. We were also able to evaluate that, both VLB12 and 
VLCD4 bind specifically to the hCD4 cell receptor and recognize conformational epitopes 
of the CD4 receptor. Since domain 1, but also domain 2, of the CD4 receptor are targeted 
by HIV-1 neutralizing antibodies, the next step was to evaluate the VLB12 and VLCD4 
ability to inhibit HIV-1 infection. 
For that, in the second part of the Thesis (Chapter 3) we evaluated the VLB12 and 
VLCD4 ability to inhibit HIV-1 infection, inhibition assays were performed with the 
HIV‐1 NL4‐3 subtype B molecular clone and with HIV‐1 subtypes J and H primary 
isolates, in TZM-bl cells in a single cycle infection assay. VL B12 was able to inhibit 
HIV‐1NL4‐3 with an IC50 = 3,89 M and VLCD4 was able to inhibit HIV‐1NL4‐3 with an 
IC50 = 6,57 M. We also performed inhibition assays with T20 and obtained an IC50 = 
0,0694 M for HIV‐1NL4‐3 . As for the primary isolates, VLB12 was able to inhibit 
HIV‐1 subtype H with an IC50 = 3,97 M and HIV‐1 subtype J with an IC50 = 3,86 M 
but VLCD4 was not able to inhibit either subtype J or subtype H primary isolates. T20 
was able to inhibit HIV‐1 subtype H with an IC50 = 1,33 nanoM and HIV‐1 subtype J 
with an IC50 = 0,42 nanoM. 
 These results indicate that VLB12 presents a potential broad inhibition spectrum as 
opposed to VLCD4 that was not able to inhibit either of the non subtype B primary 
isolates. The fact that VLCD4 was able to inhibit HIV‐1NL4‐3 with an IC50 = 6,57 M but 
was unable to inhibit either of the primary isolates may be related to the fact that NL4-3 
is a laboratory adapted molecular clone that may be more susceptible to blockage of 
viral attachment to CD4 that the subtype J or subtype H primary isolates tested. 
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Regarding T20, it presents a much lower IC50 than the dAbs and is also a more potent entry 
inhibitor against both HIV-1NL4‐3 and the primary isolates tested, but T20 has a different 
target than the dAbs. T20 targets gp41 and due to the virus high frequency of mutation 
many strains show broad cross-resistance to antiretroviral drugs, including T20. 
So, it is important to compare the VLB12 with the only entry inhibitor that targets the 
gp120-CD4 interaction, Ibalizumab.
301
 It is also important to highlight the fact that both 
VLB12 and Ibalizumab bind to domain 2 of the CD4 receptor and therefore may have 
similar mechanisms of action and one of the main advantages common to both 
antibodies is that since they both bind to domain 2 they will not interfere with the 
receptor’s effector functions. 
The IC50 for VLB12 is much higher than Ibalizumab’s, when comparing the IC50 for 
HIV‐1NL4‐3, Ibalizumab has an IC50 of 0,73 g/ml (4,93 nM)
360
 and VLB12 was only 
able to inhibit HIV‐1NL4‐3 with an IC50 = 3,89 M which is almost 1000 times higher. 
Despite of the fact that VLB12 is not an entry inhibitor as potent as Ibalizumab, there 
have already been reported in vitro studies that demonstrate the synergistic activity of 
Ibalizumab (TNX-355) and enfuvirtide (T20) against HIV-1.
360
 Implying that an entry 
inhibitor that targets the gp120-CD4 interaction, like VLB12, can also prove to be useful 
as a therapeutic aid in improving the therapeutic response of enfuvirtide and other entry 
inhibitors treated patients. Therefore, VLB12 may prove to be another non 
pharmacological therapeutical alternative in the treatment of HIV-1 infection. 
One of the interesting characteristics of the VLB12 construct is its versatility, since it 
can be used not only to inhibit HIV-1 entry into the cells, but due to the ability to bind 
CD4 can also be used as a drug delivery system when attached to nanoparticles. 
This was the purpose of the third part of this Thesis (Chapter 4), to explore the potential 
of VLB12 coated nanoparticles as a new therapeutic delivery system for gene therapy. 
For that, two different types of nanoparticle formulations were tested, Chitosan and PEI 
nanoparticles, for the delivery of FUGW-dsRed plasmid DNA to Jurkat cells. Both 
nanoparticle formulations were successful in delivery of specific CD4 targeted FUGW-
dsRed plasmid DNA as determined by immunofluorescence. The results obtained by 
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immunofluorescence indicated that PEI was a much more effective system for drug 
delivery, and both CS/DS and PEI nanoparticle systems allowed us to validate VLB12 
as an efficient method for specific delivery of nanoparticle encapsulated drugs to CD4 
positive cells. 
Chitosan nanoparticle formulation was proved to be more effective due to the lower cell 
toxicity, as determined by Flow cytometry. The optimal amount of VLB12 adsorbed to 
the nanoparticles gave a 16 % positive dsREd fluorescent population with a specific 
VLB12 targeting to CD4.  
So the goal of using VLB12 coated nanoparticles as a new therapeutic delivery system 
that had the potential to be used for gene theraphy was achieved and the VL B12/CS/DS 
nanoparticle system applications will be further explored in the future. 
As previously mentioned, in the fourth part of the Thesis (Chapter 5) we wanted to 
evaluate the VLB12 in another perspective. Taking into account the fact that the B12 
target sequence is a gp120 highly conserved and constitutively exposed region we 
wanted to evaluate its potential as a vaccine antigen. For that we performed a mice 
immunization assay to evaluate VLB12 as a vaccine antigen were we also incorporated 
the knowledge obtained from Chapter 4 regarding VLB12 and CS/DS nanoparticle 
formulations. 
To evaluate the vaccine antigen properties, of VLB12 the mucosal immunity was tested by 
using encapsulated VLB12 in nanoparticles of chitosan in comparison with subcutaneous 
routes with aluminium adjuvant and without adjuvant. Th1 or Th2 responses were evaluated 
by the ratio of antigen-specific IgG2a-IgG1 in the serum samples. HIV-1 neutralization 
assays using serum from different groups to evaluate the VLB12 as potential vaccine 
antigen were also performed. 
Surprisingly although the specific IgG titers were very high, particularly for Group V 
(subcutaneous protein with aluminium adjuvant), none of the serums from the different 
immunization groups presented inhibitory effect on HIV-1NL4-3.  This may be caused by the 
fact that the VL framework is highly immunogenic and the majority of the antibodies are 
being generated against the VL framework and not our sequence of interest that is present in 
the CDR1 of the antigen.  
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This was confirmed by the ELISA assay for serum binding to gp120, where none of the 
immunized mice groups serum could bind to the gp120, confirming the fact that the 
antibodies are only being generated against the framework and not to the b12 epitope 
present in the CDR1. This would explain the fact that the groups where the antigen is 
encapsulated in CS/DS nanoparticles that reduces the exposure of the framework to the 
mice immune system, are developing lower specific IgG titers.  
The effect caused by the presence of the rabbit framework may be minimized by 
introducing key amino acid substitutions in the framework in order to make the 
framework less immunogenic to the mouse immune system, a process similar to 
“antibody humanization”. By using a framework less immunogenic to the mouse 
immune system it may be possible to have a higher prevalence of antibodies generated 
that target our sequence of interest and therefore this VLB12 construct may yet be a 
useful vaccine antigen. 
The occurrence of an epitope that is targeted by a broadly neutralizing mAb (2F5) and 
when engrafted onto a different protein scaffold to serve as an immunogen, while 
possessing high structural fidelity, but eliciting antibodies that lack HIV-1 neutralizing 
activity has also been reported.
159
 This indicates that an antigen-driven B cell selection 
of HIV-1 neutralizing antibodies may require a complementary immunization strategy. 
Interestingly both the b12 mAb and 2F5 possess long CDRH3. For instances sequences 
of human CDRH3 vary from 2 to 28 amino acids residues, but mouse antibodies only show 
CDRH3 loops ranging from 1–19 residues and the b12 mAb CDRH3 is 18 amino acids 
long 
368
 that may prove to be difficult to achieve in mice and therefore b12 like mAbs 
may not be reproducible in the mouse system. This indicates that the eliciting of b12 
like mAbs may not be reproducible in the mouse system although the introduction of 
key amino acid substitutions in the framework to reduce immunogenicity to the mouse 
immune system should still be evaluated. If this strategy fails, another animal model 
that does not possess the same CDR length constraints as the mouse should be used to 
evaluate VLB12 as a vaccine antigen. 
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In conclusion, first and foremost this work has proved that both gp120 epitopes can be 
stably expressed in a recombinant antibody grafting and both VLCD4 and VLB12 
recognize the CD4 cell receptor outside the gp120 context indicating that these loops 
are in fact independent and both must play a part in the gp120 binding to CD4. 
VLCD4 is a synthetic antibody that targets the domain 1 of the CD4 receptor of human 
cells but presents poor inhibitory effect on HIV-1 infection. 
VLB12 on the other hand is also a synthetic antibody that targets the domain 2 of the 
CD4 receptor of human cells but inhibits HIV-1 infection in laboratory and primary 
HIV-1 strains. This molecule can also be used for gene therapy as a carrier for DNA 
biomolecules encapsulated in CS/DS nanoparticles. Its usefulness as a vaccine 
candidate needs further evaluating and a “humanized” or modified version of VLB12 
may yet be a good candidate as an HIV-1 vaccine antigen. 
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